var title_f20_17_20752="Tubal ring sterilization B";
var content_f20_17_20752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Tubal ring sterilization by laparoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20752=[""].join("\n");
var outline_f20_17_20752=null;
var title_f20_17_20753="Piebaldism - forelock";
var content_f20_17_20753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Piebaldism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A congenital depigmented patch with white hair is present on the scalp and forehead of this man with piebaldism. The patient also had depigmented patches on the trunk and extremities. Multiple family members had similar lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20753=[""].join("\n");
var outline_f20_17_20753=null;
var title_f20_17_20754="Lipoma terminal ileum CT";
var content_f20_17_20754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lipoma of terminal ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the lower abdomen demonstrates a soft tissue mass of fat density in the lumen of the terminal ileum (arrow). These characteristics are diagnostic for a lipoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20754=[""].join("\n");
var outline_f20_17_20754=null;
var title_f20_17_20755="Linaclotide: Drug information";
var content_f20_17_20755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Linaclotide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14944683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15804379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Linzess&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14959273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15838398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic idiopathic constipation (CIC):",
"     </b>",
"     Oral: 145 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Irritable bowel syndrome with constipation (IBS-C):",
"     </b>",
"     Oral: 290 mcg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15838386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not adequately studied in the elderly. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15838402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15838403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15804380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Linzess&trade;: 145 mcg, 290 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15838282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15041819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM318437.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM318437.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15838425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer at least 30 minutes before breakfast on an empty stomach; loose stools and greater stool frequency may occur after administration with a high-fat breakfast. Swallow capsule whole; do not break or chew capsules.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14944653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic idiopathic constipation (CIC); treatment of irritable bowel syndrome with constipation (IBS-C) in adults",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15838320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with use in IBS-C and CIC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (16% to 20%; severe diarrhea: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%), fatigue (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (7%), flatulence (4% to 6%), abdominal distension (2% to 3%), viral gastroenteritis (&le;3%), dyspepsia (&lt;2%), fecal incontinence (&lt;2%), gastroesophageal reflux disease (&lt;2%), vomiting (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (5%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, hematochezia, melena, rectal hemorrhage, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15838287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in pediatric patients &le;6 years of age; known or suspected mechanical gastrointestinal obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15838288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Severe diarrhea: May cause severe diarrhea; patients should be instructed to discontinue use and contact their healthcare provider if severe diarrhea occurs. Administration with a high-fat meal may worsen diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatric patients:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated in pediatric patients &le;6 years of age. Avoid use in pediatric patients 6-17 years of age. Deaths observed in young juvenile animals during nonclinical studies;",
"     </b>",
"     deaths not observed in older juvenile animals. Sufficient safety and efficacy data does not exist to support use in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15896867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15896865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15838283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15838284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Linaclotide and its metabolite are not measurable in plasma when used at recommended doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15838285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15838286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if linaclotide is excreted in breast milk; linaclotide and its metabolite are not measurable in plasma when used at recommended doses. The manufacturer recommends to use caution if administered to breastfeeding women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15838370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at least 30 minutes before breakfast on an empty stomach. Loose stools and greater stool frequency may occur after administration with a high-fat breakfast.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Linzess Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     145 mcg (30): $255.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     290 mcg (30): $255.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15838446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     IBS-C: Abdominal pain, spontaneous bowel movement quality and frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CIC: Frequency of straining during bowel movements; spontaneous bowel movement quality and frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15838368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Linaclotide and its active metabolite bind and agonize guanylate cyclase-C on the luminal surface of intestinal epithelium. Intracellular and extracellular cyclic guanosine monophosphate (cGMP) concentrations are subsequently increased resulting in chloride and bicarbonate secretion into the intestinal lumen. Intestinal fluid increases and transit time is decreased.. Extracellular cGMP may decrease visceral pain by reducing pain-sensing nerve activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15838372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimal systemic availability; plasma concentrations are not measurable when used at recommended doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Minimal tissue distribution is expected given immeasurable plasma concentrations when used at recommended doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized within GI tract to active metabolite; parent drug and metabolite undergo proteolytic degradation within the intestinal lumen to smaller peptides and amino acids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily feces (3% to 5% as the active metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86369 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20755=[""].join("\n");
var outline_f20_17_20755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944683\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804379\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959273\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838398\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838386\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838402\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838403\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804380\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838282\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15041819\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838425\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944653\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838320\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838287\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838288\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896867\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896865\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838283\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838284\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838285\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838286\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838370\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570451\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838446\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838368\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838372\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86369|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_17_20756="Metipranolol: Patient drug information";
var content_f20_17_20756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metipranolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/60/30660?source=see_link\">",
"     see \"Metipranolol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OptiPranolol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      OptiPranolol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702514",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metipranolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, slow heartbeat without a working pacemaker, or wheezing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12082 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20756=[""].join("\n");
var outline_f20_17_20756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195525\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195526\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016873\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016872\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016877\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016878\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016880\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016875\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016876\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016881\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016882\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/60/30660?source=related_link\">",
"      Metipranolol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_17_20757="Myomectomy incision";
var content_f20_17_20757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Abdominal myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical incision into the anterior uterine surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20757=[""].join("\n");
var outline_f20_17_20757=null;
var title_f20_17_20758="Hepatocellular carcinoma - very high power";
var content_f20_17_20758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatocellular carcinoma (very high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEXAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2WzZ7e3YXqh4JQQqZwfQgVcu/30Ya8th/ZuNzqrD5sD+IVnmOO4mtWuZxHHExUqTjLe5rSeSIxSIrBXT5jG3RgK3dtzucbsp3MWnNaRzW+wEsGDg4IHT860bmCzNsJHlZWClVlHDc9iawzHa3dtOwzu5yQeFz7VJpsd3zGsAjXndIxyD9BRZjlDrfYvBZWlgh812JXcRtyMDtmsiKGPTp76K6kM8UUbSpAfvKDzwe/wBKu3Q1GG0Sf7UCg+QAIAyD61VW0N6Fti6yHcCbj+JR16/0prsEY6Xexo+GRazWMszxKkYwB24xUmoRQ3FwVURuDHlM9WrzvxL4rtfDt2tnb36zqjlZIDjLPj5Tnt6Yrd8E+OYNengs761ENy2WCyDaUx1A9at0pW50tAlSnH37HRwRKsMcN8yvHsGS+AG4/pVLUb6KGNLaxlULOrZ9cD0rzLxj4im1mPWrOwuDbanYsMlh9yMHqB3HPNQ+FXFlb28dzq0epS2pJmlQ5Cq/QD3FWsO0ry+4v2dtep1d2jWMJtLRlkttpEhJIYN2x6Vz+vQzOLi509YyXTyrhHbCEHhmB9a24zHeAlyUjdSQS3JA4P5VzA043PmwwPvikZgSr5we2RVxVmdVJJbmHpei2ENw0cK7giklW5VsYIGTWjBcOWuLaxsIbeR/nC7VDZPUe/rUF1J/ZunzyauG+yRoI2WAZkVgcZB/AVhL4qha6tns0ZpULksI8llA+6T0/wDr1qry31Op01LU1deuTDoolgEltPFIqtCSMSOcqSPXIrDvbh9G0yx/tO0CxvL1QguDg4OPxxTvGLq2nW2oWLtJBGzMBJ1VWHQj1BNcdLqtxqlnb2tyPMVEyJG6hh7/AEoXY1hTvGx6St3ayLDe6XqPmhUMTBxiW3Axkbe457U291TS0hmmga6uCu5XdYNqGTgda4vSEE95b2sO6KS4Vf323cEfPXNL4gt74vdaXPKbW6FwfPUsFikUEYK+p71fsyHTSdrnRza802ialYXe5L+O1Yxxt/E2cggjqMZriWXUb3UvJkQlrjDLcFMcjkEH29qpwztBdQwW8DNcQyBWYuT5hyRgD0NdafDl1HKU064G/YCLabKtG7H7qn1B4oUFEpcq0NbwT8RptMn0qPW7ea8tULW7yZ4G4+h6kda9D1TSvJvruOzy0DESIGUfLuyWGfpXnHhbwpc3epx3V/bi2tYmaQRE72eXs3sMivUbmY3NpHDBLICrHzZNv3j3we+KzqRjBqxy1OX2numNaMum34u4ZfMjgI3IerAnBX34Nc98SfEzf8JOtrYpG6ph1QKQw4xz+FNitb26txfTyBTuZY1BwDtJOSPU4rP8fRXVrqttrKRtamQBLlwN23gZP5U1TXNqbQjFTuygNWuWnk062DG5bMkkg9AAQSPYV1Nr4ehmhE10FSwCq++MAPKRzx+fP0rhLLUY5PFljcWTru2kSMqbVbIx/KvUdVnlt7CK3tZCLmVwNrL/AAY+Yj1B5ofu6Iuu9UkjLj0PyzC9klwbOIYdW43M/T6A4rt9LkFv4alDRxwPH8rLnABHc/nXP2E0QkvUdZVWPYhUDGD2x+WKt61E39kaerSN+8QxXCkjGT0H1pW5tGefiPeaiy8viy300XTkuhhyvmFeZH2jAHtT7jxGLi4ee8NsyLCs0uw8gnIC/TjrXnotjeG5jk33UjTvb2jP9xSnB56eprY0PQLSAWsuoCa4cRkbc8KFPfHUc96JUoR1ZXsKcVcp6rHZaVZHWpoAtr5IuEXO4PIxIVAf1/CvLL9rq509Lu9so3uNSujIs2fmbHG0eg5r0+4gutWsbnS76JIWjuQ1uWGVDpkqCP7pUmuH1bR9YEKiGykiFswkR8rgYH8Nacv3nVSt9pkHhxzpfjQQWM6JDHMrSzHJCKOWx69xXtOsXapa295crPIs+HSOLknIGwNnvXm2geHjZS/Z9U3Lf3LCZYV/jBI3Mx9ACa7vVb5dSt9YGmgKnAjTb9wj09uKiSTaIq2ckcLqXijWtRlgtFmkskikIYoOFwe/sK5ux1TUItWnuzq0ltdEbhdwknfITwrY9q6OPVLV3NtMwgS4twgDDOXU5PP1zWPBptnF4hstOuFLwXqFmCHGxsnH8q0tG1kjqVktVY7XStXute0rXbS5crrdrCZQ8Q+RgMEsMdyM1zOteHrOw1221AXbNbTSoXhxkOGA6Edc5JrrNI2adqt1qM8Igh8n7PFF/fXpuJ9TWNq3h2BtQlkstTnjWMqBG4DbARyy+nHSp0V10MIv3vINKmNj4r0u2Mha2cSMJnP3drcDPtwPxr3TR75p4hLKU+zsPkX+Ljgg++a8T0zRIbLSLi9TN9mDEs8jbiW38IoHTgDNd74YuTcJHOZFSMk4TPCOOcH/AD2rOrFTXMjmxUVLU2LyWzsbma5jt2eZwSVY4Ax7etcfdiWAXe21aPcg+XgbSepPr9K6SSVLjS0MR3XokZfMYHaxJJJ+gFQXmlJdzxxWkryXDgZcdfy9KqCS3OL2zpmTqUPm6NJLbgowhG09MHH8/wDGukuJYLHQLfzSjukKK5OMbiMmpfEugi80u3s2LIsTr5mzpgdfzqp4ytba60mGCwRfKRN75bGcYAz9aUmpWQUWqjXN3OVuDcT3tqInkWRnMbODj73Ix65Gab4uRBJoVoJwLGCbyZ0tjyV2/Nn1HFVrNr9EvdTeJzHAjQW0QByGIwHx7dqq6Lp0hurCWUl3EjNJtPUKAMexNNq2rPUile99iUJbQ30llB5oDOkkCnklemB6HHFbLafJZqt2sLS3YjZskZ8lfX/eqWHRbGxmt72Db/aTy+bAu8livON2eMc/pWDeeMgs01tbal5kjMSNy/Kxz90e2e9Qlf4dRczqfAT/AGTUrt82enu+YyzDqOn5Zq/4QsRe3c17cQyeZC8aRxOMYbpuP0HSp9C8T6rYm0ub2O3gsZ5vmijXqcY659s1o6fP5WsO1m8bW927SSkfLGG7KPoKG7ppIzqTnrGxR8TeJEi8Si3TJjtGBZ26E4wcfSqmr65aq6XMaTEFQAy9BngfjVjxBJaxX1s8cCfZkUoGIzv7nNcz5ry+dFbxtI0kqhEHHlejEf0quWOjRdGCaTaN2e5+1wCzaMzJKAJCBjrkn3PFV9MgsBa7o7a5EcZ28D5s+w9K1fDEUtrbXc0sJnvJV3OzD5lxxgDp+FJDcyH7TpspW2CuNkiL94HqDWeysaXV2kj1cRxNLNFPboysVYxvz260eIYY49Kg8hDy4+TqcHt9Kozy6jLOsoEUb7dofGd/tijTjPa3qNfzGSZj+7fov+6R2rkV1q2eUo/aRFfXojjhNhbu0kbhZERduU78VvW11GYTIuc43bT3FU7q/VrwyDaj42gd/rWb9tshfywzl4rknhYslWGOu3tVWvoJx5lsWru+uLifEVtttCpyW5IOaRohFpf2iI4I5bA4YehqbT5pZXW3eJVDKUVx0z2JrD1+8h0rzg04jgxsk3SgLu7mi3RDguZ8tjjfEPw/k1Se6vrJreO3ukWZVnQna3oG9frWh4B8AatZakNSvZpHMSKBC4G3IHUH6V1Oj6hY2mni6u9Zjk0gR7Q0jjarDtnvV/Q/Hmi6jdiy0+9hnKgbQncV0OvUUXGKuTUq1pxaWxyPiTwRcy6zqepC3Ui6tjatIn31Ujnj+tc14J8B23gtru6uLl5GnBVQ/wDd7cete16vM0ltugY/MucDn8K8911FvoEaYyRtEd7oenHt6miNacly/IKMnP4nocub26s74R3qeaqNuTyl2hlY9Metc3Pq9wk9zc26MLZJCzkLgoAcgVs+NbmWUyJp/mxWkAjmJI5J/jx6Csq3u1v5bzTZ2byoUykzD74b1x161rFK17HrUkrczRPqdxYSeGb6a6leSW5YCPHJ39enY4B4rzW1vdQbwvdNEqMkc6pHkYeLqW2+ue/0rvbDTE1yK5so3VSpE0EcROVdOAfpmuPjsp0ju49QguknmJRohESQw53KMcGrjG6aubQstLlK6vJn0y3tpiX85c+YDnJHQ/0NZOpWd5ZyRxvEF8tFkYhccN0zXT6VpKTqrTxy+VAuFz8rg54J981sP4ZW4uJL6+uCxGDsJ2AgY+X61Vk9y5zUdCpFfLp/hPSYYLYPPcObyXAG4IDjaPyNVtQ8SW+uaVez6spSaLK2kQ6DHfpyaTxVpM4143+mqXtiifZ0DY8o4wVx3HX86h8NeE9W1KYqybIjJv3OAVUd2+tNR6vQwUoWvJnZeE7jT7jTtNuYLKKFCdkq7ASkqjIIPXBP866mCaeG8l22lu8mfM82XnrzwfyrH0rw+tjBpqQyloJ5XhXaBw6/MT9SM1tTwQyslu8jsjTLnYeSuO/p2rKVmzlnKPQ3bG50uxjuZb68MskmHdLVN2wZ9e1Y+s6nb2sFu1hbypHbt5yRykDdkdiDWZr0CpfwWtizIsL5nlVDhhjjkf1rOee63IsfmyQmRlkDx5GOg5qFBbjp01vc6C0VL7F3dwKkbfeC+vJz6Zwar+JLeaTQ70W5aV5o96JIQ5dAeCMdQaxri7bTrFdL1HUGi09UZ47hsBic/dP+e1S2F7c22q6XbedG8jOv2cI2Q6nuvoPaq5bPQ05H8VzmdB0eKBWMUe67I4iXgqe5J9PSuiW01AJbStbq9rAojDF/mwRyfoDzXQ2mj3JlmnhgMTgyOyMBlhnqD+fFVNHja3s1tZCbhBIwUDPA9/cZqnK+wSr8+qJNOtXcRTFCIrlBI6vw7he4/nXRW1paahDYmEjbLIJWSRsFnDf5zSeZBqGircMRGUZhFIrZKFTg4P51yF3f2ja48uoGa0sIUaKKdWOQ+c7uOmcGs173lY5nF1WbWq6K8N3d2iNCbJpPNKhQDGWGPl9+aq2QudFvrv7OFuLCazCoWbIZs4bjsf8ACvKr3xPqOpate2tlqxgjtlLW8u0/OAc7D6n0PtVGzl1TVr+KwbU7gzzREAFtuJccBj2HNVySas2dUKL5dWelyzF7qKVXHnLaONhOc7cFSfc9q0bm1uM3Ecv+qlRJh0G0lTlT7DmuH8Lvd6dFdabcrAklvuj8zJYeay45989+lXrYvfWgi1W+kdoLclGGf3mcnacd+1U4PqKUeqHeKNch8PaMtvHmfVbloys8hyUtsZC57Z4q94I1v+2ftEcESR6jBJueBuVaPG3I9u9ch8VWQ+JzbIu0R2tpBGrdDmMEsD29PwrP+H+oDTfHtm0vWYy2swVuPmGAc+mcUSiuXTcajelzdTQ1C0tUeS8njIC3DCNSDkMDjGPTNafwjgh1DxBqM9+BLeQ7VjdhlUBOOKseKNJnvLloYJZhDEzSbpOGJODj/dz3rZ8DyS6Z4pjs723hEGoRgtdxnIG1ThF/GqkrrTcupUvS8zd8RWNpdX9xp7ts+yWOVkxgM7MSBj/PWvOPJuDb3GsQzOloECgHkqqHaSfYnIr0O6hkj8UG+uEOGB2AtuAQDC5HXNcxJpFzbyjS7aF5IJjKJJUXgqxzjH1p01bT+vMwpVVCO5fs7XGlLZR3caRkCRgowc/ex6Vrw3CanqiWdiTBbyBGdF7kd/Y1oaZ4Vvb21hOwxsAoZAPnwBgkmu78N+DIdOYSFA06j7x7ms5TjDd6nJXxUXtqzCtNDe2jka2MjJs2pHnIGeua3dJ0OG1s7W6aFkkR+oyWO7gg+1dQwt7IR/apEWSYhQDwCfao72fOYYdygj72M4NcrrOWh5rcpO7Oc8RDyLOZEJJddvHr/k15hPbtp1vcxyM8itgsC2VLeg9u9el+KHMVgHt4XlkZ/LCA+v8AF+FcPeGKaylfy5fNDiLIU43cdfT1rSm/dO/COyscxquqXlxqbySHZYx4fyU43NjA+uKTw6ktmkdxp7NNJdSEqHJyQwwSR261pajB5lxGSSwjHzKOpbsB6/WqVncXpu0trK1eBMHfIRgY7Af41t8S0PRv7tirrckWk2k8Vzdztctm3DNg7VUZ2L7eprynVNSa51CPaRFaLhgg6EgdT611PiaC6nidm82W2tpHikm+9tLHOf6Vxb2Ugsg/3k8wrux27ZPYVbi0rI6qMbRudL4S1qdb2eC4vi2n+Wzv8uQMeg/pXq9pPLqHhi5e0ystlPCYo4uXx3yPcdq8m8I+H9RvbQ3KIltayuIo3z/rH3Y/KvoGH+yvh7pNp/adxbLcXMo3uerNjl274FYt2atv2OfF1I2Sjuee3but8ISz70IkOR39PbitvSdJitIptQ1K8EFs0mC/Vix57fyrb8Y6Vve31vTXR7Wf78qYcMCOCP8APeuW1NH1O2jiacWkADcu3JbGBgdMn1q1JTtbRGUKjqKy0fU1bnxV4X0uVYLFZpptuDLIx2gN1OO341FDq1pHZvJIyOSSQUG49OmK8+0+Sy022ub11jmMUm1o85MvYD6cVQbVYfEV/ELWA6ayudxtwW3ZH8XsKPZx6nR9XWyPrTT42voIjMNm0ZGDzWfrdtIkkUbMGV2ABA5FcxFqV1ar5SzhTnYrBu4qK/8AENzpcb3nnG4Zh8qyDI/LtXH7KVzyIc3NodTNZrb3QEIWZTliXPKH0rNs7wwX8xuo4xI2VUMOcdgTXM+H/F93qs7GeJRcgHDAkLj05qzqusmWzdy0E7A5dI1wy+n1qnTknaRfLJNxaOt0zWbdr8xNjPTI5Ge4rxr9oHR73ZBPp8gfTkdmktf4g5/i9x/KumjlTFveW0q3EbAbtvysD3yKfq4GpXCCWVJIG3MXcfMgI5wPStIQ5ZJl0/3c+ZHjXhHStY1TwZ4kECv9jSNJUhOcFlIJKg+2c1pfCTw/qkXiK3v0jcQpII2IwQC3T/8AVXsdvaW50m5tdMKW7RxJgu3VW+8PxqDStat4dGs7L7BGs0Dbg8Q53KTgkfhXSq+9o/13FKrOcJR7s63X9auLKz3y2eLhF3bVbCsvdh/hXJapqX2qNEMRieU8Skdcc9KreIPFP9v3kENpbP8AZYUVm3Ahi5OCMegxVg2EtykdxeuJLhS5RhwoyOBiuSMOVXasFKCglzblS702K6yQjlWjIEpPck9v89K4+O1vYla0t5SYYVIE3G4ED9fT8K7HTpnNqI5WkEzo3DcBccf1qWXSbeO32Ebok+8EODv9a1T5dGdMarjoZdppMWnSwX0J3TbV244L8c5x0zVa7jeKGd3EhWYrvIJJQnn6nHIq6ZWsEinil/eZIZOv0+lTQW4vbMzwLLOrMXbZ1J6cU9W7sam1qzmI7N0Y+VGsiSSYIHJOMleevWumex07S9NW58RtKykec5ABQN/dAqoNRt7eyvrmO2xeRRBdkv32IPTH415n8SNXa5mayjuHaQsi7I5Pk39WP64/CjV6bFuMqr12O8u/iXbNcfZbLQVbTFbCTH5SwI4I4q1p/iTT5dNlSxhnjtsB3Uj5snhlPsK8plitrqzW4t72Z4rGJPMtmBBVs4UqRwea2tE1Ix4jtnUaleZMyNykUZ6k+/tVOmktEaPDwSskegRX0lnpLQx3UTBpxJBEVyUYA1YbUFdrS72Iskt15DeWv342Tb+ea8607xPDp2ryQXcQu5TKpgERwsgYYyM9K6PQL5dWn1KyLCF7NjdspOArqwIx65xj8ajl6mdSly6s6sWSWV5JKbssgiKgn7zHn73r2qjN4r8PWcG6bVEu3kH/AB7wnG7jqSeByKnsbq01kI1qJGS5HlvYFgMZPzt9MEc1554h+Hl0peO08m5jjjd7d1k2HbuyFPYkU1Dm+J2ZnTUb2qMq6rdTatrB1GeSGWGJ2U2ZcBY1x97Pfiu10vT1WN9cdIbeW7dYrOANyhQDkem6uc8P+A7hZVudVulhtYVWXyE+czMvAU+2K6DV9ctYNUsXt5okMvmfNtysK4znHr2rSXu+6jeclUahT2R2C6z9tuLqYyyp9ldA8S8ggfeH8qpatc2iQXl8uIIHfaI2+XfuHQD1PNcX4c1S2h1YwLPK2mOJRJLLkkuecAj1HrW7PNpGsXNpqstyZLZCVaKY/KuP4h2znFYqNnqZSocstjZ+zg+ErmK0/wBSsYPlbgXUZyfp1ry/VP7RsJZptMvEuNEFyrLuILbnwG4PXHSu708xw6kPNdvLuA0UnHy4BytZ3i3wpbWYuxbvcGD/AFrKvRgRkDHXg1rBpNphSkqcrPqeVObr+35bpbWJLidnZIsYIA53AdulW/C6tdX26W5S2nnbMsvJYpkFlHYMcV0V3osn29tRs4zNDKiS3UUTfNEMDKgnseeOtaOg6RDbpbFkZBcXDNErckJjofTpV+7a51uqlGxY8P2ZvYNZmmSSAX96sjNkF0jByo/SueeZ7e6u44kZVMpWNsYK5fP+FehLZv8AYXUoqP5isIieXjz1z9M81jXWkxXLzb0kMj7uB0B5IOe/GKSknc5oVEnqcTqVteeK763RjCs8ANuskp2hivJH/wBemaLZQ+HNRk1DX2V5LNiIYkX/AFkmMjJ9Oa1xpV4wsoXb7OqIJI27sd39TXS694Qk1yGCS6ZEeJsSLu+83qQO1VotG7FzqRXXQwbHxhotyU+2PNBLLkEkEpj3A5ru/CWo6F9mj+xSwzeUpZXLZ2HHJA68V5lqPw8a18o3GowFckIqDGDnpnvW54ei8NaGFs7h5EmORPcN8xQns2OgxWUoxtpK/oZVYRqR91M9YSFby4jnjEUhkXYz46L3rpdE0PCO7LwW6EYyPSuM0XWNOiVbO0GHtxwCcCReoIbvXY6RrrTOY0fO3qPT61zVJTSsjy6lKovQ39PYQWzJIsfnB2AC9MZ4rShYmMFlIJHQ1klUuJ0kUru659K0IXGNu7JA5rmkcpDe2CXUR3AM/BBPYjpWXq0b2GmtunYO4xvHJB9q3lcFiB1FZ2vRs9i+AGI5A96cHqkwTscre+aLSORHZ9i4w4xyecn3rm75pGgIWMiR5Q0gJxtGK6O3hvZIpLW4YDzADnqeP6VQnVXjeO5VFltmBLDneK6o6HRCfK9DFuNMihuDeyAyeYQkcbHjHY1neINVazitYboInmybV28YHT8q1PEU2dMd7dgSBuQnjB6CvG/Fa39zfW/ls9yU273GdufVc1rCLlqejh4e0fvM6m+vPOeCG1jUpOzRyxAccev4iq974b0//R547O3kJQsylsJuB5JGecDNU7K8jN8WVJFeSMwwtK3CnHJP41FeTwTWTSznb5G2OSRjz16qvoaeqO5QeyNHVNSW1t9Pa3UcXIdFK4VFUEjp271nXPiqOW9v9Z1WYamgkVIbZxiM56447VLe2lpN4cuBHeW02px7crnB2nIUH0OKxfC194es7KSw122V1kdmViC3XjkdsUR5bc3yHy72V2d18PdXhkW9tI7oJpOqBzbxkn/RplGeOwBqq0F5PexRIi3PXDfeGR1PtVTRNOtrTxLpVpZRrHZ3DF4ioJUptJJyfWuht9R+w6hLLb4lEUu0oDjdkdMU2rXtrc57KM+aPVHIeNdJfT7OG3nC7JTmMkY2++R+NO0FoPD+mSrpl5HJ9oUrKDHkYI5y3atPxJfTarZ3JSzSUqwVZST8vr+VcXcaZd22iM93cpb2RcnCkBpgD39avVpHTBc0LT3PZdRf/in1leZPtBXcMgkAg5Gcc+1YtprNvLAUmUSRoMK0hO0/X3qo+si4u2FxLJb7UPmQEdfr3qXMNrZolvASksgDIecZGPyFY+phGikrNajzdqH3RRolsVJGG7etLDdW1jGkl5OASpK8jO0dM5rPIitLi1dmwqOSQvOV7/riuc8QXFjNZTazqULTzecojijJ2KhHAJ6UkkzX2a2OjgvluB/ociSGSYuSh6juB+hravLMCxELX/mSH5kQDa45ywB9vSuI8J31lqN1HPaWiW4b79uhPDr3H1FdTd3Ej3rwNxG0ZuI2YjcgzggGrk+VaGU6aclYfbajJaqx+3G6ik+VuMHA6dRzVnTb6BtTSWP90zNtOV61z2Wt2xIpYgAqrjg5PBH5ipI5B5pWVzDtUtu25AI/hxS5kKWFT1Os860k8hHWaG7t5gVmUZ+XJ3bvUUatNe3H2ZJ5DAPtHMkYPlspBAI/HFZWl3flBZLBmWXhZEfODnOev4VtWF6L3TZbTUVVXiLIuTjII7fpQ7LU5HCUGaFzc2slzFZyOizoApY9M45OaiMcUlyIhcifZ8wcHIGeozXDG2v0vIo7pfMtpdwaRiQT2BB70+G9/sm4Szmfybm1CB5zxG5PAB/DvVezstGUqK+yzuZbZZl8nhRImflFakF6thYLDpNr5iqDxINoIBwSPpmuZtNbhEg+1zrGwxF5vVBz1FaP9oJAJhDcxyFELRKeQpzwfp9Kxkm9GQ4PZlTXTHNr2nzmONXmlWMqARxyQSfrXi/iXT73QNSvYNQsonsr26LxXW3IHzZwrdvcV7Xa2Vxe3L3N6y5CAIOwJ6GquoPp0+lKk7Rx3NoobyG4yQTzg9/8a0g+XQ2p1uRpLU4PwppK3FxcCO1WPT54gk0sny7yASCv41n3Vhc6JrrSb1g+QHcPmEi7duCf73PSuzke0uzFFHDPOsgKyKn8PHB/M1JZ+HbsBxd3CGJOXR2BYgHGP1q+a+5uqvK7y+48d0nQNTgvY5rpGWEsYmYuAcEHof1r0n4c2s13Hrd3Z7c3OywhdVyJAgwW/M1APCf9qajHG5ka1Erp5Ekp5bnaBj05rt/hYkVroauIPLks5HgmTG3593UD6CnNqMdDOvVtC0ToIdK0uwNtY2Y8u5gRY5JJBhicc49aw5X0eyNxBbNcTmSU4dfu56ZHpV3XbyWa5jnAIJOd6nleoJH6CsPT1s7S6E9wFXfF87MCPw+tZRvJXbOWnGyux+o39uLOywMwowglCtgoc9T9c1z9xo6uIIbqCNXs5pYFlxy4Gcbh9D19q6y5sl1e+WK3hdLdo1DSFcKR9e/Sp4vDt5INgjNyzNvdsbee2PerWiNY4iEDzPRLWyS6kn89lliDoUIATzOQO+OnNbNnG+o2Ftp9tpZ/s6PJZwMMWYZLH6HnFek6R8M45Zmu9RZCJW3tCiBcH0qXxKB4biSO3gAWV9qqo5Lf4f4UOpBu0dWTPHqcrQRxH2OdrW30ZLlFkgbf9oCcOTzk5+tSavePeqkIhuYr2CUbnLYVwRtyfakl8XyXFxOuIbS2aNlY8OXzwWGOg7UzRIhfafK7X4uUsEBeQ8knGQhx6U2urRT5o6yM+Cxisp/Ou/Lgu/N2usZ+RlxgdPr/ADp1zd21i89rcXqSea64ePlVPuccDgVn6hBPKIXsYDcNOA8tuxIdRnqp7Vz+maNfWd9dI0F1FFKoKtdcqxJzyPTFXy31ubpRa95naOqRm3ubh7gyoUQyq+UVR39+tdXbXdilv9oEX2oqkkgUvtUBe2feqGmaFFp9pHJf6nY2Vs0Z8uC6cFmyvBArB8R32m2uhQWbLcz392XSKO3xgBD746561jo3ZMwdqj5UW4fEWjapHDLZwvaxP8/lSYYxHJGCfTqagvtXWG5+yaY0axFxJLIRuJBPIx9OledQyPFE2+N7SML5IZgdjZ6gN68muxntre6jlNoRBPJEgXcACAQBgepq3FJ6nRKjGBg+NJZdW1yYWRjWOCVFgsnAKSkLksSD3wa46G2vfsV7uljtiW80whv9Zu4AH0z0r33TPh/olrbrd+II4lHyqGlcpyF5HWs/TrXwLHMRpv2EXEQMhLMRvA9AeCRVRqU7bN2IWIS0gm7HO6Tcyv4c02KSFnJtvmReMOp4IPUY9K7fwvctpn3pEDyIssjEDdz1BrOvLbS4po4F1VA7KG8tMYUPzk1XhsJpdRW2t5TcmGQoZVOEkHXms24tWJnaotdD1mz1aFEXICkZyucHFWbO/huB50chDPlcH0FeRXeqSwOQlpMVU4kaM7s4HYelas2qf6ParFcMsTS7N8a8kbeh9OetYeyPPqYRrY9Mt9SEeo+T52fMAK5+6R/9et4qs0Py8g/jXjejazbReIHcee1kY0jTYMgOD/LrXqOhahHcoyJxtP3TWVam4O5zTg4aMzNVnt7K7EUrlZSnyFV3EisSaBJ4riWNsvOwycYKgDABrvLq1V2MiqDJjbnHauefR2Mzu42JKRuXGcY5yaqE1bQiMrHkXiMahj7NJ5ca8ASBsNs3VlSlLiaTSLOJJPIjLlxzufI29PrXoniHSJ57Xy3yZ3lKAqBnBPHWsyfSoNLdobYKW3ASyYwWOOR9BXXzqysenSrrl8zhb1LfRnWGPyZLveJWeUAlWbkrXnOt6gk11IRIwQH7rKBkgnBP866zWbYT65d3dzbM2nr87SrlsFeBgehrziaYy+Ysgz5rks2OTzxVVE4q569C1r9TotOEN+l3eyM6MmQ0y5Cu3Yn9aht7W2u9RW5mlkNiziF3UYIB7/zqWW10/SdDhhe7nka5jMsg27do7DGe9dH4EsTLp88RWJJb2LMRYcZA4/xNTGdkuYuUrLmsa2lSRzeKrW4swV0zSbcwxNKdwd2GOPpnNdHplt51i0sKSPcyzlnbbjjso9+DWNp9rcW1o5ubmFWhfcXAwvyj+fatPTfEC3WmWyQCaEPISzDg856Ght30OOrFv4S1q+nKmlLHzDA8uz5B84Xv09ea4Pc2v+I7sW0MjWdopEUbkLtRR95s9j6V3VtetfpKVTddRt5Z+cke3HauW1zRtSttcaa2VfOZAJokfYWQ9R+NaQejT3FSk4u0jFMt1ax2cszNd3bSMs0gONyj19eK7aOXfHGLqcxxKuyMsP73I5/Cuej0m5W5ikvm2qq7BG3R2x976YrqdPazvdtnOSuX2pmPlc+nrmokro6Kk0kmcrqYaRLt4gf9GSR0KdWJ56etY9vE8elTadMga2uGW7XJyOR0/OvRdYsjbOIlt4vKVArsv8QJwd2K5O10iO8nnt5ZHVVYCFEPG4HufTpUR2sVGqmrsf4LhS3sZLh1kjiiG1B0If1qla+IrnUL94tV2NLbOYtyjbuyc4I6cgVP4nu38OmCGUeZKH8xgG4KnjP51mRSzXWq22n3NmF027w0sy9C2PvZ9farUVLUHbWTOglF1Ekkk0R+VWxnrGM8cemKxNW1Qp9n+zO5ygMm7+E966W9vIobT7NcDzIIXERvY8szheit7VmeI9FiszFeS3Ba1VmeTA6qR8o/GoUFe7HCovtbkelagbYSz3V221AcIfvMdvGPrWjo2r2WpL5kUsjP5DSSQ3A+YP6Ke9cNqWpyKLm3EQi81dhLHdtyOv5U/wAK3Dza3pq2sQtngO2VwTh1HB/PNacutgqU1ZyZ7rZXsVxpMsl1JIJrf91GowQPlBzz1zXP3UNrdwySakoKFTGszxBwWPQEdsVo6zrlqLm/0+JWS5igRVlK/u5xkZHHfnANcvrd5bW9jLHb3KuoYBIX53EnnJ7YqIa7Hl06Eua60OXZrrSij2ju0QLJMx6EZOMCu18P659pngihikjjmYMEK5KkDn8OtVLK8sodKRJlt2diWeT7zgg5wR6Y4/GnWF3sa8v4VjjmibekS4VmX+Lj6VpKx1SbnFqSO4vLg3FjD5Q8ty20R7sE/wCcVpSy2ywsXgTa/wApBG5lOB3rz7Swt+0jx3TNdwy4CiTI2nlc+hrVudZu7W0IZJw6Om9gm/AHXJ9xWDj0RxOg07Jm9dzRae0stwoEBj3ERgZzg4Gf1rHlubZtPLWkknmXEZ6/wknjNVv7Vt9TnntIZJfKdCy5Xkt1/pViz054ZkztQSRRguMHIJOTjseg5pRj3NElBe9uQ20ixpG8J3KjLuVcZ34Ocmrmkyy3TalbqYFnaYSxMQQJQvX2roNVtrfStKguxbJPNI4jMY+XLHo35VreFtMmSzuJr1YfKZQY32BcLjk59KpySTkc9TEK2iOJ1Mqpt7yJJopbqcpJbE58vA5I9uBUmjvFHFLdtEbnzEYxNtwvf8PxqvqbnVtUurmFJTbQRGC3C9ZOcux9uKuG/t7eN7C4hWGA2+5Qi5D4GcKfcCnbQp80lZHRWfia3sNNiS7tXa0iADurD5D9D1FdDp3i7Q57gQxzxRIE3MzkLg+leV67fR/Z3cQE2LQifygM7WIwc9/SsWz0NLsrLZyzR3bl5ORuVTjofWpdGEtW7EfVE1dn0ha3ltdx77W4imT1jcN/KqHiTRrLXNPa1vsrn5o5UOHjbsQa+bPtmq+FrKBhFLB++L/bLRywwScgrXofw0+IUmp3iQay6O07bILheB7B/Qn8qzlhZ0/fpu9jOeFlBc6ex594j8DXltNe2VskdvfgrCTk4kTsy/XNdjovhGbwz4VhshMCUUzTHHyvIeuT14FeseIW09LQ3VzLFuh5DcE15f4r8ZW0ls8NpFKArbixXAbJrVV51UkkawrTrNR7HH634kksGV9LDFEVY2JAO/d0LHrx6VVTx7d3Vtc2qBbudHKlyNpAPGAD24xWTqrXSNNc7mTYiPGQOJQAeB71m6PZLdz3ttPGII7u3WZrhSSY5ByGx1xycitVGL+JHreyhy7G18V4LrxDaWniLTLYzw3NvHHOir81rIgwQw7A4yDWJ50+u+FDatMyaxow82IL1eMgZweueh/Cu58GWtzFplxHFbSywSRETiZ+X+UrvHqCecV5rokU+h3l2urpKlxDE3lJsO4txtAbutVHblXQyp9YX22M/Sku9f1NLWC5kRREXdZWJVQozXRqpudP0S43M9xt813zjGZMD6AYzUcPh6/FhqE1qs1vAwBDKABKCegJ5rrby1ittGtMW/lwrGsbRycELj7tDtHQ2lMT4h65ca/8SbLR9eJi0OEj7LGmR5jlcK2R1JbipNW0HRdWM2i+HMf2kW2xiR9jblDbsKevK1cuLeLxDoWj32qpCRAzA7TgoVG0e/oc1ydr4f1qz1Gy1aKdbqa1dpd0ku0+Xzkg985x9acGrJRdrfccsY2TV7WOW0SJ7G7eXWY2ivIyyKs2VKv/AHmH8QAFd/4Du3j07V4JJ0na0mVo3jchCrff+v8A9asq9sbjUrCO21HS1juFXEd1I4JjyxwOOW4I61t22lWPh7Q7YC4ZTgrcEr98k4yR9KU7Wsbt3jyvcZeT3GnEXlzczHfFJsI6OM8AjvVzT2ub61hN4jRyTOAyRZBZT0P196ztSvldCsYMMTKBbpJyeT1OenrVCXWbuyd0sZhE9r5ZY/eyQcZ57f41Nr+oODlGx3FhcSW00sanfEnztGTjkc5Br0bwzqC313FIpSIgJ5Y7sMcrXlGnCO4vZEuJg2pHEsCoD0JDfMOmcE167oWnJD5crqEcbXjlf+Dtx6Gsq1rankYuytfc7RJtzMoUjHGcdazNSvXimEQR8kbgQOnsat2okjtAzt5kgGSeuazLmVr3zjCT5sA+UY/i964oxVzguOv7M3JhnZVLgqRnjHFctfaSJra5jtnKyCTed/J564rqYZJPIiNyQsgGXQHoale1hlkSeEDKjBB7jvWkZOJcZOLujxfxho2pWmin+yLdXZEw6MM7jnpivG7nR5tLuTNqHmW1ncciVVDbGHJUivrnVjGsEzRKC33ArDq3bNeS+M9LuYJby4tIN9oVzIrLlfMx1A+vWuylPnVmj08JjXF2l1PBwUmu7u4eVpVnQooZNxJPt7V6FoDtb6doyloTc26PH5WSWQt0Yj8ax/7OFzNbfZ43tJNxa8ZQMBj02+2a6LTtKC6/BdszxJ5WCu3nzcj9DScUmevJrlQt+80dreLODJ5cQZ8gDJzxVHw/fXOpXdoyKLeNN29+ERRjAOO/NaKIJUutuJyHkWRS+HII4yO2Kx7cwWdmkd35qhGyEQj5zjBA9AKtLSxCOkjuFsryyeC8BiVGQxgYMjf32P8ASuj0xkvtdt76/cooh+Qf3yOOh5xXnHhCcX99DaSMgjllZgCNxXbyMevPBrp4nvZtLg1O4iVb+G58qQAYyqt0x2zUyV7oyq0+V2/rU07eB7mxt5SXYbFjVDg4OMZx6VZltI7bfPw0x2pGuNuOKfprQRiBosoEUqxPALeuelPvpJLiWPlYpY0z5rAZPtj+tJys7GKbbt0LEFlHPoNyLadpLuQgBnI+6ev5VxWvXcuniOEiOO/hIRgp4Yf169avzSy2rTRyXW1ixQRLhcDs2R/KqOo2tzLd5jEd5EyAEMeN3X8DUp2euxvShyvUJoDrdrLNfyxxeWFJlbA3Lj7ufrV2x0yCe+jZ7yK4ijQSCEPjaev41yEtw8+oQRu0aRWisREVOxyCMhh64PH0q1pN1HDrFtcR4UozIzL3B+6fpitLO2jNJwlZpEus6vHDFc2cUQ+zyXCqdpGFGOP1rZ0/7Nq2mzWkcn+jmAwvlt2yToCc9ecVi6j4RuryU6kIJJIGP7za2N3XBArV8IWMlvOk3lbYXCRvE2ck4ODz3o+zYmo4ct4vY8++y3sd9b2cjIt0JGR1lXDZIwPwx3rY8MWhj1a8u7eJjGuy1jUjhyT8zY/CvQtas7K+dYNVsYpJ0LFdvEo9Bn0q78ONFtr7XXtgWQQqVVmwSeMsT7jIGfrTc1a7IqYlRpuTRhfYJZbaczsiXUMxUszYEi8EY/w9q0PC/hiPxEtxHMFBWQlSrAsT6j681jfG7VWbXrfS9KkPlWeAwCqR5hznJrI8HeJbXwn4odbXdJHcwqJ0UcK/UlRz79KiPNKPMvkKSm6V47vU67VvCErwQywypG8YMK4T5gSfvN6gVDc2N0ugXLWLLLduCRJHgl8EZ598Vu+JPE1pdWaXOnMJ1mB2/MR2649fak1DT7fSPBtve3979itpT5hmzwkhGdv04pKpK3vGKnJKPN1OE0i2lt9fvJ7By9mQjSZHAcdRjuciujsZ9S1P+1LVW2rE32mLn+Dg49+uPwrMsJDf6Ra3tshliuXKB0baY27Er2rqdDspmjZ5VeFJotreX1wG/StJtWux1Z21MPwxo+qz6/JeaS32lDAQjOcAP349zXpXhLS5IEjiu/LlaZWmcr03eh+lQeGrO3eOZ9NVrco25WHBc564rvzFZx2hvpIvLYqWcR8ZPc4rnrVW9LHBiK7k+Ujj0u3uUkMyBxswA3IB7EVyPjDxPHfW1zpemyGMx/LO69gOqg+tYmt+LNY8QXraf4R+SzhxDLM/yAdjlj0NcHr/AJmjyx6Dazie7uJQ1xKp2hXJxtB+neinRbd5PXsTRw/NLXc1b/XhZQF7eQvucxyOq/u416LyfyNTwaoE8mOXDlSiyLFz5S579+Qa4aRLz+07jQLpmewG4XEgBIOCcfrium0e0l01JbtiJt0K2hUHh0QcMPcdPetpxSR6jpxjGxclurifWGNsn3G+82SQAe4+naq9tcS+ZJcxkIIpWDkcjk4/QfzqZp5Psv8AaCTqSZVXbIo38jG0479Ky5LuKDRtVaFHkuigKtzhnZuAo7Y71KuUldaGhZ6bqFra/ZNztuUyDzeQRnPHbPSr2m/YEuLJbm2iW9YhUATG588Zx74rynX9b13ULuG31W5MVvbnaIoCVj+u4dcniqdl4j1PR9Wikmaa4trV1JV23bMdQGqrO2oVMM5Ruz2Pxd4ri0OUaS9qLi7kj8y5bk+Uvf8AI1i6QlrrmF069ma7jff5EoG0c52k+noa57xQJLvxLc6lYGOV7xFlWSaTKrGygMGB64OOlcv4e1DUdB1ZLy2u4klhdUeMnbvQHgjPUf0qlH3VbcmGGUYe7uepxQRXEstjeAwzxRHYONu7PJ9wabHYiHTDFZWoiubt8STg9VAwR7ZxV7UtY07V/Ad5cFbY3kCrJYzRj96zE5cH261XmltEjhxJIEkhRgyj7qMThs/hio1JjzPRlnSHuZfED2kUqpZsFUKzYwD/AFzXQzQeGJZfsWp3UT3RQqiyDhn6ZU1z/heVrvxA08UBZvs77I3HzOw9PeuFTxWjeLJ4dQgP2FmHmq4IaFQe3cEdeKlRbe9gdJ1JWWlkdj8RbOeO1hjwJ4beJArR/KSijcTxxXm8uuzzboLVmM7fPGJCSG9sV1M/iTzL97a6aX92h8kgEb1z8uR71zepaRcQzFWjEEpctHNjorDO304zW0ItRszooR5FyyOj8Lan9qtIo75NkIZoZBEeC7Dj/A1111phjFlK0mbbytpK8hQP6e1YPh+1gtNA+z3aSOzkAmLB84Z+99RXVQatbPpFtDCyJGg2MpG4Koz8/qDUNu+hzYiTjK8UcfdXEnlrBCrO+4BPm3E/Nk/zqh4z1EQ6mJfJeaKO3X7vR2DAMSO9dZFHYwQ+RDF5kxDEs4KkFhgPu7jmszVokubKztrJ4InhBRJXIDFyRzj04zVK3MVCom00jz7VEvtWvbS7eaPEK7gFwpCZ5yp9OlZ02pedqUa3UaxwzoMEDnaDn6c9K6LUfC12l0DM8URSIASE5aTqdw7daq3fhUW2u2McytqEMkA+0R22WMZH8OR0zxWll0Or2kVojqtI1SO21Ww1hoXt7eRPIDFcBgvBP1r6D8NXNvJpw86bezfOgc8kfT8a+Xo9J1zWNQtBfwtY2tmGiheYlMrx8oVvQV7x4dlguvhpBLp02HQGCWWQF2ypwR9elc2Ignb7jyMelZNHZ3+spBZKYYJJppsrFGg5Y9znoAPesrS7mW3kCLBIJ2Bdw+CXHfB9RVnwzdq+l29pNtNzGgLNjop6A+hre8qLKvsGVGQcdK5G1HSx52iujCaY3qi2t5Ss0b7mDryQD0/lSSCUTME/1W3DsOdpzyRUs8jRTh440VsncUPTNR2bQm1k8pyAm75iOGIPP1qtkSiprZa8Bj4WPzAucdcdzVWWVFhaK4j8y3JK4AyfSrNwWlthLhiGBJA4/OpbaFZLRSOehHoapOyRR5Rr2hfYLuSa1hBjc/ebncOw+tN0y3W0njDN+5dWkUkbsH3+hr0/7HBLbOkxDpndyOhzXIa5awwSiCJgVkUlCvBBPBrfn50d1DFP4JHl1pdwR6jqpvZ3LtGxzGnzMR0z61X8QxzSWGlq00gmWN5S2BySeCfwFdM3hxru3uEtxJPqSZEKt2TPOT3NYXiKG+n1G7lurV47C0gSIA8HIHOfato25ro9aNSLkrM5/wAMzxXnizS7eHzBKJHVnJ4fPQDHQV2mpaq8uuyWb3ca2dq3yFIvkduvP415xazR211psls8jTQ3I/0nH7tVbtjua7Lx6iyS2M9vHtjMhilO3aHYDO/jtSsnUt5F1Feaudgmv+G7qXY9tOjpkMPvRe3IptzGt15MsM6tHIAsbxnIJ64Pp0ryyMqunO10txM4lCFS2wCP+9nua6jwpcldWNppm+exu41eMNyFZT94Y7+oqnT6ozlR9nqmbOvS3dhfPLbRQu+AcABgW9ea5YWNzevJ9gvfMu2Xe0YyMP1AA9sV3Edi6xO8pj34wGkVgCPX/wDVXKata/ZbqElN8iyb45Iz9/ufesomlNpqyKkcy3yr9uVY9RjUN5iDG9B95SPb1p2k3y2ml6hLNapKzSssLlcLkjge1FvBFqmuTSwW2LqbdFjkouRWxe+H1h0qS2kZIWCqXAO47s1d9LMqTinysY+vXNxodv8AazFbK3yQjzcEnOB9BVy0a7sWtDdFgz3OItwyXAyCQ1cncRx6rpTabeTQQ3dqSYZCNrPyPlx39a2p7ae1j0GyvJi8oDSKN+7bgnGMU+VGMopLlXmbvik+bfGX7MyztgLISQRgZ7dCK1/hhqbQaqcqskilizr/ABgjHJ/Ktbw9pbata/2hczi0sFUqZGGXk45xmpY59E0Uzf2bJtdoGkMk55GO+O2aylKKi4nFOoqkHTSueXfFfRm0i/W/C/abO7P7wlseVKzH73sR/KuIN2moanbLa6fbWwR8L5BYttHvXvFhqdndacsksEN4lw58xWO5GX3zWU+naXYq0ej2MdpPcTfvHgXAKZ6ZPT6CqjO2jR0U68klGSObs9MFtGNPMTKDicMeQSQMYPt3rW+KOg6lrvgfTrJ71vMsZCzJEmYpGPAJI5B+tY3izVLjTLePTY5DDHCwjjymTLk5zn0ri/DHjPXtP8Rq1zqNy1pI+24XG8bf930FLlcmvMdWEppSPS/B+kPpPhswXMp+2KFcxjO1lTPWuq07UEuWjitGKxvhSC3CqxwcH65rmdCdLmRCXYmWJ3zu4jA5JX6+h6Ve0GF9SbZaIVUn5c8bxzz/AFzVNN3uc1ayT5j1LS9OFvLJcwhUggIjVccNjg1g+MtZnjieCFTIMghQ2B15H0rd1K5NrolrHFIIlih+fPfjk/nXC6lZR6loOqxC5xPKGEWX4Q9gCfXtXPBXd2cNGHO7yOb8Z+I4hJaaXDeNGlqS99FAgHJOc8elcNrHii5uNfa4sbWNUMSyIJxukdc53cd8VllheaZf3cLPbXNu6R3CP/dyRwOp5rY8LaBDd+G4r2yR31ZSzE5yOvHHautRUdz2oU6dKKOk8NeQFutSkn89pyVHOBk9QufQHpV2wYRXyPAzC1RgE5+4cHOR3yeapKttpdhDbSSNLdiQywxGPaJJ36nHofSrqasssn9mXkSW0DnBZDkrJnjryKzeuwmr6mveywQSSQzWzLLdSo+5FzEy4GS3ocisDXkEemaiLYKPK2bVzkEcjODyeufwq/JdWxtVe5jUzRNsQhzmRemfccVHJc29xK8FzFGrzKUDtyTHg8H3pLTUmCcTzfU9PlGjJaQusk7qJFRpNrR8/MMdMfWsO2tpEt5FumVoiW3KDlgRjOa7jxV4WLNFfWt75jR7NsZHzFenX296pt4enu7iG8uY9sNy2JBHIDIT3A/ujpzVXT1ud0ZxfvMbo7R6h4TtrN2WTUY2DQ4HzQqMjLDurDH6GqWrw2epXr3L3P2e6gs2Ux3C5Msij+EjjHPFd1pMekac0N35S/aBm3cLklVUcKT7cfWtLU7a0tZPMhiiS7iiM+XIKujjkEe1OMktDmc1F2SPPvh7ew29pqzywl444kMLc7Y3Jwevrmup0a8W/wBIa3Mgj/s+VoNq/N5kQbPPsMkVR12zu/8AhGVisrcQRyzqshhTAXnKjHfJ71Y8IaM14dT2yS2tvEFjmPG7zWHU+3qKckrOTCTi48zDXdeSwtb6ODTbkO21orwzYdcjCsm0Y475rMt9BGp2cM8UMq/bY8RSS5PmupywLfnxUdxpF3BNfWoE0syuI95kOzaPY89/1rr9F0W/tdLltkiuRaWqGTzWcbV/vYHrmi6itAco01dPU3dD0dNO0SK5bTo59QEZkeSYg4GeF/LpWmNH8PtZ2x1MosUyu8kEh+4x5NV9K1H+yfB9xe6l5k8EKgRW0mNzFjwSfqfyryGTVpNR+2IZ3ZHnUiV3J8oHOR9KyUZS62OWFOVaUtdj1+48EaRDbDUvD9y72Jf/AFZc4A74qt/ZDWl9bzRASxxMJPIz99e/sPoaNDkvJ9YtrWwDS6W2ns654Iccf59qh12WX7RbWNhdh7jYGMuch2zjyz+ppKUno2ZNSvyt3LWpDTphPeyakkIlTy0huIyjL7Z9PpXPWkEbMYbgW91FN+73RcYOOCDWqltDPcxQXLtLCZUViw4GQS2324qtrRWbVnjgjMMdoyuihcBUDdV9apLSxELUvdiVrm3hk1VoXieZYbTy2BO0M4x1PfANa5u5dIP+hQQW7SlfnUAFuM4X3FFmkOoXF3E8AM8jee2DiQgjt6dBWDrn2iy0G5lKbHTeygndsUjBIz3+lLfQ2XvtRY++lj1LxBBDdTgLcqRtumyw446dDXVfCx3tb/XPDkpeJZEFzAQeVOcHH4YNeNT2dxerazWVxGpaZHuZdxKxAD5Qf89a9b8CaouqeMtGv4Ix81jJFcMBjLrxSn8Dt/TQsZT5YWPRtIjke2zv826QZuAMKzODxn8MVvOrKCZGKg4JXNR2qLHcSNGFXzSCwA6kd6qeKbv7JY+aVdtrDhfSuR+9Kx417lpkhVZJPukjGcdR6VgrJPaxSpcsp8x90YVfug9qx9Q8QxLLEk0rR/aVMUS7sbm9h61maNq12DDbXTl3djHI3Ug9vyrVUpJXZsqUjpbudxCIuXQ/NuB5BrI8S+JE0nSxGqNJJIhUFRnyz0GfxqfUJV06K6aPARkwGzkhj3/rXMTWn9pta+ZN5vnDMLqcAADr7mrhFXu9i6UFLV7GbL8Q4dIht7W+3TXUj/vGRflQZ5Na2l3a3l4NQmk/cFco23GFPQHNc3oPhu1g8RanPrtuJYjve1ducgDoRVC6v0thbxwwHyJLnfHEWO7b6kfToK2cY3agjslShLSO50uo3cNnPItldp9rmk2Im3mIepP41x3iWX7Qs4t4bu+glQtcrHkFSOGbA6r7VveIdStrB4W+zuTI+8RKMEjtnP4Vxuj3eoXurTrdNJFObj/VJwFUn7oNXFWXObYeLepymjQsYHtYCzQXM68MMfdOR15FeiWtpLeaG0WsIVC/uxIRt2rnhlHeud8XLO2uTR28EUNlZyAzOox+8P65rsdL8RReIPB81hYxH+24dzsWXrt+tTJNNPZflc66s7wUor+u5Brfw41JLh0stQinsJwhdJs7o8DHA6Yrb8O2+h+FYCILeWW5gRvMlCbTu9FH5Vfmj1FAoldoY3QjzQc7h6g9q4fxJMbHU7RJBmGQEmRznc/XOe/HalzSmuVswgnWVpO52dpqcF7HFiQ2zyEMI5OgbGevb6VWn0ObWbozgpFEnyF8bt2ByQPwrAS9zpZXzIZnkfZuQZZATkYrpF1X7XZk2m1ZbdMxlW9OMkVMo22FKMoaxOZ169tdK09RbS+QzPKu7yyGlK9AvpWPoutrKtxFcj98q+YyN8ysvcE9iOtdnrmkQa/BI+rK9tDbESx3UbAFpCOcAdOa8rm1bUtJultbxCyAMDvG3zAe+e+eKqGunU6KVpx8zsLvRl8Vx29/o7Rx3UAJJKkq54A+hFaug+G7rSLi5v8AVAl7qDW7qhUKERehOB1NM0GKTw14Mv8AW5YwFVQYIycgk98fjVLS9d1SS1ge6MTPcRAA7cKE7jim27NLZGL5p3UdjvzKLnTbCxtZd0MabjCF6cZ69ua5HXtMgXUL46u7onkqFCvyDjIx7Vt3QtrbwzpJlRP367hKAd6uegz1xnFVl1WJ4i3mpdWzr5cqzjJJHcE1ndp6GNK61W3/AAThNKu7m3e3WRttqC21FO8DsMjtmu20+8uJrRLZ5U8suVZQvzgY4Ge3U1X0rSdMkuJDCjwK8n71ZDuU9wQe3pReldNsri9dPMxMyxGJ88D/AD3qptSOiUlN2tqSeItPF5pFtDeJDNNCRJDHIcMY84AB7kYrmLDQpo5WIsVWRmZfmUfMOxH5jNdJHfWWsWscd0s9q9svnJIRuKJnOMD8a27GKMz7Z5oTFgSxyg4O3jqOxzilGTjuZuq6UbGf4a0O+WGysxC0F5EHieVe+epA+mK76ytYLFYYIogm1RGDjrj3rhtW+KOj6BfJZ6awum4+0TKm7y2JwQxHfjtXZQahFrOhwX1nL+780Mhxk/KeRU1HJq7VkebW9pKSclZMp+J7lLlo4Y2UMQEVh39Dj2Jrk7h4/soURO97BOiyuTgOATh8VJf3kIvJXkZ/OZ8DaeQo/kazH1CzvVFrIsocksZGJGUGejdyOOKcU0jupUrJFTX1stS8RLa3+nR/ZWaKOWVf3buMZGCOorofFF3ZeF/D+lPYwRQ2zTBStuoUnjgMfXg1gwCPUoxDqSNI1tIWWRcruTGF57461tah9iu/Cz6erQyYQSKXPI4x39KbexrOKvHsef8AjK4+wa/Z6zBObmB3854myDHzjaf6GrWqafcyJBq2mtIyXMIu54pGUG2kGSvPcEVr32ownRIzbJazzJ+7JkAym3pgHrnHSo7m4S9soZXRraK/Ty53jOEIU8gr9elaKVtjpi3ZCQSRvZW99qUzBruItEU+6jY4GPrnIqPLy6SvmARSxP5VvJt5I74PU1sxDS9R0C2tolnKWM/lLIFx8nU7h+NautaFE2hbkcBoW8yMKPmkUjHI7c1KkloYyqqLVzgbC6NzZSrdl2WI79yttl64x7+1aUem20wtbOK6/f7S43eh9vUjFdBH4Oe+u7uxtYw7QsuMqAGZsMPwAHNbreBb61EBaZI22mN1iThR7HrySaJSinuTLFU72ucvo1hF9vC2kUkUe4F/Ni5bI5Na1zGl5qj6fDCvk3DRRl0UM2M5PPata60jUIowhDqsYBjAbBIxjBPrWpDDY6bHFO1nIt9KEDIy5UcH5vas3NbmE6qeu5la9YWMT3VvOzIkYDOeoZgMce9csLUaVpEMelmSS1ug0k6HBkd2IK9e3FbGrwtAx+1yOkM8jPKgTgnPy8/lWLPJGkGy1LNNGMyMOcLnr9BVK9tyqS0IoGa8uWMYP2hWQsc/MjE4Le/HFaen+ILiwj1ay1JfLjuGEEarhunH69a5O6ljs1guJXuFScOhaNfmPOQV/Gp9fvbQX8SrDPP9qgjIlI2tGw5JH1NDjd6nQ6anoXfHGrB5bDQ7zc1qyq82wfM7MeOO3QZ+tc5pttbRprFvIi2nlDz2MTblIxlcZ7cD861EmTV0insY3a7t7R1y524mztIz34rP0O4uI7eW11TfHfRhxOHbOUAyAapaRNacVGNkbvhjU57bTbNo7nyZ5FMTxbiQUYnkenQVJeW91HdK6r5bxDfM2Mb268enBrlkvElm3QRExsnmRSlsZCnoB610SXp1W6ubtYVCOSsoBPHyjkfpUK6ZNSnZ8yNeJmNq7NM0sVpGQp6mV2POT7ZxUc8zQXUEQug8pCqQDiQH056gVki+TTooJWaKO1lLkp0YkeqntjkU3T57F7s6hIzTfZ8NERLu3SEZx/KqV0Yez6milwba6i1UMFaIvGN77eGJznucYzXPaxdyT6k1hJLPLIimUktmN0xlQKvRkJZXuoaqUlvChQoDgID0/nVKPVI7CTTbkQpcL5flsHOSB0zj05qvQ1pxs7lXQ7GzuJdPs5JDHbXjNvVDyz9ifTBxj616P8PLV9N1KZYwGt4j5aYP3s8n8c1zmpPANet5IVWA2480l1AEbED7vqK3vCNxdw+J7URRTPazL52SpwVz94H19amUW4OxxYytzKx7bbLly3QCszV7QakfslwpaLJJAJAI+tbFmp3O5xhxnFMu7WORt2CGxjgkV56lZ3PHR4l440q707W0MyCWyjZJbNh1Rk6g/hmoxdTRSQ3j7okdxIilNuCchtx75Nek6zp95eTSP5UNwmMJG4xjjrmuJ1HQGieS3mCPISSSWOFB7gGvQjUUlqd1KsuVRkXdfaZ9OnRnCbo+GAyRx1xXE+FdZF1AbWxikeO3iJ+0tyQc4IHoa6HULa7+yXEsbuI2iWONgemDyaoWelLpFs1vCJVM7CQSY4b1GKUbctuptT5YxaZb1q/t4bCKJpPssNydjSyN82PX864S4mvovE+nxTSIUtQZBO6jEinp+NdlqmmC61KK5a0E8Ea7Y1Ycbj1Neda5KTcuGMhEbbjuUgKueBmrglayOjDqLdkX/Hmsy/Yb6NWVbyB44vKPLbT8xPselQ+B5Zb3xBFrL5BSBmktxkqCOFP44zWZrSy3txdXwKLcKELeYMCT+7j3rpPDVpPpex53Z5rqPfIUAChcYA+nNU2uVI15fZxOS1k3FtqF/dQRNcyGd5JHb7ig9D160/4dXN9Y3jXMMgEcxJkfIOV789q17mF7jUIJtPlhhmUtG6ygupY55PtiptH0OPSLeVriRJ1Qbm2qQpY/0qqlpKxspqEbPtY9Zu5BfWq+ehgV/kkiLDIA6c1k6z4Nj1ewjXyzFKT5qxbs7OwbPvjpT11U6hFaTW1pGGYhBHOeHx3+uK5nWfEWo273V1FcfZ5YW2ssh3fKOygda54xd7LQ46MJ/Y0MNtFutNv5IbmKdIgc71csGJ9Aa63wPGILRjbWRnuGG1l2knYak0XXE8U2qCeSIX0eDGJE2iUen15rI8Z+JpfB+gQW9hMqXV0SsGF5iUN8zH1OelXKUvhe5rOcqnuNanXXdvP9mEcOm3gl3gLuIAUAHkjPOa5ywhlvdRSfWbVWiycR5BIIPp+Ga88vb7W7Em/N/PqFlM6SSTuSJkJHTrwfTtXX+HfFj6pEJTAbq4Qm3kLnDugOQSB0O3qal02kHs5QXqYfxG8Q3txu08mS1tHlwtugB2rnIJPv1xVCETW8SXEjlo0b5QDhTxyR6V1viDRxfW/9oaY0V1c2SlXhl/5bRdRz/eX1rgrS7ujZiO6WSSCR2kWQHIh9sdxWkHdWR1U3FrRHpt3dbvAnm27y/b1iCoB8wSMfx49e1czAJbHwkLtJoJpnfbtZueeDuWtmK5GmaPC8itNbshiTbx5kjDKr7c1yOrTIrx/aIRDLc4kkKKQsLg42kfnQk9TKjHp5nWeF9V8y8tYftAcAFXwMiQg7h9PSrnjXzY4GVY5Pst1IZI2UjIIGScVzugvPLpkmoWtpEiCUoSowwIOFx+HNbGra7bs+n28iLOsW4h8cg4wSfQiplF3ukLl/eXic4jMkcs8bPb3AIV/LkDDy8dx6f41uRT3Nzpccsby79hgkwvUYyDWIkP2idTFtAJwyoeHA681teH5rt9Xkggj2WyqQSVxnOBkihJvc0rtRjzI8w/4RXV5L6C0eykZpXO11/wCWjE8E+1fROnWg0Pwhp2lJMDcWse1mUZ3OeTgfjXUXFtHbQ2qNGkssUWAcAkA+nr9a4bxjcTRaQMBnmklNuuH28NyeexwCM1PtOe0UeWp+2cTm9Q1qza6lFrLHM0TYuEwysvbIyOce1UoEF3A8lndJNbdX2kkKwHfvisLStTRLzXbO0tsqvDMpMm6MHnB7HPOa2PDGmQ/2cLZZmDlXbaucqCcqQe9aSsloelGPItDpPDunmaxmlmjiMSxq3kvMw29ycemDVXWLNDbedbyyW86SIsQjQlHQ8H9KueEJmh1O3F/tLyK0MykEbmHRV+uBVu9uUuRLGUaKaEt8nLeUTngD1xxms22mZ3amzigyPI0s0KySJ8+VGQ/uR1FdVp9y2q2EEc1tvjVQyKpUBG9h6dD71n3ltMI7OOG2H72P55yu3AJwFJ7/AFrQtIPJtWtZseZuMsJ67wvPUe1KUk9jWTTSZq22nGyto7aO3KyNLvmIICuMDIOD6c1bngu5Ne82EF7doPL8uRvlXBzkfpWcuo3KaTBcjyXlmk2gMSxIOBnHUDiqy3012JraOZ1hMwicd1HX+lONzknCUtT0b4a3EDx6lIro9wswMm052nH8vf2rR8S+L7HSXZJAZpgMsiduM8muU+DEKvNqy7XTzgE5GCVIOCfevPPHctxBesuWDMWRufQ4rGUE5u55nsZSrclzt7j4p6YblEu7N1UcgqwbHv0rS1bUrPWNFa/0W/SSaFdxR1zkejCvnSd2ldmckH+dbPgrW59K1eJo2ym7lCeHHdT7EfrUx5b+6etLL/Zx5k9j1bUDa6miQ3NyfJjaPBQ4AIGck+3NZstlpyB5La68uJ0fz7p224Ddhnr+FaXi3SVsLi0ubElrK9XzolZeBkcg9s4NecePhcppOm3FvuMMW4SKAGVCRxuHT1roguZaPcVKKmvdehc8S+LdBijsrSydrk2TL+/RNiyISMrz16dadYpDem/1eK4jOmJFtSN2+dMHcNv4nmvJre2ub24Ted0CIN7r0Va7jwtpB1Hwu8NoAZw7SAE43ANhc/rVuPY6oxUI2udT4diXUNEvobbKKmXi34DMQ278c5xVO902HQfFIi1Ly5HuLdJpcscjKngD65pfDd7NC+nMI43s3do5WIIYHBDA/iOK6Pxp4fhltf7Smd/NhQssrHJ8sdFHqfT8ajaVn1Jc+Sdm9GcJGEW8t4nkBjlV/LfysBSfur9cVraMslhNLpUMxRvOVpFkTIVQOWDfj+lWpWeLTI0n0uPYSWjbod2R37cVNrG14ra8fMUcLJuC8iUkEc/57U0rjnUvocp4s1L7f4khS0gh/suECEPIeMj7xJ96m8OB7u4vJLaJUi83yNrfdQ9Sw9gK5S5guZ47y3LurCUyYK4B655rpPBVlPL4cu1ivPImaRWUtg/MOeB7gVclbY0a5YHQXOm3Vpo00caR3H2s7ZfmyBg9W9OKxILCw0mzmj1KUyXLRk2jwnCg5/pmuxsryyvrEG8ZLaW4Ad7SXKAuOMjsBxWHZeHtV13X45gscVnAoWORyDHCvRiR0zRDvLSxz+2smmyTwrpMvjDWNPtXuH8lnRJ5tp5VFyR+OK+ndM063tbCKCOIIkf3BjoO1c74F8O2mi6fHb2ceI1JfzDyzserfjXYHjvXFiKzqOy2R4uIq+0loBAUdqrSSKCfmBHb61U8QanBpdn9ouJBGq/Nk+n0rHvpJNS0B/sEgEgxIG6BlPPBrJQdrswUWx1vqpttTW3vQIZJVLRxg7gOe59ak1jT0vCZYYY2nI2sT1ArirKaabWY0mfzbsYjXK8oP4j/ACwa3n8RLb273MCPJCsywO/p82CfwNaOLUvdN5UnFqxlWtrcW+lTR3KECF2Hrj2+lNuN6mFtjLjGO/J46eldjcWhu4lulnYqG3PGuMMO4NYuoReVB9ptCRGM53DBz2FXGfMxc/c5uZLqzTYyqkYYhue/bFcP4m0eS7uniESGOUF2MZwQRjAz3rt9ULajHa3Jm8qQttZEP8Xc4PejUltoo1julZxwgVD8w3d62hJxex00qnI7nkK6eltptywupEkutkYaYdCCDtX8utdLMIdPtLcp5tw0y+Uzod3ljqevpUfiy3lkngtLKJRboWdy6j5R2qLw7qdvPfta4MFzbD5ZJM7T6+3IrZq6ud0pucecYbtBH5yqqW7Ft25MGX0+lX7B7K4tiLWSRkDhx5g4xjpnuBXSS6RHJY+ZD5LxlCNsZ3BjnO7Bqi5Syso7W2t1Rg+BGy4BBHPPepTT2M3UUlbqZyvFaQpFDcy3DyJu8k/eB25+U+nrXPSCS81yIm3EfnfOFlc7lwMY/nxVi51Sb7BBMZIwsWUSMLgoO+D7ioNP1D+1Jpb23SQrp0WZGY43HsBRDV3O1QcFd9R+hRpY+JbqYyp9nQFhuGdvuPenfFi0jvksNRiVljhBSd8Z2Z7gfXnj1p1rbtqN/bXkNvAn20RqEViNpJ+9zxXUy6asNxcp5jyeX0DICFH8QxRNWtfoZyqJVOc828FanYadpl1DfyI6O+FZ8EN6delSeFLQW9zqt5b3Eotnb9wyj/Wdc4/PFa15o3hUaolvHHCb133CJ3IGCOMrWkixMFsHgWK3RDslUk7Rjp7e2KL31sOVSOtjudKgjOm2btDFbqBmOcD5i2eVPsfeqWteCbGK5TUwsMisSQ0ajZjOTuUHGaqvHeanbWtnpMJEKkYmlJXaR7d663StMntrF7XU76HzZBxhMqB6YqJe673PLnWlB3izhdaQ31tPDGUMkE4eOLGEwMYf0rI1C2eO3v457Nd88bOzk7v3pxjB9OK9Zl0xba0VbwGa1VvkMKYYn6U9NDstRtI4rW3NvNy3nTk+uTx3NP20UthRxjhsjgPDWnW2n2VpaRhpIogslw7vhS2c5x65rqdO8LWevXcj2sPlQfMHdgPmz1BFc58S/Bet2M9tf6aWuo2YK0cKHhvUj+tdz4RN5YaekUafMo5yOp70qkk488XqKpObXPGW5Xg+FumW/lK15cuEJ4GADn1rKg0aCzSWwm3KTIVMmTyq5PXtxiu4utVmtLd5Lk+WRyNy/KfbNcrqF7Be6lcXUqyW8gIjELAfvQRzj0JBrnjObfvO46cqjXvFNLiLTNOVXnMaiPeWY5YccYNZc9vb+JvDlxZ3DqZC27IOApHIPtXJ+O5Ih4igF9I39mwhVSCNSXXPUkfQHFYOi6jqVhJPqLmW1sDOQA69QOhI78Y4rqjC6vfU644d2UovUmsfDt7YuLVvkf5wxQgNJk8A54xiul060SIW10jq00YVSueemOcen9amHimz1CS3nlsp3yDGfJUMMY+9jrjNYMepRSwyGNjE5yI/PGGZQ3HHtSlzP4kdKc5qz0Ny6NujxzJI1sUi85ZGbA4PWq1/r1vYRW7aOPNudRAkPm8qB3LfSsbXLv7bY+btRFZVt1VmPzJnnA+vNYVzIbYG3jgYxKQMg4YgHBwfTOKqKVlcuNC+5b1TxFdwTL9q1i7u4ZEZ9kDBI/ZeB2NbWla/aR27q0im6sV8yMbd29W/hPuDn8K5iK0mbVZdPuIMWkT5EmBuZTzyehp2n2qz70C+W7zPvf8AjMY6Y9803ZnQ6Ubdj0Kzury4ukUC3hYIDnqOeQM9iasyKrzzukKIjDJ+Ygocj8+c1irKkDQyIrME2NGFHXBwd49cdq6JnZ7ZpFYAK7MsTHse2OoqNEcdSNnodF8OXS28XymCRvs88OMA/LuXoeaPHXhYatfXTWZU3LNvEYPU+3+Fc7pU0sVxaXK+XGyLtwrfNhj1x3PGK6Zbu3upv7Tt5TBMvySRPnazAZH41nJa8x5tWlJVOeJ4trvh7UoIGS5tJIzDJkZXB9xTPCPha/1fVIoYIXJYjnHA+te2P40mMAh17Q/NZSAzqwlBB6EZ571LP4ptYbeSLSLZbfYQHbZ5ec1KjJbL8Tq+t1uTk5dWY3xZ8R6V4f0zRtL1gXcNoCipfrD5sDMi4ZG2ncD3xjkfQgcHeeJdN1CNoNEvLCUyoMtGf4c8hk65/DpTvGPifStdiuINV/f2axMI4sELIR3B7HPftXzxqmnyWV6wgWTyi+I26kHsCfX+dOSnRV2roxiquFipNXR7rLFosN/DG+mopjOHZlxu3DPK9ABWz8LP+J1rN5HLarHp5uBajySBInysVI9RxXnnhbU/NsYNDvlum1h3WMC5fkqSSSpPXsBg9q9w+GXgK80fxNpWoyyf6IsZmPlnC7iCNpHc1s6kfZ3bsa16sZU+a+pr6p8JJTbr/ZOp7HXkJKuBn61R1TSfFNrBHb3mnR3FqsSxPIh3BgOpwBwa9gur62t9/mSr8nLY52/Wkhvra4t/OgnR4+hZT09q5FXqW97U85YiorX1PAJVNvbpFcWsiRljkN8wRc/KPc1HHYxamGtJrpYbZoxKQB829WwAPrzXu+oalpEAUX1zZqDwBIV5rldV8ZeDrIr5ghmc52rFCDkjr9K2jVnL4YM2jiZvZHj58I2T6dcTbg05Lo0bjEjAEYYDpzjNO8KeGZLee3FnZ3N9MJ+h+VYx1BJPBz6V7HoN1p93ai/NgNOtpSWjEwBds98elbttqWlQnZbyx7jgkKMfjSlXktLFyxtRJxZyK+CrvWJ4W17yTBHyIQoJ9vm9B6V1Vr4Y0+DT2sRAptmbJjPQj0+lTtr1ishj85fMXqM8fnVCXxdaKZBGhZlGQM/e+lYN1JHHKc5G5ZWYs3ZYWBgPRCOV9gfSk1TUINNsJru6bEcS7iB1PsK5W6+IVhbQCQ2d4wYhVwowefrXI+INftdYnuYzdzor4lSOZcRLgcqceppxoybvIIUpTeo/V7u88bahFplsksaeYJJZT1VAc4A9+Bmu58NT2Er3Wl23mI9oRDIjgj5sdiev4Vy3h3XbDTokw+Jzta5ZVyuzHCg0tz8SfD2lXjq8uW2mVywwQewz3q3CdTSK9Deqr+5BaI6b+ybTTdQnu3VEMz/Kx78dP0qhf6bZ2WjkQndHK3mArgg7jk8Vz6fFTw/rNvbLco32eaUAnIPl+57jiuwgis9fsF/sW4hkhiX5CeQSOg+lKUZwtzqxn78bc5j6Jr40idNMvX8yK4OYZTjK+zV1MVrY3kTKuWST5ztbg1wms+H5VhgvoLIz3Un7tI1PG8HGWz0HetjTfD+o6dawztqey7h+ZgqDyyndcenWply7p6lzhBrnTM7xDoN3bvdTEs0LnbEiYyo9frXO3tn9n8i4aQNMRt3Of6etewKyXUWTGGRxj1rzf4haOmnXVpID/ocknOBkhjxWlOpzuzIpTu1Fnn/i6zuNYjTT7SRYJFIMsrtnzMepFZWgWMMGpJHeyKCSfLX17H/Jp3iO1mtbuEPPOIfNDBl6tz9386utALvU7G+hb/SI50DoQd5XnOe1dafu2uepFOMLLZna6ZY/Z5ngiVoo1Q7eeg9RUUkayOTcFXA6kdiOh9jWtp0/ni9H2Ro4z8nmE9MfxD8e1WINElbNxdSxGRjvZ0GMrjuKw50tzzuZpts5qX4U3r3HnG2LQAcIZhg+vHat+HwpqOl2TQWOiQJbFCrKhQ7s+pJzXpOoaisFt5mfkbjPSk0rUIrxNqP5hHXisPbTau0KeLqSs5M8kXSL22vY7ibQprhIYwkKLtAX1wB/OjxAt3qdtPbpbXGkkDzRLLGD5gHG3Nev6hGvlHyhtIHbiuY1FllRIXkITqSeeO9V7Vz6Equ+a543D8OraW7W/wBZuM3AUGNk6j61atrxrW5e0021W5jiwZJZ2Pz+u2tbUGm1fWrm2tVaOzVdjSnjb7j3NJZ6PDpsSweezp1kldsCLNdHNp733HZF82s3dmjpPi3TdTiNjtt4bkEr5cZxxjk5qvqumtZxq8000jMTj58KpxnPPasiTQpdSvFFqqxCPciCNxuAxwwx1Bx1q1p1/NrPh22gnjljeCRY2JwQ5X15zilZLWI/ZRi7x2NnSNclS0jlhkD2oRjK8rHAUEZYe1Rt8Q4pr5obO2kljQbkcY+YDqQK8/1zU31qa6sHu2t9GUnPkjJcKccd8Z5/CudTWEsLwaVcagqXMYO+ZoimUxkIMdMj1q/ZxesjRYOD1kfTuieJrO8hjSWVBvUYBPT2remgieENAF9RjvXzR8NJZbqx1Iz7lFrMhhiLZ+Vs4IPcV6e2savo7x3VpFK1oyKWjYbwOOenI+tc9XDpP3WebVoOlNxWtjpNXla7t3t4E3/NskYjhB3PvXO69psk/nXEiSIWYYUDlUA+U1t6d4x0ua7VrqN4pGI4K+3JxXVNLY6hAGV0kjPRlNYNSp7oqFfk0seISaTaeIb0TKXVkcRJcpwW4yQfXB5rl/GfgrVIbS4ngZr+3km8whBhkPQkivS/jDajQfCsV7oVusTwz7mdckRg9X29/wD69eL6H8Q9XtdfhNw7SWDLmSB+SR13Z967qKlKPNB6dmehSqVJR56eqNDw9Pb2kcqW4lsbh4RD5zndtPXgfXiq0mnmDWYpJN13Kync7/KgznLfhXrfifw4XtmksbRC0yKYztwADg5+tYt5p1sUiSV280Rhm3LlQ/p9KXtU9Ua08TGWq6nJ6tpn/EkRbueNxIyeR8vzEHjOfwFQXkDXYtInljFxBuRABjeuBx9P61f1GF7qyit4wAseArE4YHdyR9KyjaXnnosKyMzMYwSO4PPP60X0Oqm+tyn/AGPqSWuzUdkivIVMxfdtz059u+a2PD9laWsluZthuI87H52qM4AH4960JF3o1sZnYn55VUZHpz9cVla1qC200aMEM6w5KL0XByM0K8tC+Zy0NmS0Syd5Z7hVikfzCGG3IPpnr7fSo3nkGqaeZGDqjc5IAIwcZ9eOK4XXfEVxJfQNcPBcSxbI/L3Epj09O/NWrPWYLCxmR4t0E1x8jMcrH3IVvTgfnVcjJlB9TrJdUkud80jiFEZgo3YwDgbRWjFqiQ2USIS/mS/PIW3Dfjg+w4P51wFrqcl/DCtxCPKu3+zRkn5twOQ2B9fxrVivGs0l3uVd18jywM4KNwf5mm4kSpJqx1Yv5Lq8hs3LHL+YWTgxAYwKtwOsSLp95uuLiaOTa0o+VnYlh83tniuIl1NkuZZZPN8podmerDBGfqK2tNuLqz0/WnV/liWIxtJnIU5Py+rcdaloznS5UeY3KW7+VZ67I9kLT92AiEkkkk8envWxo9nc6jImkackV6xeOWWRceWI1PG7I64xXoUrxa3Zr9qtbQCRl5eLLg8En2H+Na+k6QuiWBubOyiilmkIXa+cvn37cVo6lumpNTEWVuoni/wl4du4odBvbNXMMEfluow0b9XYN1HX9KfHf+MPhlHHAkreMPCiKCCoH2+0Tr06SKPz/wB0CqURuL2We+uZ3N+DxGp4UepNaR1JIhLaNb3MyJESJYQPnwOcfjXLOkpep5s6Ep+pow+IbHxjpaavo12fsW4iQupRmI42H8amaW5itEtYp0s4928mQ43FjinWGp6HFZTJNcQh875LSQhSrdSOOpOc59a5LU/ETa3e2zSRoliFcPleHA+7j1xThF/cXTpSl7ttEZ+qaWNUVoZ7kT7GCxsJP4wfvgVoWWj2mjzxanfbZDGQcnBVfrn19K5PT9Sc3LyafAnmBWVMNgkDkgdhWXq/igyabdW16DEk7iQjO7Lhsn6cY5rd8z0vod/sJWsnoeuHxFCbmaT7VFLPK6eSJAcIp5xgelc895dXdzchrgm4aAyKYk2jbuwCfcfyrkLO9tpFiaC5aWVnIjUcsoIPB/xpur39wdGjiAe1gFwsS/PteY85beewzUxS6CWFjDRHZ+GtVsbk3yw3BZLSPzZm6hjzznsKxNf8Zyafqn2a2t1a6lgXLgYRF6hvpj86x7nVIbHRJ7eylWCEBFcxcMyk4bcO4x3rmtevJYtXvbWO4jdZIEBdurpjoCfbFUoq92XHDpz1Oz0X4g65quoR2Ky2EdsQ6r5EGQ7KMjOecE0/SfF0d1ZC5vYYtN1WGYxSvEhVScEgEe/9KwPDVtpnhvSrnVNQun89otkEW0KWY9RnOeD3rJtzLJp13Lf5N5qEyyqcZ2d935dKXutbFewhz2itt/U9Ug15dQs4jJeQsrt5brbxAM+euPSmanBoO+aHUIbVkhjTLfwqcfdc/wB41wfhadf+Ep0xxDI9tCGSWVhld3r7DpVTxsJF1O4EjTI8tzvZV/1fB6n8MYpxgr2IeHSnZG1qVx4TgukhsdALqqbpjtKsDjgrz0rX8J+LobGOJNGujaFV5hZcBcnHB+lebW95cPLLN9qczQMDvx1TpgevWrktxHqAgjs7Xy3SNlEjAL3zyf8AGqsmrGssLBqz1PoK08V3TKb18OUK74y3Lqf41roNP1+31GxdSCOGyXbO5DyDXhHgS6e6nkguZHHkSAAq5BZa7G3hkhuCHMhtM8TKSMdeMd6wlSjex5lXCKLaPWfBcnk6aiSzCSW4YzBQc7Aewq/4q0ZNc0qS0kJG7AJHXGc8e9eb6drDWEUF6Su5yFBQcnaMYx6Gum0rx1BdbGWMkE4kzxt5rCVOalzxOGSaldHA+LdKlXUZY5d6iB0wwU5z2aqXhoDTtWluri4BaQkkt2I6cV6p4ue0nsluxNF02hie3cGuF0KTRpba6a9KE2+SjyJ97J7YreMrw2OuniW4NM62WJ7uyt57eMBAAXGc5/CoUmfzpUlTy9mCCG+UqegpdAnU20jWsoWBgJNzEEY6AD0rT1KwjuLZWdzvwNu3pWN7e6zne9jk/G+p36aPDJp5naFsbUlXGT2z3rpvBC3y+HLeaeJVmC7pFVujf/Xq01uslgs12z+VMCpbHC++Ks2EsWn6REbZ2ZCmdx5LD1/+tQ5+44pCnNOCikSXWqvqSLBBG8Ts4Vtwxkd8Gue8Ryi2vFhQAg8H35rWsriaS5SaY+Sqk5j6/hXKeMpAmoFt3yZ6qSSv1/GiEbSSMox1aOY1bTkbXhbm7e3V3Dq6kgFvQ1zvxQTWLa+sk0+8RLaaEeZuYDc2ffr2rq9WtYdTV8o0zRQgRrkqd2fvA/0rlvEXhfVIb0CdZb+3QI8MchBAXHOCeproi1pdnsYWWqcn0IND1m50zTheXVmVmdiqs+QSAvX6c1paJuls7a9SeTzGl82ROm5QOVHtzWWsVzewOjW1xFYRMdkl0CG2n+EL65/St1ESzv7Zbi2KR8M/2cjcgK459qba2RvUs7tbmB4gtLiw1DSL+3ijbTod0rIo3SBXJyD64ri/EV3p9/q15cpA8+pXPzcpxk8KAAeMDFezu8SazGqbJRcuy7P4QuDgntkmuY1RLaOBZoLZWuGUyzPCgG0ZOF6UKW10OlVu9VqafheK2h021gnAhm+WFlAOZQACPpzk132pyta2AulvWWNFUSAKGJHcYrzbw3rMcc9tGbtZTHN5srsOjEep9O1dR4i8RQ6fp+p3klqWUoPLVPn8455AHrgkn0qaqlzWOGpSbqGhZapBqMUkk9qn7w8OB8wGcKRVCIXYluZra9khkiHKBuHGeOPWvO7z4jX1pYM1holnbSxAETSSE4Qjj5ema5u08R61qs32i8uJ5pJT67EGOQABj86qNJ3tsaRwknuj6Nh8SxtaPpesxJexyfI0bL82CO46N+Fc5J8M9F1TxCmqRXQ+x2qgJbKM5C/w56964rT/ABAs2sRJLzE0HmSKW+7wOVbsQc11X9t3Wk3lqDPvtGQzQSYG4AYyG/vUvZyg7x0uYTo1KN1B7m98YtcvtJ8BSXWknErSLbLtByoIzkfQCvGPAet6vql5FHe3DzQyP5Y3/e3dcH0+tfQ2jXGmeJdHl03U4UEUxLKpbBz/AHkPb2rI0n4OaVouqS32m3EsksnANwxJQd8YqadWFOLhNamVGtCEHFrU52bTxLEklqirINytu5+fPIx+VLa6PHJAyykQS53KHPJ4/SvXbLQrS2RWZBJMWLs5H3mxjOPoKZdaHa3Mu45BAIIU4Bz61i6y2BYuSVjw66hJV0gJYEhHdMDhT1rhdfimj193vZJFSfm2kPETrjC5Pr7Gvoe9+HtrKytHIy7fRiv8qzH+F1tNBPE7x7ZlwSwYkd61hWgup1wx8Yny69osLNHLJ9ovWkUCLacHPv8AlV+5M82nw6ZtWSOFvn2feRx97j9K+iLT4SWNhHmKaBJBnDlSTzVJPhJp4uPMkv1j+YuwiDDJPBOc1ssRS6s1/tOD6Hj2kJEmoxXbTH+z7CMzSIesTY2qg75zyTWvJOscEI06VHxH94LuYkknJ45PvXoNx8HdKlafy9WnjjnO6RYkHPTjJNWr7Q9D8Nxxtb3iN9mYMsQi3n6cUOrTlpEh41N3jqcJpOgX1xCs8tn5iO4Zt/y/Keprq76w2aS6t5c0suE2L9yNQSQM+pq9ql1N5f2po/NtXThYMhTnoGPasPVdd/s+VEUeYYkLCNQRGhyAWb1PPWo1kS6tSsyK1kj0yLffq1sky7U/iZpP4QPTNZMktxf6soa8nl8iF5ZI2ASOMngY9TnP5Vn+IbzU3upWikhuIZShIicHyS3pnoSPSqNxqf8AaBudCjt7lnjhOLgvguEBGR7Z796taanVCjs+5Paao8U5isZvMeGVSdp3FlGQcmtbxD4tudNimW3CNNbWqzyNISNodsLGo+nOa4zwnb27210bKYRzODE+eWKjr8vbOai8QyCe40vfKViubQQu5PEjxOw579DTsm9TSdNNpGZcXV1qEUmsNcuzzSZmZU2iI+nv2xXV6BcXepWt2t3J5stlFH5KjgOGydxHrgdKxNeksbeCK10GEwif5LiJzneVOM8njmt7wcslppmuOF23plS3jc8jjqP++Tiib0uzR/CXfD+by4uZobYhBEcxryNoBJwB1J4rz3+zHm0+7kWRVZJANrDB9T+A/pXXX9jNNd3I0S8kgiRRKy52spOBxjvnPFc3q9ndmwl82VY5Ub5mXq+eO1SmndFrq0W/h/Gk/imwSdi1rztZfkD4HOTR8QLi41DWEjhDtaQRELFnAjUdseuOaZZRLp9yWjcvFZW/mA+7DHb3JrN8RR241dfKuZJHeMNMUGQjnsKIrRsU43mrlrRpWe9tNP1BY3jlhK/L98oQSFNaeq6dFd6TavKJkktg8YnC5OF/h/8A11m6NDOfF1lMEA8mRP3nTAA4613F55sWo6lBbLG9qZnba4yEBXJP55qVvZhN2dmY58Ow2+jjUZ55ruePZ5WRgJuy3Q9eOvvVDWrdk1HTYbIEPksm9eqHnn14rt7toriOAbRPb29siKgI+dzxuI7YrNulbUJ7ieRg88QEYkxho1x/CO1UtdzONR3uzI+3zQ2V+1mNkMEp2g/LuwOQoq9Prtpb6QbjUsS3EoDR28h6njilmtbfTtFuBbMs80jJ5RdsESH726uI8Qy+frLI0e+NfkRS33SfQ+xo03KUVPY6UNd3ln9sWKzgCIWeNcHCg8Z/2qz4FivbqRmctcFfNVYRw4GB+J9RWJYw3/8AaDQIxDzZhdT0Hua3dFu7ezubq41CRElhhKRRxKAd3r+nWne60La5E2dzZQactqZITsmXBiVTkqc8hgKp3+sTmS5M92rxWsilI4uMnvn1q3ptxY3KfaNKiX7YsSxSYGS7GuRk2PbSQTr5DSXQ8wBvmXPBOO/SnBdzmS5pe8ddaawpFs+9CMZmicjCknhh7YxWmxthHJHKYYbhVLErNjgHqf51yPm2ej2qyTRKQ0bB9w+bIwF59Tmufivopr6W2uVZ7mabzCzdPLxwv40JX1IlQUnZHpgvIJgqC5M6FMgNIXRq5vxj4raa5htbcpb2SQl1WMYWQqOR0yaxrzzrBvNjdEt1Iddv8HYU+6sk1aBJWCNNGN0bAEBCT39jVRai7k/VIr3jttGNyNGsr5LiZLaZQD3UZHQ+1dv4a1ppLQ6ZK5ilj+ZWkbKyIOu0+uO1ed+G1vrawms75BGoTdEN4ZGH+zSX6yQRRul0kbou7EhI3nPAFTKCmrM5K1FOT5T3+fTw6RpNcebEhJATgeuDVCe1Xz44I3YOg/1fYjqCPpUenpff2xcu0gks5IQzAEjawGPlFR2Op213Ok0LbZBmGIty3HUCuFJnDZq5Q1u6uLee0thGVEkg+bOAay9QaHVZb7ZbSsZpdilWAAK4zzTfGErLqH2SW8XKASb+64HP61f0+FdN8MSG3wbjymKZ7secn8a1XuxubKPwpbnN6toz6fIIrvVlUzECFQPuDuAR3rNe9v4bS4t0WS6aHl4wScAdxVS/c3jR3GoRf6ZHEXyCduc8fSodK1gWsMkwlwwPzKOdxPbmqu3uenCi1FPcvwzmeOGcb2iKhSjDk5Pf9MVl2WmagfEr32sIqWzu8axBuXHb8sV02gzWLrFa3KrumO6Ns7cDPQgVo6jpdz1sBE27CBnbPl5OCR9OtHNYydblbgzkLi/h+zS28MDGTzVkRl67/wCmBTYIBPa3Lb3ikCNGyTHKyEchRU1t4cvob9UjkWV4pXCsjYMo28GspGazMtvf2k6yeZhpmUtGpxyQRVpX2NY8q+FmHJqM39lw2cFrHDI7F5FVfm2r2/PmtHxRdPpOkeHpUMjr5Uv2hlJbJbG76NVa0gMUjXEF3CrzbhuDbTgjgc9M1Aj6xfMNO0y3knVXLSMB8pkPYE9QO4qvebOl8t010MHWZk8RHT9K0hHndGKQZBLSlsfqP5V3E3gm2sbG08n9/wDZI1WRkYgyS/xEfTkV6R4M8H+TYxSJZwRzygu06JtMXHO3vzz0rnNa09LKSWTTJtsMOdwYnJXgE88dTUOa2icjxSqTXL0PP7GBIGSDhhIxjdpGyzbh8qj0xXVvqMc+nR2kKK11GWheM9VJBBX8gKzTFaS3V3Y3iz2xt3MrXEacBh0qx9lQCW/iUi8nVYzK7AIW7N/vGtE77m82na51Xge3kl1WxglSQrGm1gGyYiARg/pXcp4g1LR7yW0uzHcBQXVScME7YPfiuH8AwzaBaS3lxOVRwTmTqz55x70niT+2RKNQto2lgu+GXqY+3XsfaspJSlq9Dy6tFTqNHq9r4ktrxEjkbyZHXcMkUy68S2djcwQlhL5w+VkPTHrXhcXjnStMu3s59/2W2byGkHzMM84H09a3tM19NWtrmLTgkTMFZZJACwi9QOmah4dLW2hlLBzjueyx6kk+DvRFB5O4HNVtV8RabYlkkvYFdfvDeOK+e73Urx754ba5UsZAoVlwzIOSfSpfFGpwW/hqbW7JLcXqEoAVBBbIXOO+M5FL2Eb7lrATTV2eia18RNHsvMaW72ZBKb1wZD0+Uda5u4+LWmWup29rcafcoZcEyysCAD9DXzVqOr3Wo3jvfXE00p5DsckGrPh6xu9YvBFv2og3M78hV9aUZ0VLltc7qeCpvTc+kfE/i65tbGSO2kjjuZc7Qg3fJ13enTNedp4yvNMuLF0dJZZFLHzE9T19zik128bU72K1tVwyWYhMpG1chdpP0xUk+n6f/ZyW9rPFLezIiCQgEADAIWuiFkrWOinh6dNWa1Z2ena02vWupm6D21uJY5AEPyZUZKj2bris/wAaava3GnXUSLKlzIoUbU5jYjI/DmrmlapbR2sOlukSXezKqi/K6jgvn19q5S9vLSyk1AavJB89uEiRcl5ME4I9x600lfYwhTSndLY4qV/KsSgSWG8GXmAJwCD8ufqa19C1OSwlJulaaFLN8O442lgdv0ya0bGLTfEF7KLW5cyvGFeOVdjtj+72NWNd0Ga0urO3jSTyJiA7oeA393BHQmnJq9md/NFrlZzNnaWy2Md5FbyCN5iYRE3zbsj5W9gMgYrU8a6TIukyXCEldPuUbcvVVkUc/UMK7Kz02Ky1KDR7ezErQS/apLgg4ARhu46cZOKytdu3hn1SOECcyRB2j2koQHyVYeuO9TzNvQhz59EecGW8v72xaV0Esm4CQjBZs8k/pXf2UctrHLYyoFZ8zkoeQ+3lfr3rGi0tNJ1SG7a2fcu6SKMktgN0I9x/St2Ni2jTarv338RaBzgEupbO/wCuCKTdy5OxWnFwlw6PI7zSR5cBcbE46eoA5rMTTrprOTaYWt5VeEMRjAJ+Vvr1ropOYbO82O935AgaDGDtx95jWZp0ZhuoFmBK7zIy5zgDPzY6cCi7BS0IdOshp8EMsaKYRKoKsM+apOGHPX1xW1438Oad/Z2n61o7WcUbjyZU2naxByGJHcdKzLHydSv2mvZ9hBL2ys2BEqdwvcn9c1j6dfyGfULG4l82J5gVRxg4OTuHpTs073Jd5STT1R0HhDTFj1i5g1BC89xJtj2ZxtHI2/7JGetTR3QM0vm8K6BWZhgdTsPr7U3Q7l5bi1lYsxgBgZt2CIz0OfWs3XdUUPLaJEshRFAGPnAHckdRk5qYxbbuKSbkbdtdiEQxJtSdgGyAMqg7EVKX8m4S4kilSObBAXpheMt6/SsWwmuGuFhih+0TyAFCOjK2MZ+nNdFrF4lrbDTppopXjbyp1jGRHkZyDVdTOWjsjJvbCOVYvPfy5G3tu9CTwcfTpXNa3pAYxMksHn2+2HqSZj1yR2PNdfBqcbrEY3tssgDZGQJAcAEntjFamn20b6Zf2wt1ub1XUrI7bcBvf+IUXtuHtHDc4u9tH0bT5Ji6yyyxeb5jAH6Ad64y2vI9NmS7kjju5XRs7jxn3+nSvXdb8N3WtRTrEYYIhGsJTcMrjpjPXJ9K4mb4f6lb3A+126rZwtmRgSd2O+3GRTurWvqVGopat6mT4S1G9HiCFdg/ejcFQYHrk16T/Ztu8p1CMq3lK3mwAfe9OO9Ymg6CkGpwx20kcxwEyedq55CnsME10lyYoL2U2juQRtYL95fTFJXvuZ1ppbMyb+wt7/SpZ7uI72cKyk4OWHykD2NcxP4V1e1kMkN1ZTzQxjBDHeQfQdyOldtpekzajIiNcl42O53T5GU9ge2a0ptCnt1ktbCQTo21mETAzKR1NUpW0uZRxHK7XOE1Kzn1WCAyAoIjskiHHzEc0ttA0KIoleNIv3ZRmwCexIHJrpr37bbXTF9PuP3pCbmG3GP4jVay8L3Oq6uftOIQi+a7lsbR6596TdtWdMaytrsVNHu5bOSSURQmKGMunm8hz3YA9PpVNtfn1QO8gH2ZUYY74z2pPGGq2lvqkkOnXH2stB5IRYwFBzjCnv8AWq8llaaTYWzXk2y4xl43O3k/096p6erCPJJczPo+yW/iumh3LDELdWIBzjngA1gatNbaNbTXUVwI1JKwIf756kfjW9c6kNMtlW9SMMoKs24k5B6fjXius6rqXiTxdLFYiOYwgiGEL8sZ9SenvmuejBzfkePh6bk23ojrtBkS5a4E2ySWBSWeJ94kyRwT/ezTfEWsXdowhtykwMn+rBwVXHSomtz4b0SDTt6T6hcMGluIhheOw9hz9ay3djcPMYsOy/M7HIxnpjtRUkm9NjroUlJuXToWYNUS606T+0dLMixMUbacMq55rzW0na18Ra1G+420amSGKT7xXOePfFegxXF4Zi6K0azrtYr90qehxUH/AAjUCXovrwTefbDAlU8SofbsRSi1udaapnOeGdVj1iSee3R4jCvzAds9APxr1T4ezNqM82japt8yeGQwSI2WUgdzXlumy2tr45ttUsYStokREyOuAWwQeB17V6Z4D8LyWGt3Hiy/neztdpNrbyDBbIxuI7Dk4FaSso66afic2MfuvvpYyLO91fR7lIZIm8uCcxbcbsAfxZPrXpWnz6RcxxRXHkPdNlmBODn0xWX4mitzbJq8hHkFlMhX6YzXG/vr7xAt+VCWVqpdYuRJMCp+b2ANZ/xF72hyyUay5o6Hc6l4Y8Pzq7iytV8/OcrnOfQ1o6Gmn6dBaaZZwRRLEpcyH+7nJP8A+uvmefx9qqNKZvOk+cqu5sKmehXHFek/AnxUuqailnqEwaWWNoj5hyXYnjAPsKqVFqL1uVWw9SFO83seqa54gidYY9MnVllRvKMfOSOPyrE1DSY5bEz6zcqFaJiwiHLHH+TXjPiHVr7w98SJ0jDxWIfbAoOFAJ5PtXWjxS5tr+K5BlZlCIm7Gc9x/jUqla3KxrBzgk4lrTdBuY7WfyrsS3FzIC7Og3bSe31FJ4na20ue3hEP2ieNTJ5JUFVdjwSPfFTeDNRhvUlvrwrBb6YrfaMnAPy5T+ZrFs9YQ6pJq0gMrSAh1cDIBPG3PaqkpX1NafNOTutiS/uNUutCk1eRY4rexPmuH+6OcDC+lUtG8YWcljqV680qwiIRLF5hz5rH7wB6jrXOXN/rmteKZ7GyFw+m3rGKSPZlGX/aI9M1g6ppsmn6JdC4keQJcKsZQcKBuHX0wP1rRJWszojQTdpdzCiklvEmt7WIyFGdmfHzFSepr0j4dWd/bWNpqbRFlSJsCRsBkUnGBXEeD9MuNRvDdRzvbu0ojUbCRID1HFfTieGrSx8OXF9qcS+bbWrsgjJAUbdxGPqKmpO0fUMTiYwtFngt9qxeadmaSS5uhh/lwsI6lPbim389hNpMdnHC/wBn2hsyvg5Jx+XFZugR3fiKa6NkgDvIZJjI/G08Z/pSapdNFYW1r5Yjt0ONw6Hkjn3oqaOyO2lFNKxnXWhQG/kudMjkk05QCxkHrx2rU8NWax+Z5Qfay77hTwyopyQPTpV+LWtHi04pa7hK0flvHkkccqR+NakV1a63qMAtoFSeaFI5BF0CZwwJ9e+ax5PIfPZWtoM0G603bqFxa+cySodnn4UqoOcD0qG2uLNtVlu443is/KG1Gxw7d/fk10EngsabeC3lzJYSk/vlP3QB0qWHRHs7Fo5Njmba8LLH8kYRuh+ua2g1uckq0Ltp3Kmh6bLYTTecylnyYJFcN5e0ZGPauR0SGxumutS1kkeXKzNcM3ODwu1e4Bz0r0WaKe3jfTHEcru8hSeMf6lsZCEDpyT1rz+/0iK88ARXVzdxpe6cjRrBGuWmAkwd3uM/rWkddyadS+ptXNhZTeFzdaPcvcXsGDL5GMozLwyeo4rq/C18/iLQrWd8rJsQTIR99xwxGe+cmvLdLT/hG5o7eZbkXk7JIFZdqKuevv616Z4Q8qGzi8tghkkYnPBLHJzUz1iKtFpXbuzeeG93Sz+YJGVNsqLwzD3GOeK87uBJA7yxSbkupDE+4YJXIyOemDXqVlcpJcQCYu7gOoBGeSOBn0JrzrXNOzdTMij96WRkBOEPt6Cs49mZ4ed20zQ1j7JeQQGOX/SrSEEyY5fGS2R39Kx9AmEsqxplWYNIAoG0p/dP+NVNOnlu9LS6DBHh+TA4brjkd+RTbSQ+dZttO0oWO3oCCRTSVrHVyNRsdBdXc7XguI4/LhaFkcKAWwO5/kKradYK2pRbgsZuoHRcj+8Pl+nGK2oLbdFp0nyIhs3d1cfelHOOfak0zbaWNlcXKeeVuNrKi5Zl54HuBn8qXoYc9lZHl0MB1C5QPcrDNbK8Dq4GMqDtx68jGazprmWLUmjuWS4uYWVFk+oGfrgnit7X9DitbvVHihWW2Z/9ElBJOGPoO/P6Vm+GtAdtZjlkLm1iYyJlfmYr04/pWspaHdGV0pHQ3jJpWk23nIUM92peRc42Dnk+pNZU17afaby6kRowzMqFRkHPQE/Sus8SxF/D0dlPlVBJG4DOSeB+H9aYui6ZBo9uLydFtoWjWRRjcZDnDZ7cUovT1MVUSu2dL8N1/se5ubjUodyyWZ+znbkADrj/AOvXJ2gnu43u5I9vnq8v7wjb8ucAjtXZm/NxdW19tMWjRR+VA7sF+YYyXA7HFZEsQk1O8utNWMI4f5nyUdeMhB0PNTHS9zljN87l3MSGPStJiS51N2uL3G+OBfkiXI4BPVqa3ixlvEkSBEiyu4RAk5/hH+FO1bQ7h9Jb7TCVuRt+dmJGOTgjtU/hvSbmBvtV1aLE5ZfLcsM5Hr9ar3bX3NrwfvSZsaFfTYjku7LfJNIyksRtI9x612ugx3sVhcefcPJGThXlG4KuOQM+1c/pUESXOboFLmXH7phwSQfmx3+tdTayxWMlwXlk+zhOVIBySMVjJ30OCu10RgR2mmafDM0EqKZR9njnyD15/AnoK5q401vskFzayPIfMKbzkAlex9CM1U8Ru0SxX0KpLbsQvlMcLjPyk46NVi31tdN0+U3haOINkOr53MeSQPXFa2cXo9zdU2o825PCtvbWjbLpt8K/MgUgEZ5PvVcai9pcm5tZGLKcrIDztqxpd1pOomOSGBTeksrOrncFP+z6+1IdFimUmHfG7DbuA+UtnoR2+op3VrM5alP3rs19O8W2uoSmHU4vnkG0SgDg+9UfG2pJoujrb7dkuoSAGRTgLGv+PpVdPCq2Cma5mRi38KnJFV/HFuuraLbIYpZV06NpMbsO6k9QO+KVNR501sXGEXJJbHnl/qFqz2YK79rnyrpBgYLZO4Hv6Gs/xK7/APCQzLcsXgLjJV8kRkZAGe1TSaKx02ZbOZZ8MspIbnb6Y7mpWtYNQjdbyRYhEvN1jO3HQEdx7Vq5O7PV5ba9j6S8bw3F5YXFwqI8rHCx5JAAP9TXKfD/AEeW1F/e3cHlq5JmLcFBjtXoOsaQZ77TnQkYblCeMep9f8axjDgahNvzBCxJQ55A7Y71z05Wi0j59Vmoci62OF8U2d2yWBt5hDZwKVjd8gl+oPv2rJfUL3TIjLrduZIcfNNbru5zwcCvStVlXVUjSGJTJFESkZGcHHXFYDaNc+VbyS7bOZkO4ucg+4H9KmTa0aPQw9dOKUjzJvibbW2rI9rDLPGpICSfKB7kd62tH8V6x4zY2cOnGMxnzBOqnEgB+6TXXjRPBTjOs2cFzdL9+aFQqr/jXQ3/AIq8PaBpCQeGxabQNuVGWDAdD71SaUbcmpE60nNcsdfQq+CvB0lvqcuq61Gtn5TsYoB0HoazvF06yyywahqEl4rZVAXI2vng8e1UbrxRqF9oouJZnSPeFYgkY9s+4rEv54b+7EkDb5pAP3eOhxzimoyUrsqFOUpc0zqdLtZ7izt9Je9cwzxMoAbO1g27cQeoxXSLpyWWnXIuEL3bAruDfLsxj8qw/h1aSyXSTgv+6hZQrD+LsM+9TeJbu7k1Zrc3KnfGMRoMheehxRK8pctzmknzuK2R5rrGhabd20kl0VtrfzSFWNgMyAYIrrfCel2PhzSdO1ae2D3YHn2vkcsADg/UjH61H4z8Nfatbszp8v2efat3cQOhAfBAx6cV1en2Un9haNb35SFCkkz3GcNlnAx7DBq20kmjatWbgk3ozgvijcpqWpz35hJtSFkTKcglc4FeOjW7175ZmmbcnCrnt6V7r4nsxeXFxYSIqJA/lISeuOO3tivFvEnhu7tvEQSOF9jncpX5gfXpWEG4tKJ6FOV6cUuh1lnr8baHrMDW8iw38UMTAP8Adbdwffmt34aXFtd6xHaX5Mi2i5Unoew+p9qXwh4BBt/+Jmcs6ZSENhlZTkMfbNdL4N8Jz3fiCWS6s/s1rBLI0zo2DMzj7o9h1rqlyNO5zVa0IKVmRadp91Nq7aZ4YuLny7i4L+YQV+U/eGcfdGK3PEnhnRx4am0vUfOefAYzwNj593p6cV2csWn+EvD76fp8kjXTr5fmDmRFPp9K84F6I4vM1K9aOKdiJJZDjG3gAVzp822xyKrKrLmWiRf8HSadYQWdy6RWtvbzeQqumTleMge/XNdX4rubrU4tT053SGykiMiyKckgdVz0Ga5ryiNGje0jgmMruIQB1GCcn3qx4hnl03Q9MW6ZIpruRmeNByAFyVz26UNJvQzlHnmpdTym90bU9CvFi0yMWqTgBVIz5pPv2xXJ6vLPcRPb3roHjlLyj7oYjj9a9g8UR/2nodveXVypmtoRGI1b5pnzkf4V4l4q1qaDUru3S3iUZDyKwDlWIGQDU1J21ke3QrRcOaRzss81vIywsUOdygntXVaFqzWmibIQyzBi0si8FUOOnuaxbKbS9Q1GD+1VliV2Cs8OMKD7Vr6nppsrlrawSSWzk5UnqcCs6Eve30LguaT1ujd86a0uYYd7TvcwlkimnYqrZGAADwetdl4amura/tYhdxzWWxpJbN5CRCTjABPuTXkV15rTLP8AvXlciPaBggY7YrtJbO207ToEhTUJBcRLLxIdvndMY716HxLU569OOzR63fWNjPpl3q2mRzi4nmU3Gw42MvGR6A4wTXAeI9DvUe8+x2zyxPKs7wxnDKeMn3B4z7123hS6kewlsvL3XM8YlmjIIKDHAP1J61oaRpdxZy3V1JKGifKLHIwZgOM49s81jzODZ58a3sW7nk0MN5q1/Fc6kuGVVWLkGQNjv6Diuu0ZzKn+itlQi7UYYz/ex711Vx4FjnupptOmVNQyJBHJyrA9Mehqjb6ffaDqDG9tnXaMkqm7LHuPbk0OalsbPFQqRsi/F5kDPJKxZI8OBt+9jqM+tc3NZ3F1PBdIrRNJL56QbQcKOMt+Ga7O20S8visksLIjuCsbHGF9SO1bVvoxgCvcKS7HaAMEjJrF1FE541lB3PJ9Q0cX+tyixtzbo+WmKHC7i2c4/DtVO/0WSxS9I3eZCcowHyuCcgn0rvLGS4utVeO3sWjjDMHuW5XaCR/31mqWqpdf2l9niG6Jx+8LrlGj9fr6Vavex0RxT2ZkeI3Gm6Ta7XYy5COAAQh6Yz6EVy2geKfser3suqTG3eOdTGuzKJwRnPfjitnWleTR7myhlBySkauuQxGcMD6ivPUsLy4jjnvIxOrkRtErYwe1aK3LaRvRgpxdz07xHbWOoTh7NBBMUUR7pcxzO3I9s+9Rm0SLUZlvoGtdvzFg+fMfjIU9jWLqGo3dr4MW4EcaXUEqQovbfuwpP0Ga5abVdcns7m4mv7a4W3XfJDImcYbHB78+lJQutxRjJJpbI7wvaWelXsutv9qgVh9kil4Yu3AU+y4qlDpnhmGzuNTuZZLtLOP9/EHOVkPcjpjtiszWNWi17w/qA+wJbzBAksWd3lnGQyH0PNTWFzazeGX0iWJWuZYlc5O3zcEcep7GqSa3uPklZ9BX1OxuLlDpC7dJvoXintuR9mfHyv8AjXQrMsXhaC2f97cnBRUPyheB+eOa5q5s7Gz8SfYra1a3WWE+UmTydvzE571Xtr6+eGHEjyhrdBGFG3BzsPPcU5K9mh+zT0R0TeI2ntLQ20YRUkMEwZd3mIvy/N7960tLlEk8en3irHKSHRmGQ3+z6Ej+VcJbX32TWLXQWh8+VpC0rA4O9uv4YxWzDJCRqFifMa4ilBjVc4CggZz2AzUyghSpK2h1ljcz3VzcxXMc3mW6lEfuAvP5CtOJZPI8q63ENGzB3HHHPUVmabcGTKSPC5ICmZW++AMfn/hW60sjQpGVAAI6Dlu2QKye5yTVtDh5vswuAGk2IykyL95QRyG+tcTe3FpqFzJOXuFsIZN7vCucjsWH9a6LxMTHe620T7EjQgjbyBjp9K4TR7G7u7aWOKZxbgFzjGCB1BrfRas76MbrmLcN9FJ50mns7z5Dho2KleeuK7jSdRvPKaS4kQ7wSeqtIAfvfWvN41s7GLdbyyNJJ8jMBwBnp9a7TSrcvLDi42xRgsF64A7n0zUXb3KrQVtTvtKgC2qz3RL3Eo3BgeV9M+vFVdQuXcM+Ek2JtfaQOOmRVjAkP2iMKYJAqpH93GO5qmQJJDDuhVzjcWHX5v5Ul3Z58F71zEvfD2kG4E0gktriZ1G+DgNleeBxwa57xnYtYaDEtsD5KSEysqYyf4SfY112sF7K4aG1cOEPlmQccnONv1rIE0sq7Z1JkYeWEB4BB/wq02mnudcG5K9z6C06KbJZsvOCAZAcgYHA9q5yDUGhsNTaNVur4NuijH8TfT0GaqaTd3iWkt7qM3mPJL5bRRkjDYwP0qjo999m1KR7p0t0MgGSMuEI6CsVDc8SNPXvYyvDNzqG2W7vpG88PMrMRjn+ED06VjzXUt3C7eZO8nnBsLkk5HGfbFdLql48mp3nlozQciNBjLHufpWIbG5LNcWkkgG0wmNecH1I7/0rWXvanfQajJtmLq+irNpsEYuoY5ppADHliC3ue1c54jurDSNVfTpLqTYGDuQn3WwMj1r02zWPUPNt3hAgcADaMHI6MPfNZ3hb4VapZ67c3+pwwavZ3CkBJf8AWA54PPepUuXRs6frKiveZzOi+J5Li+gsYrEDSbiJ8HyywY4xuPoak0S9t7a9YxKjzbisTj+8DjvXf31lqGn6TPZxaJNpsMkyjzIwrgJnnkdPpWLo/gMWdxZan5YEQc3KrN94sSQR7fQ1XNBu5CrQcX5nV+B7uW4u75Y40iVV+eRhgRsOg9+Kw9E1XQLKaeK2t5ZdQuUYyTu/A+bnb610FtBNYC/u4raD7A8TF4wx3A44/CuH2abqPnPbRxQxTOHLRknY+BgAdahWbfyOeEFOUn0NlPFcEGpvdi3e4unDW6q5yUGMbiPTNWrzU7uTTLKWdI0SEqGDcBVY5wPbIrm7SwlS9jD2ySPC6vM27mT0H0/wq34i1CHTNfuTd7ZIXSNljV/lAIOAfoael0kaOjBy91HXaD/ZutjUryUPHcWyuskIwAc/xD1zXFx6WJ/KbCRt5uEjEgAYtwMfjV/SPFVnNZ3n2GOFZtm4iJwfl5wB6nFdJYaBaa/omn6jcqLUWkqyLsG3f7fWp+DVmDlKjchvbaSK8W3W5Wa7t1xcbWy3k4/xFdX4a0ea90nN5cENId6+WMY9P0xWTINFkurm4nuGhukh8naRy6diTWlZ6o1nZxx6XAZFjjDRhjgNk4NRK7WhyVG5JWOY8W3lzpPigQvbC4cRAqmMs7c4OfSvKviVoWo6klreaUHaAwmWS2zjy2/ix2r1TV2/tbxNcXF7IrSKqjaTtRAO3uPes/8AsWK7QfYsNOGeE7ixRlY8ECrTcUjuoTVO19zgfhhq+v3EN/BP5sluyq5lbnaRhcL/AMB9K7Xx3Y3F4pvbKc3MVsVMVuv3gQOc56980+wsrvSzJaZjjmt0JZAvOW61T8XahPH4cvlgQ2uyJZPtL8Mqs23aAO5zVzlzSui7p1E4HCeI9Sujf2M0kbxKi7gmcYIyMsPrXnvifTbu41G7vkHnJMfMMqKQvParepeI5Jl8hfuKgjLtyxxUDa5dvEPPupVSIYVAeMemK5KzjL3WerGnBx5Wc8yP+6iBJ43MT1+ldhBPLJbw+RsYqgfJ6qOmayVkt9X1QyRBbYyHjPIyf8a9BsPA1/LpZiccY+ZlI/d4PPSs6EOXqODhSTlfQ3vh94Uk1GafVJGWCC1geZd65Vn+6AfTrmvU7Hwrp2j+HBd6zfySJbQCaZY4wu5j+ZxkjpXN+BtMk0RG0SS6aRLuJpWnKkjGQFxnvXb3MYu9+najExQM8aKoxkAZH6+tdcpPa+n6HhYqvOdV66Hndtp1rBqf2gyyr9rXzRIz5LIONox1Fa1oravqsMNtxJF8xkU8Fe4Pv0rDXe94txJdRxLboyLC3JI37WUY6HkH8a6qO6g8Nz3E8MTSwqCsTqd24HAJP0rST6oitey7li80vU7KaEwq7knCuhwc9QG9q6zStQaSREvwqugxk9enQ/41wni/4my2eoRR6faRPBsLeZIMh/YfSoPCfjqDxIs0EiR2uqg/Jg/LKh6/QisZRlKPvIxlh6nJztaHoHiXxPa6TZnyE8y6flU7hQcEn6VxWjeMjf8AiC1+dxDJJt3vwMEelJ4k08G2to4kcXFwrb5AfmA7KPeszw/Yi3uL2V1jkkSEtAkg2glVPzZ9f8KuEIRiTSUba7nY+HtT0fSor2Ka4NyjzFJVVSdhYk9K6BtK0rWI/M0u6UbMKUiPA9iOor568LandxeICs7pMJM7yxwsi9wfQjHBrrbe4gg0WHxJpz3MFsyt5hEuGRgdvA784odDXR6lVqE6bvc6jxl4AM2iXrQeY8mAY1iPIIOeK8oOh6zo8tvFrdqRa7vNWUfKGyMEN6HPSvVtH+I8lrpRGqQTXCLtIuAMNgjuK6fT9W03xPZOhMNxG0ZSRHXkAjkMKFKdNWmrruaUcVUpKzWh8/eLLOW88MazFA+545UvlViAHQDaVHriuN1S6gXwBbpaxeZLuRJHXqvU4P6cV6lquiPceEr1recG4s1+zRKvHyq2Tn6jFcdZ6Q011c6tdp5Gmwqsjxtx5jdNuO9bR29D1Kc4yi2mT+FbNrrU9HsdSVIZL2zk3hASy7U+SRsdM0++8PTJcCCMyo8ZDW84fgEHJQn9RXR+GptJfxNa3okeO7vYQjJjAWNeMKO3Sut8V6bbhIZipkaWTDIoypUjILelHM4y5X2MKmLdOepwNhqc91JKbhTNcW8gB3KCynHIx24qA20wv3tIg0ckV2ZrWQLkYYElSP7uR+dacsFmsk9/ORGUjLsI+CWBwM/UVWgvZdQaZPKSJAjBZN2MZH60vNG8J865kjFuJptKvoNSS1ZtReXc8pUMrAHPykdOODTorqfWJpNZZUSWVWhWCM8Ng8jj2rT05JBeQxhsYDqN3AJAzkdsGopJLe3jkuDEsNyqq8BVcKWPU47Ur323Nr2fmWtOIguXjYuJsj5FI+6x7D2PX6122jXsXlI4l34Ow7ztII9R+dedw6uzzzb7VJJmG5pFYZjHQg49Tg1qwXEccEPliMBVILyH/WbuW47Y7UpwfUzqU+cZ4thtRquo3QO2GYiKaDJPvuB7DNecsl5DHd29rHJteUr5hGAy+gNd9Zw+VcuscUSeYxBjZyQV6557Go5vCc1zHOLK7dLTcZIoXG/k9RuHb602+hdOapK0tjhvCuitqerpaSyFYhlpmP3VArsjKbucwWUHIjAghiXLbV4GT703TNKl0nS3klZFe4kKtGF5PsPbFT+EZxZ+HdR1Jgsl8ZQsEm8L5anjn2pQXX5BVqOTutbGncalNCrhtOmjMjou9fmQY657ioLq6t/OMtoDLL5qlDn7yk5P4ZrN8M+Kb3VtQns5YrdbdFacbuW3A4yD1NWPsz2WpmVVR7OQkwc5CsTnGe2ea0stUZqHK/eEv9QP9rSb2zDcEgE5wCoHI+nIp37gCVoZnlRCu7I+6CMde4zmqV/GCvmSzCIBpADkZU+3tmqv9opCiW9w0blgpdi/LH0IpW6myhdKx9Jaj4eMlrPDbIRFJIdp6bMfqelcxcaDYtLOVDJJGFY7z2xyBXqYu4fkD5Vn+6O5rmtV0tJ7i489GCsRsfZ2749K4qdSWzPnYVWtUzzm18qTWY/s8m0KhG5iAuMckjvzR5l1aXMdxPMIbLrG5XAlIJ4HuTXTax4RtVsJrvTWEICgyx4yCAckD0JxWNdQ2mpSaU2pK4+yn5VC/dzyMjvXQpKWx0qpFu/Q2/Dc0UoF3eaa9ujkSIcfxdz/ACq94k8ZQ2iotoOpAYnjr6e9Y3jHXLqzMFlZo5KqQkhOcjuQK8sfUZ7yS2/tEtJMLs4lY/eI77fTBrPk5nd7F0cN7V88judQ8ZXMkb+bGEiXDpnq/OOfQVmS6rdTNbWYAjjuFZnO7JAB4YVQm0+4MUrOzSW8a4RTyxTPGT9aXQdPlhtGGo4toIzuEjDJOedo/HFForY7I0qcY3RqN4k/suG2tdpmXy9rFny0mTyT6YFN0m20m80KZtPtGnle9IVUHzjJH6YrNOk3l1DaCGUDy2ctIDk55KipL9pvB+kvHsWO8mj84YbBBJ6jvnJrR8q23JUF8MHqdFcGbToPKaK1jlnAVU35YxZ6H/a715T8U47290+ya1ifaXeIqo544BI9+au6NqC3kq3N2JXeEFyWPDY789+tetI2k3vh2wvLhITM6uhVOclTgZIpSioju8NJJ63PnDwt4S1q6ubZwxtbcODLI7bNi56mvou41mDV7OPTrdkFnarGYpo+DK6kZ/A4zWHrVxpDWavJB9nmB2tFHyJAPUnpUDRTQ2sRsYgpmcR4Q/MoH9386rdJMyrWrWexLq+r6dfX17Zamy2k6BhFKRnaQOhrQ8GyS2dpfpdPFcwafEskM8J3b0c5I4/lWbqegzeJJJroW3k6pAgV4ZOVnXGCVPqAOtX/AAHaJpdvf2YhkMcqjHYFhkhf1pacrSMqnLyaEmsXtjbWMtybdmCJuw/BYEZYfkaqeBfE0epyWbaXbJFaiQhjKckhckkfqK5n4lx3V05sNNLx2Um1n3kjEpBDDP8AIVs/DnRIPCNjJc6iZPNAaNoZj8oYqCvy9gadlyFujFU7vdna63Naaxps01mfMmt1ZjInGF64B71414slTU/DKxyXkrs0iM0spx8vOBjv0rUmub+XTLuMFbMQje0SMQh3NgkH25qlqVxbX+kTS3MGYoohDEIx97B5b+tSko6HRQo+yauecf2B59jc3NuCyJjPmDHOeo/SqUHhjVbycwRWvnSqdpIYYHeux8PvNNqDQ5D6fcxcryCy/wCPvXeRarDp2my2egwW8FysQLuUBdQTjfk96ynST3PRqztokef+FfB1xY6of7WsgwiRnIxwoA5Pviup8M6rPdags8V3DBZZ8uIFcs6nPLDvnNZvirX30OKTw7Y6lNNqMys9/ehugK8QjP5kj1xVLwzpN5dWVu2ks0ojGS6DlXbnjPpirhFJGT/exblojuPF+p6nbQWkmhnetq4JKEenX6Ajv60nh3X9W+1C/ubqeW38lVeOSQPncfvAjocn9K6HwPoGrwXS3k0kSwxja8TAHzQfvZ/z2rb8YaMbe5tU02yiFkwLTKq4BIIKn+f51qqkElDR+Z5U5QTcLXfcxPKtraG5XTwFZZ3MUjcmViob5vYEHitO4tba40W3ikl2ajPGB5iDdlm+8CPTP86zZBpyzq9rIZZgDI8aHKq390n15qbQIWTW7OKXy9kjbo2IJA5zjP1xUN9Tnmna4/WfDsK+HEsLq3C3CsCCRkxr3INcZ4Z8NabpOti6ld7uaNWMEcfygnHGT2+ld5491B7ZIraa72XEkbN5oAxFknmuX0e3kexgmSJZJriZklAOScrhT7ZzRFaXuaU5VPZPXRm7rF5uSxiPE/3jGpyV3dM1kW+oR2MGrX0qH7LjyIlHzF3PZT6Hmq2oRzpKPJike9RB525uXC9FBNVRYW+qQWa3TT2DspKrEcoJAPT+taJJIKdGKs2ebtrg0+/aIWeIWLB9xJfaTzj3Fej+A2j1DwY9ndORH9oZYxjBIJyD9KxNM8JzWtxc3CwrqMSozK0q4Ibrj6k8V3Hh7TItPf8AtNyqXIt9yWsnCsRzilfc68XOlOPLHczLW9Wzt5IfsqvbQ7i6v1kA4PPbnpVzR5pv+Et0280tkW3BxKM8MNvKt65zisy31W41bXr6WK2g8mdmgSPdjaDyQR65710XhbTzp+v2b3jNHHdFlhUD5QynBXPr3H0qptRT7nnOFty14g01bVLqSSQ2unMhMzrjcpz6fhXI+OobW08O6IthfNcrcRPNu2Z6Adcd+TXW/EKzmvLSa2lmiliuwGM2eCBkEH06DmvNriO+1G2torctbpAjW20MArBj0P4jr6UUraNs6sNFuKlfRFTwHZT6xrOnTQtNLcQT+XPcFfl8oHjHv2zXuvjNxHvaJAjtHtUeoxxmuE8G6FcaRNZQAf6XsWV5M/u8Z5A9eOK7z4gIIobNjkFkPP07frUTlzVF2OPHVOaXu7Hk06wW0Dx3Q/1uA+4ZXZkn8/esuzkmuoJEjgK2KuNr4/X8q2NSZorTbIpaOZjGrE/cI6c9h1rHmF4hmtYBIrxNkKDwFyOc961kenhXeBpjTjctx5kQiPzu/RlHPArO8RWcb2ixWskkkkDhpJ4+y8HGfb0q3dRSSXclrM8rSYC5VsYJGQenpT7CW10/wBd3Lb5DJITtI4GOoP1xURTujVSa1bOVtormzknv0liu967AwAUrzuxj1q3YavaXc0UwKiCQrHJCFyU56g0yx1Sxv9amOlRhoNo/0SQbdw7gEdTzwaYLK20y52WUNzHLI+9fNUcoe31BrR9job/mNy8uBb3UcMLxs3l4DvwVGOD+VUIrp7fyN9xOttIVzh/uduPaujbTrS4tor6aVQfLUzRj74IyCVHcVXt4LSC2VrcxzWyKWMbHDMR3Hv7VimjDnjaxHqKXV2X8qQuiIVjkx0z3/wDr1V0/RG1zwRJZadJBbaok4t5I2JVx6r71vwyW2yKWxT/Q5GAaMnlVYcj8+1Z2t6Akk8kt01zBKqCRLu1bbJgDjP8Aex+dXF7GDk0rbHOaRpMui281ndWub2xkci6X5gwPb1xj9a6K0XzdA1BZ41aBkjMEkZxls5BJ9e1VlS6S0Kqn2wFPLaYkrIR1xz1Naiie/wBPt4GtnsLZdy7QN24gcE49Kq1jSdRtWZwWqGW6tWt7cM90GDup5HHJGazoWku5opGUQydmbodvBWtjWLRtEQ3MM5icNhDjczHvx7mtX4a+G59T1e4nvkjSyZWeaDhtuec7uxPpVSSiuZ7HS68Yxuj3dtSlm8iQIycDdKCMD6Ctofa5bNVjuD5MqEb25bjqaKK4ZJJHzTVmjE1G9vLB4YLRop1uJVMvmLj5ewrE8VSvoniHdbwwym5BkVXJwDiiitKdnOK73NEtf67mhK0A0mLUbtwZ5yqAKp5HevG/H/xEKeKJtJsdGs4IrWUJ5igb3z+g60UVdOCctTtwcea7f9bm6Nalt5jHIoeCLbJIncED/GsfxFr88ls8m1gikkgkH5j3ooqIK+p6ipxUk7G/o2qX9mqQSwIzSwiQMWGckDn24FaPiHRpPE17a+eSHjAwuRll9Sf6UUUqrs9Dhm/Z+/HcyfEFgPDn9n2reVNIf3boFwMkZ25/rXUWMNsmk3VgsAt0t0AGznlhuz+dFFNPmhdkVJNqLZycdxHHoVylyx8sOXkk27pOD6/Wqc+qx2l5pmpXpdPMTdBBGSdzZwCx6D/69FFbbuxvCKd0/M63UfHWpW/iCxjlt4BZllt3TA3KcdQR79q9OsLaKTSZfJVI7llGHUchsZz+tFFctVLkTRwYynGnyuJwVr4QkfVZV1CV3CSrNs3ArJjn8K5PU/EL6jqmstcx4WeZoNq9gpwGH0xRRWtJ8718i6EnJtvoRa/ZPdvDdCUCF8EIq4+Tbjketc/r94Ub7FsVLNk8tMKCTtAyfaiinHV2O/CycnqZek3xtdFgtYFjZULpJLg7xHknFb95YNZTWUtnERa3sayNK7gsTgY47DPaiioqvllZHZs15nleoWUp8S3trcuHm89tzk5yc163o/iDT9A02z0yNnhikQt9oVMs755BHpRRShHnWpdSClFJkyeNb2KBY4ZvJWNi8jKu4eUQcEA9z6V12hfEu31O1a01yFt7hUiliBHI6AgfzoorZU4y0scdfC03Bytqi5e6BYaSXkLvLBqB3wRgY8rJ65/A1Q06yja+N05lL2AZpEDYDY/iHp8vaiisk21dv+tjzIyco3Zw2uX8uu3F9d2e02x/dK0gIIXsMVS0jV9Q8KxWlwrrPbysyFZTk/L0/LiiitXpPlPVjGLp8ltD0y8a5lt1TUDCl1cRecZos5UY3bcd+/Nct4b1y31QT3cqmZrZBHGxGArluuP50UU4RTi2efCCdzqtL8UXMjvM9rDJYwqweMIq5J4Uj3rmPifqglewWRZF3uiwRqRwD1BPv0oop04pSukTThFTui34NtVngiF5bRW6/MGVcFmbPB3D0Fbdrc3AvWgDKq28jr5brnJXJB475FFFS92Q/em7nAW0t5HqMQ1C5d1u45ZioPATbnj06GrNosdrq89lMhks5IjLayZy+7APP40UUX5tz0uVbG/omsXFnYWy3TpO0S5LlPmALYx+dddfeI4ryXT9MvLcSJOpZif4Mc0UU3BN3POrUouRxHiMLpOrT2rqJ45AsgDDIKkUzSba1mt5FEz24GEdcFgATgY/Giinb3EzKE3FKxe1HTWsWQZLXM0bbJgcDA6ZFcvqMK2GjtpjFJklUOwYHq3PH0NFFKk27XO2jJy0Zx1xpub1JNPAtp4lALKcYI53fzrvG18am0FrcRRzhk3yM6YaORf4lPow6iiitFFPc7Ki5rXJvDbC5a5S8blc+WQo+VeOPyqOGwtY4bxbiJtkchJKN1B5GPTrRRWbWrMNU7eh0ml2kcUMRECPp7LgSFvmB65x1rcvLOK4s28+PzocEDnBA/GiisdmefVk1Ihms/JKwxCNAyAkgZzxirFpo11OEsrMRxzCPLOxzRRTlJwjdHPKbk9TnLj4R3upaoz6tqEYsHBaV4xmRgT91c/d+tdHqFhpXhrQ/sWlW629ooHyrnc7Dux7miiphWnWa52aRqSm1F7H/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a bile droplet (arrow) in a dilated bile canaliculus in this well differentiated hepatocellular carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20758=[""].join("\n");
var outline_f20_17_20758=null;
var title_f20_17_20759="Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)";
var content_f20_17_20759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20759/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20759/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20759/contributors\">",
"     Sabina A Murphy, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20759/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20759/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/17/20759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reocclusion of the infarct-related artery following successful reperfusion with fibrinolysis in patients with ST-elevation myocardial infarction (STEMI) remains a major limitation. Despite adjunctive pharmacologic therapy with antiplatelet and anticoagulant therapy, early thrombotic reocclusion occurs in 5 to 10 percent of patients before hospital discharge and in up to 25 percent by three months in studies prior to the use of dual antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Early reinfarction occurs in 3 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Reocclusion is clinically silent in over 50 percent of cases.",
"   </p>",
"   <p>",
"    Whether symptomatic or silent, reocclusion is associated with significant morbidity and mortality in both the short and long term. Among 810 patients evaluated by the TAMI study group, the in-hospital mortality rate was significantly higher in those with reocclusion (11 versus 4 percent with a patent coronary artery) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/1\">",
"     1",
"    </a>",
"    ]. In a study of 20,101 patients enrolled in the TIMI trials, the increase in mortality with early reocclusion persisted at two years (19.6 versus 10.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, percutaneous coronary intervention is often recommended even in clinically stable patients after fibrinolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H1293488#H1293488\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Pharmacoinvasive strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the predictors of coronary artery reocclusion following fibrinolysis. The role of coronary artery patency in outcome after myocardial infarction and the general principals of the clinical use of fibrinolytic therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link\">",
"     \"Coronary artery patency and outcome after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PREDICTORS OF REOCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demographic and clinical variables have not proven very helpful in predicting which patients will develop reocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, one large series did find that clinical predictors of reinfarction included advanced age, shorter time to fibrinolysis, nonsmoking status, prior infarction or angina, female sex, anterior infarction, and lower systolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLE OF FIBRINOLYSIS IN REOCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolysis itself may be important in reocclusion, based on the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During fibrinolysis, thrombin bound to fibrin is released locally into the circulation. Released and newly generated thrombin converts fibrinogen to fibrin, activates platelets, stimulates tissue factor release, and is autocatalytic.",
"     </li>",
"     <li>",
"      Plasmin activated during fibrinolysis can activate factors XII and VII, stimulating both intrinsic and extrinsic coagulation pathway activity, and may increase platelet activation and aggregation.",
"     </li>",
"     <li>",
"      Plasmin may also produce an undesirable decrease in plasma and monocyte surface-associated tissue factor pathway inhibitor (TFPI)-1, which results from proteolysis by plasmin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/9\">",
"       9",
"      </a>",
"      ]. TFPI-1 inhibits tissue factor-mediated activation of the coagulation pathway, which occurs with plaque rupture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link&amp;anchor=H13452790#H13452790\">",
"       \"The role of the vulnerable plaque in acute coronary syndromes\", section on 'Plaque rupture'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may also be lesion-related morphologic characteristics that predispose to early reocclusion of the infarct-related artery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10-17\">",
"     10-17",
"    </a>",
"    ]. If such",
"    <strong>",
"     angiographic",
"    </strong>",
"    risk factors could be identified, adjunctive pharmacologic or mechanical strategies might be applied selectively in this subset of high-risk patients. The notion that certain coronary lesion morphologies are associated with subsequent vessel closure is well supported by studies of patients with unstable angina in whom intraluminal thrombus and lesion eccentricity appear to predispose to the subsequent development of vessel occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANGIOGRAPHIC PREDICTORS OF REOCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI 4 trial attempted to identify angiographic predictors of reocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10\">",
"     10",
"    </a>",
"    ]. In this trial, 278 patients with acute myocardial infarction were randomized to therapy with anisoylated plasminogen streptokinase activator complex (APSAC) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA); lesion characteristics that were associated with reocclusion 18 to 36 hours after successful fibrinolysis were assessed. The following angiographic variables, identified at 90 minutes after thrombolytic therapy, were associated with a significantly higher rate of infarct-related artery reocclusion (",
"    <a class=\"graphic graphic_figure graphicRef73125 \" href=\"UTD.htm?8/20/8526\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of TIMI grade 2 (delayed or sluggish antegrade flow with complete filling of the distal territory) versus TIMI grade 3 (normal flow which fills the distal coronary bed completely) flow (10.4 versus 2.2 percent). The TIMI flow grade classification is described below (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Lack of restoration of normal coronary flow'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Lesion ulceration &mdash; 10.7 versus 3.0 without ulceration.",
"     </li>",
"     <li>",
"      The presence of collaterals &mdash; 18.2 versus 5.6 percent without collaterals",
"     </li>",
"     <li>",
"      Lesions that were eccentric (7.3 versus 2.3 percent for non-eccentric lesions) or thrombotic (8.4 versus 3.3 percent for non-thrombotic lesions).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these findings, other studies such as the GUSTO and TAMI trials did not find angiographic features at a 90 minute baseline study to be helpful for predicting reocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. There were, however, important differences among these trials that could explain the different findings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIMI 4 utilized only angiographically documented reocclusion rather than clinical events or angiographic findings as the end point.",
"     </li>",
"     <li>",
"      TIMI 4 found that the 90 minute lesion characteristics appeared to be related to the subsequent risk of",
"      <strong>",
"       early",
"      </strong>",
"      vessel reocclusion, but were less predictive of",
"      <strong>",
"       later",
"      </strong>",
"      clinical events, some of which may or may not be related to infarct vessel reocclusion.",
"     </li>",
"     <li>",
"      TIMI 4 used a shorter time interval (18 to 36 hours) for early follow-up angiography compared to five to ten days in the other studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lesion ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unstable angina whose angiograms are characterized by irregular lesions or the presence of filling defects indicative of ulceration are more likely to experience persistent symptoms or adverse in-hospital clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The plaque contains collagen and a lipid-rich core which is a repository for macrophage-derived tissue factor (thromboplastin), one of the most potent activators of the extrinsic coagulation pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lesion ulceration is also an important risk factor for reocclusion after fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10,16,23\">",
"     10,16,23",
"    </a>",
"    ]. One study, for example, examined the relationship of several morphologic features of infarct-related lesions to reocclusion in 72 patients who underwent angiography one to eight days after treatment with streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/16\">",
"     16",
"    </a>",
"    ]. An \"ulceration index\" was calculated based upon the depth of the ulcer. Clinical instability, eg, unstable angina, developed in 58 percent of patients with an ulceration index &gt;6 versus only 8 percent of those with a lower index (p&lt;0.001).",
"   </p>",
"   <p>",
"    Another report evaluated the angiographic findings in 47 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/23\">",
"     23",
"    </a>",
"    ]. Although the baseline angiogram were not predictive, all of the patients with recurrent ischemia had complex lesions on angiography performed 24 hours after therapy and none had a",
"    <span class=\"nowrap\">",
"     concentric/hourglass",
"    </span>",
"    lesion morphology; in contrast, 44 percent of the patients who remained free of clinical events had concentric narrowings (p = 0.016).",
"   </p>",
"   <p>",
"    Thus, the presence of ulceration appears to identify a disrupted and thrombogenic lesion with an enhanced susceptibility to reocclusion. Paradoxically, complete fibrinolysis may increase the risk of reocclusion by reexposing the original ruptured plaque. Ulcerated lesions are associated with a large transcardiac release of serotonin (5-hydroxytryptamine) which may reflect ulceration-induced platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, platelet aggregation within ulcerated plaques can lead to both thrombotic occlusion and distal embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     High grade residual stenosis and reduced lumen area",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual stenosis consists of persistent, nonocclusive thrombus and ruptured atheromatous plaque. The thrombus contains large amounts of thrombin substrate and is a highly thrombogenic surface, increasing platelet deposition two- to fourfold compared with adjacent areas of endothelium. Thrombolytic studies involving patients treated with either streptokinase or APSAC have shown that the presence of a high grade residual stenosis is one of the stronger predictors of recurrent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 50 patients, for example, a diameter stenosis of more than 58 percent after fibrinolysis was present in 63 percent of 27 patients who developed reocclusion, versus only 6 percent of 33 patients whose vessels remained patent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, the APRICOT study, which involved 300 patients, found that a visual stenosis &gt;90 percent was an independent predictor of reocclusion with an odds ratio of 2.3 (p = 0.006) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/15\">",
"     15",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    A small minimum lumen area is also associated with an increased incidence of reocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one series, a minimum lumen area of less than 0.4 mm2 was present in 54 percent of patients experiencing reocclusion; in contrast, all of the arteries that remained patent had a larger minimum lumen area [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lack of restoration of normal coronary flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI classification characterizes coronary blood flow in the infarct-related artery, which is usually measured at 60 to 90 minutes after the administration of thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TIMI 0 refers to the absence of any antegrade flow beyond a coronary occlusion.",
"     </li>",
"     <li>",
"      TIMI 1 flow is faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete.",
"     </li>",
"     <li>",
"      TIMI 2 flow is delayed or sluggish antegrade flow with complete filling of the distal territory",
"     </li>",
"     <li>",
"      TIMI 3 flow is normal flow which fills the distal coronary bed completely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of trials have documented less favorable outcomes in patients with TIMI grade 2 flow compared with those with TIMI grade 3 flow [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10,17,24,32-34\">",
"     10,17,24,32-34",
"    </a>",
"    ]. In the TIMI 4 trial, for example, the reocclusion rate in these two groups was 10.4 versus 2.2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10\">",
"     10",
"    </a>",
"    ]. Recurrent ischemic events are also more likely with TIMI grade 2 flow (44 versus 18 percent in the TAMI 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/31\">",
"     31",
"    </a>",
"    ]. Slowed flow may promote reocclusion by increasing the residence time of thrombogenic blood constituents, thereby favoring clot propagation in regions of low shear stress or in regions of flow reversal, stagnation, or turbulence.",
"   </p>",
"   <p>",
"    The presence of collaterals is another risk factor for reocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of competitive flow from collaterals might contribute rheologically to poststenotic flow reversal and turbulence which could facilitate thrombosis or clot propagation along the trailing edge of the lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=see_link\">",
"     \"Coronary collateral circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANGIOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary angioscopy provides direct visualization of the intravascular lumen, thereby permitting a complete description of the plaque surface. Findings with this modality suggest that continued plaque instability may account for the high rate of reocclusion. In one study of 56 patients, angioscopy was performed between 24 hours and 4 weeks after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/35\">",
"     35",
"    </a>",
"    ]. Characteristics of plaque instability were found in the majority of patients, including complex morphology and ulcerated shape, yellow color, and the presence of thrombus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSSIBLE STRATEGIES TO MINIMIZE REOCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several new antithrombotic agents and adjunctive therapies aimed at reducing reocclusion are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As an example, prolonged infusion of therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or fibrinolytic therapy may decrease reocclusion and allow immediate and delayed improvement in lumen diameter after initially successful fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H21647326#H21647326\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Direct thrombin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of patients at increased risk for early reocclusion might permit the more selective application of mechanical intervention or antithrombotic therapy (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/41\">",
"     41",
"    </a>",
"    ]. Among the 20,101 patients enrolled in the TIMI trials, percutaneous coronary intervention during the index hospitalization was associated with a lower rate of in-hospital reinfarction (1.6 versus 4.5 percent) and a lower two-year mortality rate (5.6 versus 11.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20759/abstract/5\">",
"     5",
"    </a>",
"    ]. However, no recommendation can be made regarding the optimal management of such patients in the absence of their prospective randomization among different adjunctive therapies (eg, angioplasty, coronary artery bypass grafting, or prolonged infusion of an antithrombotic agent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the low rate of reocclusion, large trials are needed to evaluate the risk of reocclusion with newer thrombolytic agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    , nPA, staphylokinase, and TNK) and newer antithrombotic regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, the routine use of percutaneous coronary intervention after fibrinolysis has likely reduced the incidence of reocclusion in recent years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H27#H27\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116884421\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical predictors of reinfarction include advanced age, shorter time to fibrinolysis, nonsmoking status, prior infarction or angina, female sex, anterior infarction, and lower systolic blood pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical predictors of reocclusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible angiographic predictors of reocclusion include TIMI flow grade, presence of ulcerated lesions or collaterals, and high grade residual stenosis.",
"     </li>",
"     <li>",
"      The routine use of aggressive antiplatelet therapy and percutaneous coronary intervention in many patients who have received fibrinolytic therapy has likely reduced the incidence of reocclusion in recent years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Possible strategies to minimize reocclusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/1\">",
"      Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/2\">",
"      Ellis SG, Topol EJ, George BS, et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation 1989; 80:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/3\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/4\">",
"      Meijer A, Verheugt FW, Werter CJ, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 1993; 87:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/5\">",
"      Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/6\">",
"      Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/7\">",
"      Birnbaum Y, Herz I, Sclarovsky S, et al. Admission clinical and electrocardiographic characteristics predicting an increased risk for early reinfarction after thrombolytic therapy. Am Heart J 1998; 135:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/8\">",
"      Becker RC. Reocclusion following successful thrombolysis. Emerging concepts. Cardiology 1993; 82:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/9\">",
"      Ott I, Malcouvier V, Sch&ouml;mig A, Neumann FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002; 105:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/10\">",
"      Gibson CM, Cannon CP, Piana RN, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1995; 25:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/11\">",
"      Serruys PW, Wijns W, van den Brand M, et al. Is transluminal coronary angioplasty mandatory after successful thrombolysis? Quantitative coronary angiographic study. Br Heart J 1983; 50:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/12\">",
"      Gash AK, Spann JF, Sherry S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986; 57:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/13\">",
"      Harrison DG, Ferguson DW, Collins SM, et al. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation 1984; 69:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/14\">",
"      Badger RS, Brown BG, Kennedy JW, et al. Usefulness of recanalization to luminal diameter of 0.6 millimeter or more with intracoronary streptokinase during acute myocardial infarction in predicting \"normal\" perfusion status, continued arterial patency and survival at one year. Am J Cardiol 1987; 59:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/15\">",
"      Veen G, Meyer A, Verheugt FW, et al. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. J Am Coll Cardiol 1993; 22:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/16\">",
"      Davies SW, Marchant B, Lyons JP, et al. Irregular coronary lesion morphology after thrombolysis predicts early clinical instability. J Am Coll Cardiol 1991; 18:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/17\">",
"      Grines CL, Topol EJ, Bates ER, et al. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. Am Heart J 1988; 115:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/18\">",
"      Alison HW, Russell RO Jr, Mantle JA, et al. Coronary anatomy and arteriography in patients with unstable angina pectoris. Am J Cardiol 1978; 41:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/19\">",
"      Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/20\">",
"      Wilson RF, Holida MD, White CW. Quantitative angiographic morphology of coronary stenoses leading to myocardial infarction or unstable angina. Circulation 1986; 73:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/21\">",
"      Bresnahan DR, Davis JL, Holmes DR Jr, Smith HC. Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: role of unstable angina. J Am Coll Cardiol 1985; 6:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/22\">",
"      McMahon MM, Brown BG, Cukingnan R, et al. Quantitative coronary angiography: measurement of the \"critical\" stenosis in patients with unstable angina and single-vessel disease without collaterals. Circulation 1979; 60:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/23\">",
"      Wall TC, Mark DB, Califf RM, et al. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. Am J Cardiol 1989; 63:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/24\">",
"      Reiner JS, Lundergan CF, van den Brand M, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1994; 24:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/25\">",
"      Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. Circulation 1989; 80:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/26\">",
"      Sansa M, Cernigliaro C, Bolognese L, et al. Angiographic morphology and response to therapy in unstable angina. Clin Cardiol 1988; 11:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/27\">",
"      Bugiardini R, Pozzati A, Borghi A, et al. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome. Am J Cardiol 1991; 67:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/28\">",
"      van den Berg EK, Schmitz JM, Benedict CR, et al. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/29\">",
"      Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/30\">",
"      Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/31\">",
"      Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/32\">",
"      Karagounis L, Sorensen SG, Menlove RL, et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/33\">",
"      Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/34\">",
"      Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/35\">",
"      Van Belle E, Lablanche JM, Bauters C, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 1998; 97:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/36\">",
"      Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/37\">",
"      von Essen R, Zeymer U, Tebbe U, et al. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhaus&auml;rzte. Coron Artery Dis 1998; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/38\">",
"      Johns JA, Gold HK, Leinbach RC, et al. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Circulation 1988; 78:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/39\">",
"      Serruys PW, Arnold AE, Brower RW, et al. Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction--a quantitative coronary angiography study of a randomized trial. Eur Heart J 1987; 8:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/40\">",
"      Arnout J, Simoons M, de Bono D, et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992; 20:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20759/abstract/41\">",
"      Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993; 22:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 62 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20759=[""].join("\n");
var outline_f20_17_20759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116884421\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PREDICTORS OF REOCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLE OF FIBRINOLYSIS IN REOCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANGIOGRAPHIC PREDICTORS OF REOCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lesion ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      High grade residual stenosis and reduced lumen area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lack of restoration of normal coronary flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANGIOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSSIBLE STRATEGIES TO MINIMIZE REOCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116884421\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/62\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/62|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/20/8526\" title=\"figure 1\">",
"      Angiographic variables associated with reocclusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=related_link\">",
"      Coronary collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_17_20760="Conjunctivitis";
var content_f20_17_20760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Conjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20760/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20760/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20760/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20760/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/17/20760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctivitis is a common patient complaint. It is the most likely diagnosis in a patient with a red eye and discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute conjunctivitis is usually a benign, self-limited condition or one that is easily treated. When making a diagnosis of acute conjunctivitis, one needs to make certain that sight-threatening and pathologic processes have been ruled out. In contrast to acute conjunctivitis, these entities, such as acute angle closure glaucoma, iritis, and infectious keratitis, must be managed by ophthalmologists and will not be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctivitis literally means \"inflammation of the conjunctiva.\" The conjunctiva is the mucous membrane that lines the inside surface of the lids and covers the surface of the globe up to the limbus (the junction of the sclera and the cornea). The portion covering the globe is the \"bulbar conjunctiva,\" and the portion lining the lids is the \"tarsal conjunctiva.\"",
"   </p>",
"   <p>",
"    The conjunctiva is comprised of an epithelium and a substantia propria. The epithelium is a non-keratinized squamous epithelium that also contains goblet cells. The substantia propria is highly vascularized and is the site of considerable immunologic activity.",
"   </p>",
"   <p>",
"    The conjunctiva is generally transparent. When it is inflamed, as in conjunctivitis, it looks pink or red at a distance. Up close the examiner can discern fine blood vessels, termed \"injection,\" in contrast to extravasated blood, which is seen in subconjunctival hemorrhage. Degenerative, inflammatory, and infiltrative processes can cause the conjunctiva to become opacified, taking on a white, yellow, or fleshy appearance. All conjunctivitis is characterized by a red eye, but not all red eyes are conjunctivitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute conjunctivitis can be classified as infectious or noninfectious and further divided into four main types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bacterial",
"     </li>",
"     <li>",
"      Viral",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninfectious",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Allergic",
"     </li>",
"     <li>",
"      Nonallergic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of each is different in pediatric and adult populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Bacterial conjunctivitis is more common in children than in adults. Although published studies suggest that the majority of cases in children are bacterial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/1,3\">",
"     1,3",
"    </a>",
"    ], the prevalence of bacterial conjunctivitis seen in studies presumably reflects the greater likelihood that patients with copious discharge will present for care. Clinical experience suggests that most infectious conjunctivitis is viral in both adults and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bacterial conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial conjunctivitis is commonly caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. S. aureus infection is common in adults; the other pathogens are more common in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial conjunctivitis is spread by direct contact with the patient and his or her secretions or with contaminated objects and surfaces. It is highly contagious. As an example, outbreaks have been described caused by atypical unencapsulated strains of S. pneumoniae in which attack rates were as high as 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with bacterial conjunctivitis typically complain of redness and discharge in one eye, although it can also be bilateral. Similar to viral and allergic conjunctivitis (see below), the affected eye often is \"stuck shut\" in the morning. This point of history is not generally useful in distinguishing the various types of conjunctivitis. As an example, in a cohort of 184 adults with a red eye and either an eye stuck shut in the morning or purulent or mucopurulent discharge, among 57 patients with bacterial conjunctivitis, 53 percent had one eye stuck shut and 39 percent had two eyes stuck shut; among 120 patients without bacterial conjunctivitis, 62 percent had one eye stuck shut and 11 percent had two eyes stuck shut [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The purulent discharge continues throughout the day. The discharge is thick and globular; it may be yellow, white, or green (",
"    <a class=\"graphic graphic_picture graphicRef55606 \" href=\"UTD.htm?10/0/10241\">",
"     picture 1",
"    </a>",
"    ). The appearance differs from that of viral or allergic conjunctivitis, which often present with a mostly watery discharge during the day, with a scanty, stringy component that is mucus rather than pus.",
"   </p>",
"   <p>",
"    On examination, the patient with bacterial conjunctivitis typically will have purulent discharge at the lid margins and in the corners of the eye. More purulent discharge appears within minutes of wiping the lids. This contrasts with patients with viral or allergic conjunctivitis, in whom the eyes appear watery, there may be mucus present on close inspection of the tear film or if one pulls down the lower lid, but pus does not appear spontaneously and continuously at the lid margin and in the corners of the eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hyperacute bacterial conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neisseria species, particularly N. gonorrhoeae, can cause a hyperacute bacterial conjunctivitis that is severe and sight-threatening, requiring immediate ophthalmologic referral [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/8\">",
"     8",
"    </a>",
"    ]. The organism is usually transmitted from the genitalia to the hands and then to the eyes. Concurrent urethritis is typically present.",
"   </p>",
"   <p>",
"    The eye infection is characterized by a profuse purulent discharge present within 12 hours of inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/9\">",
"     9",
"    </a>",
"    ]; the amount of discharge is striking. Other symptoms are rapidly progressive and include redness, irritation, and tenderness to palpation. There is typically marked chemosis, lid swelling, and tender preauricular adenopathy. Gram negative diplococci can be identified on Gram stain of the discharge.",
"   </p>",
"   <p>",
"    These patients require hospitalization for systemic and topical therapy and for monitoring of the ocular component. Keratitis and perforation can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Viral conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral conjunctivitis is typically caused by adenovirus, with many serotypes implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/10\">",
"     10",
"    </a>",
"    ]. The conjunctivitis may be part of a viral prodrome followed by adenopathy, fever, pharyngitis, and upper respiratory tract infection, or the eye infection may be the only manifestation of the disease. Viral conjunctivitis is highly contagious; it is spread by direct contact with the patient and his or her secretions or with contaminated objects and surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral conjunctivitis typically presents as injection; watery or mucoserous discharge (",
"    <a class=\"graphic graphic_picture graphicRef56481 \" href=\"UTD.htm?0/40/642\">",
"     picture 2",
"    </a>",
"    ); and a burning, sandy, or gritty feeling in one eye. Patients may report \"pus\" in the eye, but on further questioning they have morning crusting followed by watery discharge, perhaps with some scanty mucus throughout the day.",
"   </p>",
"   <p>",
"    The second eye usually becomes involved within 24 to 48 hours, although unilateral signs and symptoms do not rule out a viral process. Patients often believe that they have a bacterial conjunctivitis that has spread to the fellow eye; they do not appreciate that this is the ocular manifestation of a systemic problem, even if they are miserable from viral symptoms at the same time.",
"   </p>",
"   <p>",
"    On examination there typically is only mucoid discharge if one pulls down the lower lid or looks very closely in the corner of the eye. Usually there is profuse tearing rather than discharge. The tarsal conjunctiva may have a follicular or \"bumpy\" appearance. There may be an enlarged and tender preauricular node.",
"   </p>",
"   <p>",
"    Viral conjunctivitis is a self-limited process. The clinical course parallels that of the common cold. While recovery can begin with days, the symptoms frequently get worse for the first three to five days, with very gradual resolution over the following one to two weeks for a total course of two to three weeks. Just as a patient with a cold can have morning coughing and nasal congestion or discharge two weeks after symptoms first arise, patients with viral conjunctivitis may have morning crusting two weeks after the initial symptoms, although the daytime redness, irritation, and tearing should be much improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Epidemic keratoconjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One form of viral conjunctivitis, epidemic keratoconjunctivitis (EKC), is particularly fulminant, causing a keratitis (inflammation of the cornea) in addition to conjunctivitis. It is typically caused by adenovirus types 8, 19, and 37 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/12\">",
"     12",
"    </a>",
"    ]; the same viral strain that causes EKC in one patient may cause ordinary viral conjunctivitis in another, probably due to variation in host immune factors. The corneal and conjunctival epithelium are both involved. In addition to the typical symptoms of viral conjunctivitis, the patient develops a foreign body sensation and multiple corneal infiltrates barely visible with a penlight to the skilled observer. The foreign body sensation is severe enough to preclude opening the eyes spontaneously, and the infiltrates typically degrade acuity by two or three lines to the",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    range.",
"   </p>",
"   <p>",
"    Keratitis is potentially vision-threatening, and these patients should be referred to an ophthalmologist to confirm the diagnosis and to decide if a course of topical glucocorticoids is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic conjunctivitis is caused by airborne allergens contacting the eye that, with specific IgE, cause local mast cell degranulation and the release of chemical mediators including histamine, eosinophil chemotactic factors, and platelet-activating factor, among others. It typically presents as bilateral redness, watery discharge, and itching (",
"    <a class=\"graphic graphic_picture graphicRef79978 \" href=\"UTD.htm?22/53/23377\">",
"     picture 3",
"    </a>",
"    ). Itching is the cardinal symptom of allergy, distinguishing it from a viral etiology, which is more typically described as grittiness, burning, or irritation. Eye rubbing can worsen symptoms. Patients with allergic conjunctivitis often have a history of atopy, seasonal allergy, or specific allergy (eg, to cats).",
"   </p>",
"   <p>",
"    Similar to viral conjunctivitis, allergic conjunctivitis causes diffuse injection with a follicular appearance to the tarsal conjunctiva and profuse watery or mucoserous discharge. There may be morning crusting. It is the complaint of itching and the history of allergy or hay fever as well as a recent exposure that allows the distinction between allergic and viral conjunctivitis; the clinical findings are the same.",
"   </p>",
"   <p>",
"    In some cases of allergic conjunctivitis, there is marked chemosis (conjunctival edema); in extreme instances, there can be bullous chemosis, in which the bulging, edematous conjunctiva extends forward beyond the lid margins. Bullous chemosis is most commonly seen in patients with extreme hypersensitivity to cats. A detailed discussion of allergic disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Noninfectious, nonallergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can develop a red eye and discharge that is not related to an infectious or inflammatory process. The discharge is more likely mucus than pus. Usually the cause is a transient mechanical or chemical insult.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with dry eye may report chronic or intermittent redness or discharge and may interpret these symptoms as being related to an infectious cause.",
"     </li>",
"     <li>",
"      Patients whose eyes are irrigated after a chemical splash may have redness and discharge; this is often related to the mechanical irritation of irrigation rather than superinfection.",
"     </li>",
"     <li>",
"      A patient with an ocular foreign body that was spontaneously expelled may have redness and discharge for 12 to 24 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these causes generally improve spontaneously within 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chlamydial infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Trachoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctivitis is the major clinical manifestation of active trachoma, a disorder that is largely limited to endemic areas in underdeveloped regions. Issues related to trachoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, diagnosis, and management of trachoma\", section on 'Active trachoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adult inclusion conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult inclusion conjunctivitis is not strictly an acute conjunctivitis, but rather a chronic, indolent conjunctivitis. It is a sexually transmitted infection caused by certain serotypes of Chlamydia trachomatis. Concurrent asymptomatic urogenital infection is typically present.",
"   </p>",
"   <p>",
"    The eye infection presents as a unilateral, or sometimes bilateral, follicular conjunctivitis of weeks to months duration that has not responded to topical antibiotic therapy. There can be an associated keratitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctivitis is a clinical diagnosis of exclusion. The diagnosis can be made in a patient with a red eye and discharge only if the vision is normal and there is no evidence of keratitis, iritis, or angle closure glaucoma. A detailed description of how to take a history and examine a patient with a red eye is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with all types of conjunctivitis complain of morning crusting and daytime redness and discharge. On examination, there should be no focal pathology in the lids such as hordeolum (stye), cancerous mound or ulceration, or blepharitis (diffuse eyelid margin thickening and hyperemia with lash crusts) (",
"    <a class=\"graphic graphic_picture graphicRef53218 \" href=\"UTD.htm?12/11/12465\">",
"     picture 4",
"    </a>",
"    ). In these other disorders, conjunctival hyperemia, if present, is reactive rather than primary.",
"   </p>",
"   <p>",
"    The redness or injection in conjunctivitis should be diffuse, involving the bulbar (globe) conjunctiva for 360&ordm; as well as the palpebral or tarsal conjunctiva (the mucus membrane on the inner surface of the lids). Another diagnosis such as foreign body, pterygium, or episcleritis should be considered if the conjunctival injection is localized rather than diffuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41879?source=see_link\">",
"     \"Pterygium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serious conditions that cause a red eye, keratitis, iritis, and angle closure, will cause 360&ordm; involvement of the bulbar conjunctiva, often in a ciliary flush pattern, but will spare the tarsal conjunctiva. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Red flags'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Distinguishing bacterial conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms that distinguish bacterial conjunctivitis from other etiologies are discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Bacterial conjunctivitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cultures are not necessary for the initial diagnosis and therapy of conjunctivitis. Ophthalmologists do not generally perform cultures even when they are referred cases that have not responded to initial therapy. Typically there are points in the history, findings on examination, or errors in initial diagnosis or therapy that guide subsequent therapy, rather than the detection of a resistant organism. The exception is patients with symptoms of hyperacute conjunctivitis in whom Giemsa and Gram stains may be helpful to identify Neisseria gonorrhoeae. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Hyperacute bacterial conjunctivitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A rapid (10 minute) test for adenoviral conjunctivitis is now available. As discussed above, adenovirus is the major cause of viral conjunctivitis and likely accounts for a significant proportion of clinical encounters for conjunctivitis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Viral conjunctivitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This test has reasonable sensitivity and specificity under study conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/13\">",
"     13",
"    </a>",
"    ] and might aid clinicians in determining a viral, as opposed to bacterial etiology, thereby avoiding empiric antibiotic therapy. Elimination of empiric antibiotic therapy has theoretical benefits including prescription drug savings, avoidance of side effects, and reduction of antibiotic resistance. A modelled cost effectiveness analysis suggests a potential for significant cost savings with point of care testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pitfalls in diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often call all cases of red eye \"conjunctivitis\" and presume that all cases are bacterial and require antibiotics. When a patient calls to report \"conjunctivitis\" or \"pink eye,\" clinicians should not accept that as a diagnosis but should rather review the history, symptoms, and signs prior to treating. One should be wary of the diagnosis of conjunctivitis in any patient with a recent history of trauma; there may be a corneal or conjunctival foreign body or traumatic iritis. Warning signs for sight-threatening conditions should be excluded. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Red flags'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients will call all types of discharge \"pus.\" It is worthwhile to distinguish the character of the discharge to make a more specific diagnosis. As mentioned above, in bacterial conjunctivitis the complaint of discharge predominates, while in viral and allergic conjunctivitis patients report a burning and gritty feeling or itching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Contact lens wearers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of conjunctivitis should be made carefully in contact lens wearers, who are subject to myriad secondary chronic conjunctivitides that require a change in contact lens fit, lens type, or lens hygiene, and may require suppression of hypersensitivity. More importantly, soft contact lens wearers have a high risk of pseudomonal keratitis, especially with use of extended-wear lenses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This causes an acute red eye and discharge in association with an ulcerative keratitis. The ulcerative keratitis can lead to ocular perforation within 24 hours if it is not recognized and treated appropriately. Thus, the presence of keratitis should be ruled out prior to presuming and treating conjunctivitis. Keratitis causes objective foreign body sensation, and the patient is usually unable to spontaneously open the eye or keep it open; there is typically a corneal opacity visible with a penlight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A contact lens wearer with an acute red eye and discharge should be advised to discontinue contact lens wear immediately and to be seen by an eye care provider if the symptoms do not improve in 12 to 24 hours. The patient may be treated for acute conjunctivitis only if there is no evidence of keratitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the red eye\", section on 'Infectious keratitis'",
"    </a>",
"    .) Chronic conjunctivitis in these patients is best addressed by a knowledgeable",
"    <span class=\"nowrap\">",
"     optometrist/ophthalmologist",
"    </span>",
"    team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Red flags",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed description of how to take a history and examine a patient with a red eye is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .) Warning signs of a more serious problem that should prompt evaluation by an ophthalmologist include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction of visual acuity",
"     </li>",
"     <li>",
"      Ciliary flush: A pattern of injection in which the redness is most pronounced in a ring at the limbus (the limbus is the transition zone between the cornea and the sclera)",
"     </li>",
"     <li>",
"      Photophobia",
"     </li>",
"     <li>",
"      Severe foreign body sensation that prevents the patient from keeping the eye open",
"     </li>",
"     <li>",
"      Corneal opacity",
"     </li>",
"     <li>",
"      Fixed pupil",
"     </li>",
"     <li>",
"      Severe headache with nausea",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral, allergic, and nonspecific conjunctivitis are all self-limited processes; specific therapy reduces symptoms but does nothing to alter the clinical course of the condition. Bacterial conjunctivitis also is likely to be self-limited in most cases (",
"    <a class=\"graphic graphic_figure graphicRef65460 \" href=\"UTD.htm?15/11/15550\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/17\">",
"     17",
"    </a>",
"    ]. Treatment with antibiotic eye drops, however, probably shortens the clinical course if given early, before day six [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should be directed at the likely etiology of conjunctivitis suggested by the history and physical exam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bacterial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate choices for bacterial conjunctivitis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ophthalmic ointment or",
"    <span class=\"nowrap\">",
"     polymyxin/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"      trimethoprim",
"     </a>",
"    </span>",
"    drops (",
"    <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"     table 1",
"    </a>",
"    ). The dose is 0.5 inch (1.25 cm) of ointment deposited inside the lower lid or 1 to 2 drops instilled four times daily for five to seven days. It is reasonable to reduce the dose from four times daily to twice daily, if there is improvement in symptoms after a few days. Sulfa ophthalmic drops are also available but are not a first-line option because of the potential for rare but serious allergic events.",
"   </p>",
"   <p>",
"    These agents cover the most common pathogens responsible for bacterial conjunctivitis, and patients should respond to this treatment within one to two days by showing a decrease in discharge, redness, and irritation. Patients who do not respond should be referred to an ophthalmologist.",
"   </p>",
"   <p>",
"    Ointment is preferred over drops for children, those with poor compliance, or those in whom it is difficult to administer eye medications. Ointment stays on the lids and can have therapeutic effect even if it is not clear that any of the dose was applied directly to the conjunctiva. Because ointments blur vision for 20 minutes after the dose is administered, drops are preferable for most adults who need to read, drive, and perform other tasks that require clear vision immediately after dosing.",
"   </p>",
"   <p>",
"    Alternative therapies include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ointment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    ointment, polymyxin-bacitracin ointment, fluoroquinolone drops, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    drops. Aminoglycoside drops and ointments are poor choices since they are toxic to the corneal epithelium and can cause a reactive keratoconjunctivitis after several days of use.",
"   </p>",
"   <p>",
"    The fluoroquinolones are effective and well-tolerated; they are the treatment of choice for corneal ulcers and are extremely effective against pseudomonas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    .) However, fluoroquinolones are not first-line therapy for routine cases of bacterial conjunctivitis because of concerns regarding emerging resistance and cost. The exception is conjunctivitis in a contact lens wearer; once keratitis has been ruled out, it is reasonable to treat these individuals with a fluoroquinolone due to the high incidence of pseudomonas infection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    was approved in the United States in 2008 as an ophthalmic solution for bacterial conjunctivitis in patients one year of age and older. It is dosed less frequently than other ophthalmic solutions (1 drop twice daily for two days, then one drop daily for five days), but is considerably more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    , and its availability raises a concern about promoting the emergence of organisms resistant to azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, any contact lens wearer with a red eye should discontinue contact lens wear. If the diagnosis is conjunctivitis, contact lens wear can resume when the eye is white and has no discharge for 24 hours after the completion of antibiotic therapy. The lens case should be discarded and the lenses subjected to overnight disinfection or replaced if disposable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Viral",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific antiviral agent for the treatment of viral conjunctivitis. Some patients derive symptomatic relief from topical",
"    <span class=\"nowrap\">",
"     antihistamine/decongestants.",
"    </span>",
"    These are available over-the-counter (Naphcon-A&reg;, Ocuhist&reg;, generics). It is worthwhile to explain that these agents treat the symptoms but not the disease; just as \"cold remedies\" treat the symptoms rather than the cause of a cold. Warm or cool compresses may provide additional symptomatic relief. Systemic agents play no role in viral conjunctivitis.",
"   </p>",
"   <p>",
"    Some providers prescribe antibiotic ointments for viral conjunctivitis to provide lubrication. A more sensible alternative is to use nonantibiotic lubricating agents such as those used for noninfectious conjunctivitis (",
"    <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Noninfectious, nonallergic conjunctivitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients must be told that the eye irritation and discharge may get worse for three to five days before getting better, that symptoms can persist for two to three weeks, and that use of any topical agent for that duration might result in irritation and toxicity, which can itself cause redness and discharge. Clinicians must be wary of trying one agent after another in patients with viral conjunctivitis who are expecting drugs to \"cure\" their symptoms. Patient education is often more effective than prolonged or additional therapies for patients who experience improvement but incomplete resolution of symptoms after a few days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Adult inclusion conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis can be confirmed with Giemsa or DFA (direct fluorescent antibody) staining of conjunctival smears or by culture or PCR of swabbed specimens.",
"   </p>",
"   <p>",
"    Systemic therapy is required to eradicate the infection. Treatment is typically with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Allergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous therapies available for allergic conjunctivitis (",
"    <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Noninfectious nonallergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conjunctival surface regenerates rapidly from insults that precipitate noninfectious conjunctivitis, leading to spontaneous resolution of symptoms. Nevertheless, these patients may feel better more quickly with the use of topical lubricants, which can be purchased over-the-counter as drops and ointments (",
"    <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"     table 1",
"    </a>",
"    ). Preservative-free preparations are more expensive and are necessary only in severe cases of dry eye or in highly allergic patients.",
"   </p>",
"   <p>",
"    Lubricant drops can be used as often as hourly with no side effects. The ointment provides longer lasting relief but blurs vision; thus, many patients use the ointment only at bedtime. It may be worthwhile to switch brands if a patient finds one brand of drop or ointment irritating since each preparation contains different active ingredients, vehicles, and preservatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Empiric approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers are often pressured to prescribe antibiotics for conjunctivitis, even when there is nothing to suggest a bacterial process. This can be a particular issue for parents because most daycare centers and schools require that students with conjunctivitis receive 24 hours of topical therapy before returning to school. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Returning to work or school'",
"    </a>",
"    below.) Patients may sometimes request to be treated without being examined.",
"   </p>",
"   <p>",
"    We believe that no patient should be treated for conjunctivitis without an examination. In principle, only those diagnosed with bacterial conjunctivitis should receive antibiotics. If the decision is made to treat empirically with antibiotics, we recommend choosing an inexpensive nontoxic antibiotic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ophthalmic ointment or sulfa ophthalmic drops (except in the case of contact lens wearers as discussed above). Ointment is preferred over drops for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Glucocorticoid use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical glucocorticoids have",
"    <strong>",
"     no role",
"    </strong>",
"    in the management of acute conjunctivitis by primary care clinicians. They can cause sight-threatening complications (eg, corneal scarring, melting, and perforation) when used inappropriately in herpes simplex, fungal, other viral or bacterial keratitis, all of which can present as a red eye and discharge. Chronic topical glucocorticoid treatments can also cause cataract and glaucoma. Ophthalmologists may prescribe glucocorticoids in certain cases of ocular allergy, viral keratitis, and chronic blepharitis. One study from a specialty eye care center in the United Kingdom suggested patients perceived benefit from a short course of topical glucocorticoids in presumed viral conjunctivitis with no harmful effect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20760/abstract/22\">",
"     22",
"    </a>",
"    ], but this study also found that most patients receiving lubricant drops also perceived benefit. Combination",
"    <span class=\"nowrap\">",
"     steroid/antibiotic",
"    </span>",
"    drops present similar risk without proven benefit and are not recommend in the treatment of acute conjunctivitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Lack of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, patients with acute bacterial conjunctivitis should respond to treatment within one to two days by showing a decrease in discharge, redness, and irritation. Patients who do not respond should be referred to an ophthalmologist. Patients with other forms of acute conjunctivitis should respond within two weeks, and those who do not should also be referred to an ophthalmologist.",
"   </p>",
"   <p>",
"    Diagnoses to consider in patients who fail to respond to therapy include dry eye, medicamentosa (drug toxicity), pterygium (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41879?source=see_link\">",
"     \"Pterygium\"",
"    </a>",
"    ), blepharoconjunctivitis, and adult inclusion conjunctivitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RETURNING TO WORK OR SCHOOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are often asked to advise patients and families as to when it is safe to return to work or school. Bacterial and viral conjunctivitis are both highly contagious and spread by direct contact with secretions or contact with contaminated objects. Infected individuals should not share handkerchiefs, tissues, towels, cosmetics, linens, or silverware. The safest approach to prevent spread to others is to stay home until there is no longer any discharge, but this is not feasible for most students and for those who work outside the home. Most daycare centers and schools require that students receive 24 hours of topical therapy before returning to school. Such therapy will probably reduce the transmission of conjunctivitis due to bacterial infection but will do nothing to reduce the spread of viral infections.",
"   </p>",
"   <p>",
"    We suggest advising patients to consider that their problem is like a cold, and their decision to return to work or school should be similar to the one they would make in that situation. Those who have contact with the very old, the very young, and immune-compromised individuals should take care to avoid spread of infection from their eye secretions to these susceptible people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       \"Patient information: Conjunctivitis (pinkeye) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       \"Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/27/5553?source=see_link\">",
"       \"Patient information: Allergic conjunctivitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjunctivitis is a common condition. The diagnosis can be made in a patient with a red eye and discharge only if the vision is normal and there is no evidence of keratitis, iritis, or angle closure glaucoma. Warning signs for these conditions are discussed above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Red flags'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conjunctivitis may be infectious (bacterial or viral) or noninfectious (allergic, toxic, dryness, and others). Most infectious conjunctivitis is probably viral, although bacterial conjunctivitis is more common in children than in adults. Viral and bacterial conjunctivitis are both highly contagious. All etiologies of conjunctivitis can cause symptoms of the eyes being stuck closed in the morning.",
"     </li>",
"     <li>",
"      A diagnosis of bacterial conjunctivitis should only be made in patients with thick purulent discharge that continues throughout the day. The discharge can generally be seen at the lid margins and at the corner of the eye. Bacterial conjunctivitis is usually unilateral but can be bilateral. Neisseria species can cause a hyperacute bacterial conjunctivitis that is severe and sight-threatening, requiring immediate ophthalmologic referral.",
"     </li>",
"     <li>",
"      Viral conjunctivitis typically presents as injection, mucoid or serous discharge, and a burning, sandy, or gritty feeling in one eye. It may be part of a viral prodrome or systemic viral illness, or it may be an isolated manifestation of viral illness. The second eye usually becomes involved within 24 to 48 hours, although unilateral signs and symptoms do not rule out a viral process. On examination there typically is only mucoid discharge if one pulls down the lower lid or looks very closely in the corner of the eye. Usually there is profuse tearing rather than discharge. The tarsal conjunctiva may have a follicular or \"bumpy\" appearance. There may be an enlarged and tender preauricular node. The clinical course parallels that of the common cold. The symptoms generally get worse for the first three to five days, with very gradual resolution over the following one to two weeks for a total course of two to three weeks.",
"     </li>",
"     <li>",
"      Allergic conjunctivitis typically presents as bilateral redness, watery discharge, and itching. Itching is the cardinal symptom of allergy, distinguishing it from a viral etiology, which is more typically described as grittiness, burning, or irritation; the clinical findings are the same as with viral conjunctivitis. Patients with allergic conjunctivitis often have a history of atopy, seasonal allergy, or specific allergy (eg, to cats).",
"     </li>",
"     <li>",
"      Other noninfectious conjunctivitis presents as a red eye and mucoid discharge. The usual causes are mechanical or chemical insult, or a dry eye from exposure or lack of tear production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial conjunctivitis should be treated with inexpensive nontoxic topical antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment (",
"      <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"       table 1",
"      </a>",
"      ). The dose is 0.5 inch (1.25 cm) of ointment inside the lower lid or 1 to 2 drops four times daily for five to seven days. The dose may be reduced to twice daily if there is improvement in symptoms after a few days.",
"     </li>",
"     <li>",
"      Ointment is preferred over drops for children, those with poor compliance, and those in whom it is difficult to administer eye medications. However, ointments blur vision for 20 minutes after the dose is administered.",
"     </li>",
"     <li>",
"      Patients with bacterial conjunctivitis should respond in one to two days with a decrease in discharge, redness, and irritation. Patients who do not respond should be referred to an ophthalmologist.",
"     </li>",
"     <li>",
"      There is no specific therapy for viral conjunctivitis, although patients may receive symptomatic benefit from topical",
"      <span class=\"nowrap\">",
"       antihistamine/decongestants",
"      </span>",
"      or from lubricating agents like those used for noninfectious conjunctivitis (",
"      <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The management of allergic conjunctivitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"       \"Allergic conjunctivitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with noninfectious conjunctivitis may feel better with topical lubricants that can be used as often as hourly (",
"      <a class=\"graphic graphic_table graphicRef55299 \" href=\"UTD.htm?36/58/37804\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Primary care clinicians should not prescribe topical glucocorticoids for acute conjunctivitis.",
"     </li>",
"     <li>",
"      Although we do not recommend antibiotic therapy for nonbacterial conjunctivitis, if this is required for the patient to return to school or daycare, providers should select an inexpensive topical antibiotic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      or sulfa.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/1\">",
"      Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr 1993; 122:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/2\">",
"      Fitch CP, Rapoza PA, Owens S, et al. Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital. Ophthalmology 1989; 96:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/3\">",
"      Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunctivitis in children. J Pediatr 1981; 98:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/4\">",
"      Friedlaender MH. A review of the causes and treatment of bacterial and allergic conjunctivitis. Clin Ther 1995; 17:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/5\">",
"      Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med 2003; 348:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/6\">",
"      Crum NF, Barrozo CP, Chapman FA, et al. An outbreak of conjunctivitis due to a novel unencapsulated Streptococcus pneumoniae among military trainees. Clin Infect Dis 2004; 39:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/7\">",
"      Rietveld RP, ter Riet G, Bindels PJ, et al. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004; 329:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/8\">",
"      Ullman S, Roussel TJ, Culbertson WW, et al. Neisseria gonorrhoeae keratoconjunctivitis. Ophthalmology 1987; 94:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/9\">",
"      Wan WL, Farkas GC, May WN, Robin JB. The clinical characteristics and course of adult gonococcal conjunctivitis. Am J Ophthalmol 1986; 102:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/10\">",
"      Roba LA, Kowalski RP, Gordon AT, et al. Adenoviral ocular isolates demonstrate serotype-dependent differences in in vitro infectivity titers and clinical course. Cornea 1995; 14:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/11\">",
"      Azar MJ, Dhaliwal DK, Bower KS, et al. Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol 1996; 121:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/12\">",
"      Jernigan JA, Lowry BS, Hayden FG, et al. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis 1993; 167:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/13\">",
"      Sambursky R, Tauber S, Schirra F, et al. The RPS adeno detector for diagnosing adenoviral conjunctivitis. Ophthalmology 2006; 113:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/14\">",
"      Udeh BL, Schneider JE, Ohsfeldt RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. Am J Med Sci 2008; 336:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/15\">",
"      Cheng KH, Leung SL, Hoekman HW, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 1999; 354:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/16\">",
"      Tabbara KF, El-Sheikh HF, Aabed B. Extended wear contact lens related bacterial keratitis. Br J Ophthalmol 2000; 84:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/17\">",
"      Rose PW, Harnden A, Brueggemann AB, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet 2005; 366:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/18\">",
"      Sheikh A, Hurwitz B, van Schayck CP, et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2012; 9:CD001211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/19\">",
"      Ophthalmic azithromycin (AzaSite). Med Lett Drugs Ther 2008; 50:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/20\">",
"      Friedlaender MH. The current and future therapy of allergic conjunctivitis. Curr Opin Ophthalmol 1998; 9:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/21\">",
"      Ciprandi G, Buscaglia S, Cerqueti PM, Canonica GW. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs 1992; 43:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20760/abstract/22\">",
"      Wilkins MR, Khan S, Bunce C, et al. A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis. Br J Ophthalmol 2011; 95:1299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6907 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20760=[""].join("\n");
var outline_f20_17_20760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bacterial conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hyperacute bacterial conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Viral conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Epidemic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Noninfectious, nonallergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chlamydial infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Trachoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adult inclusion conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Distinguishing bacterial conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pitfalls in diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Contact lens wearers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Red flags",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bacterial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Viral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Adult inclusion conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Allergic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Noninfectious nonallergic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Empiric approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Glucocorticoid use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Lack of response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RETURNING TO WORK OR SCHOOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6907|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/11/15550\" title=\"figure 1\">",
"      Abx for infect conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6907|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/0/10241\" title=\"picture 1\">",
"      Bacterial conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/40/642\" title=\"picture 2\">",
"      Viral conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/53/23377\" title=\"picture 3\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/11/12465\" title=\"picture 4\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/58/37804\" title=\"table 1\">",
"      Treatment of conjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/27/5553?source=related_link\">",
"      Patient information: Allergic conjunctivitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41879?source=related_link\">",
"      Pterygium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_17_20761="Abdominal compartment syndrome";
var content_f20_17_20761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal compartment syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Mark Gestring, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20761/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/17/20761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal compartment syndrome refers to organ dysfunction caused by intraabdominal hypertension. It may be under-recognized because it primarily affects patients who are already quite ill and whose organ dysfunction may be incorrectly ascribed to progression of the primary illness. Since treatment can improve organ dysfunction, it is important that the diagnosis be considered in the appropriate clinical situation. The definition, incidence, risk factors, clinical presentation, diagnosis, management, and prognosis of intraabdominal hypertension and abdominal compartment syndrome are reviewed here.",
"   </p>",
"   <p>",
"    The management of the open abdomen following abdominal decompression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"     \"Management of the open abdomen in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal hypertension (IAH) and abdominal compartment syndrome (ACS) are distinct clinical entities and should not be used interchangeably.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intraabdominal pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal pressure (IAP) is the steady state pressure concealed within the abdominal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"     1",
"    </a>",
"    ]. For most critically ill patients, an IAP of 5 to 7 mmHg is considered normal. In a prospective cohort study of 77 supine hospitalized patients, the IAP averaged 6.5 mmHg and was directly related to body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal range described above is not applicable for all patients. Patients with increased abdominal girth that developed slowly may have higher baseline intraabdominal pressures. As an example, morbidly obese and pregnant individuals can have chronically elevated intraabdominal pressure (as high as 10 to 15 mmHg) without adverse sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264093045\">",
"    <span class=\"h2\">",
"     Abdominal perfusion pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal perfusion pressure (APP) is calculated as the mean arterial pressure (MAP) minus the IAP: APP = MAP - IAP. Elevated intraabdominal pressure reduces blood flow to the abdominal viscera [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/3\">",
"     3",
"    </a>",
"    ]. Multiple regression analysis has found that APP is better than other resuscitation endpoints such as arterial pH, base deficit, arterial lactate, and hourly urinary output for predicting outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/4\">",
"     4",
"    </a>",
"    ]. A target APP of at least 60 mmHg is correlated with improved survival from IAH and ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intraabdominal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal hypertension (IAH) is defined as a sustained intraabdominal pressure &ge;12 mmHg (",
"    <a class=\"graphic graphic_figure graphicRef69364 \" href=\"UTD.htm?33/42/34479\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. Although this value was established arbitrarily, it is used in many research studies and distinguishes most patients whose intraabdominal pressure is inappropriately elevated. Intraabdominal pressure can be further graded as follows: Grade I = IAP 12 to 15 mmHg; Grade II = IAP 16 to 20 mmHg; Grade III = IAP 21 to 25 mmHg; Grade IV = IAP &gt;25 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperacute IAH refers to elevation of the intraabdominal pressure lasting only seconds. It is due to laughing, coughing, straining, sneezing, defecation, or physical activity. IAH with ACS due to gastric over-distention following endoscopy has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute IAH refers to elevation of the intraabdominal pressure that develops over hours. It is usually the result of trauma or intraabdominal hemorrhage and can lead to the rapid development of ACS.",
"     </li>",
"     <li>",
"      Subacute IAH refers to elevation of the intraabdominal pressure that develops over days. It is most common in medical patients and can also lead to ACS.",
"     </li>",
"     <li>",
"      Chronic IAH refers to elevation of intraabdominal pressure that develops over months (pregnancy) or years (morbid obesity) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/10\">",
"       10",
"      </a>",
"      ]. It does not cause ACS, but does place the individual at higher risk for ACS if they develop superimposed acute or subacute IAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abdominal compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;For research purposes, ACS is defined as a sustained intraabdominal pressure &gt;20 mmHg (with or without APP &lt;60 mmHg) that is associated with new organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. For clinical purposes, ACS is better defined as IAH-induced new organ dysfunction without a strict intraabdominal pressure threshold, since no intraabdominal pressure can predictably diagnose ACS in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with an intraabdominal pressure below 10 mmHg generally do not have ACS, while patients with an intraabdominal pressure above 25 mmHg usually have ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients with an intraabdominal pressure between 10 and 25 mmHg may or may not have ACS, depending upon individual variables such as blood pressure and abdominal wall compliance (",
"    <a class=\"graphic graphic_figure graphicRef69364 \" href=\"UTD.htm?33/42/34479\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/11,14-16\">",
"     11,14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher systemic blood pressure may maintain abdominal organ perfusion when the intraabdominal pressure is increased, since the perfusion pressure (APP) is the difference between the mean arterial pressure and the intraabdominal pressure. (See",
"      <a class=\"local\" href=\"#H264093045\">",
"       'Abdominal perfusion pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal wall compliance initially minimizes the extent to which an increasing abdominal girth can elevate the intraabdominal pressure. But when a critical abdominal girth is reached, abdominal wall compliance decreases abruptly. Further increases in abdominal girth beyond this critical level result in a rapid rise of intraabdominal pressure and ACS if untreated. Increased abdominal wall compliance due to chronic increased abdominal girth (eg, pregnancy, cirrhosis with ascites, morbid obesity) may be protective against ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies evaluating the incidence of ACS have been performed in trauma patients, with estimates of incidence varying considerably [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The largest study (n=706) reported an incidence of ACS of 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, two smaller observational studies (n=128 and n=188) reported an incidence of ACS of 9 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The incidence of IAH is less well characterized.",
"   </p>",
"   <p>",
"    The variable estimates do not appear to be related to the definition of ACS because the studies defined ACS similarly. ACS was considered present if there was persistent IAH, progression organ dysfunction despite resuscitation, and improvement following decompression.",
"   </p>",
"   <p>",
"    The different estimates likely relate to the different patient populations studied. The largest study enrolled all patients with trauma who were admitted to an intensive care unit. The smaller studies enrolled patients with major torso trauma (flail chest, two or more abdominal injuries, major vascular injury, complex pelvic fracture, or two or more long bone fractures), an early arterial base deficit (&ge;6",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    and either an age &ge;65 years or the need for transfusion of &ge;6 units of packed red blood cells. These different enrollment criteria suggest that the incidence of ACS is highest among the most critically ill patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACS can be classified as primary or secondary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"     1",
"    </a>",
"    ]. Primary ACS is due to injury or disease in the abdominopelvic region (eg, abdominal trauma, hemoperitoneum, pancreatitis); intervention (surgical or radiologic) of the primary condition is often needed. Secondary ACS refers to conditions that do not originate in the abdomen or pelvis (eg, fluid resuscitation, sepsis, burns). Recurrent ACS defines a condition in which ACS develops again following previous surgical or medical treatment of primary or secondary ACS.",
"   </p>",
"   <p>",
"    ACS generally occurs in patients who are critically ill due to any of a wide variety of medical and surgical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. Some of these include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma &ndash; Injured patients in shock who require aggressive fluid resuscitation are at risk for ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Burns &ndash; Patients with severe burns (&gt;30 percent total body surface area) with or without concomitant trauma are also at risk for ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Importantly, ACS must be distinguished from other intraabdominal problems that occur in these critically ill patients (eg, necrotizing enterocolitis, ischemic bowel).",
"     </li>",
"     <li>",
"      Liver transplantation &ndash; A prospective cohort study found IAH (IAP &gt;25 mmHg) following liver transplantation in 32 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal conditions &ndash; Massive ascites, bowel distension, abdominal surgery, or intraperitoneal bleeding can increase intraabdominal pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retroperitoneal conditions &ndash; Retroperitoneal pathologies, such as ruptured abdominal aortic aneurysm, pelvic fracture with bleeding, and pancreatitis, can lead to abdominal compartment syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medical illness &ndash; Conditions that require extensive fluid resuscitation (eg, sepsis) and are associated with third spacing of fluids and tissue edema can increase intraabdominal pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1,31\">",
"       1,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Post-surgical patients &ndash; Patients undergoing operations in which they are given large volume resuscitation, particularly with crystalloid in the face of hemorrhagic or septic shock, are at risk for ACS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of secondary ACS is often related to the need for and extent of volume resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Careful attention needs to be paid to the amount of fluid being administered and alterations in fluid management may be needed in patients who are exhibiting early",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    of ACS. The fluid management of hypovolemic patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Hemodynamic support'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link\">",
"     \"Overview of inpatient management in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following trials illustrate the correlation between fluid administration and ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 71 patients with severe acute pancreatitis to rapid fluid expansion or controlled fluid expansion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/33\">",
"       33",
"      </a>",
"      ]. The rapid expansion group received significantly greater volumes of crystalloid (4028 versus 2472 mL) and colloid (1336 versus 970 mL) on the day of admission with no differences after four days. The incidence of abdominal compartment syndrome was higher in the rapid expansion group (72 versus 38 percent).",
"     </li>",
"     <li>",
"      Abdominal compartment pressures were measured (bladder catheter transduction) in 31 severely burned patients who were randomly assigned to resuscitation using crystalloid (Parkland formula) or plasma administration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/32\">",
"       32",
"      </a>",
"      ]. Significantly increased abdominal compartment pressure (27 versus 11 mmHg) was found in the group receiving crystalloid which correlated to increased volume of administered fluid (0.26",
"      <span class=\"nowrap\">",
"       L/kg",
"      </span>",
"      versus 0.21",
"      <span class=\"nowrap\">",
"       L/kg).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;IAH can impair the function of nearly every organ system, thereby causing ACS (",
"    <a class=\"graphic graphic_table graphicRef70250 \" href=\"UTD.htm?31/61/32732\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;IAH decreases cardiac output by impairing cardiac function and reducing venous return:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired cardiac function &mdash; IAH causes cephalad movement of the diaphragm, which leads to cardiac compression. The end result is reduced ventricular compliance and contractility [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Elevation of the diaphragm may occur at pressures as low as 10 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced venous return &mdash; IAH functionally obstructs blood flow in the inferior vena cava, leading to diminished venous blood flow from the lower extremities [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/38\">",
"       38",
"      </a>",
"      ]. The resulting rise in lower extremity venous hydrostatic pressure promotes the formation of peripheral edema and increases the risk of deep vein thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IAH generally causes an elevated central venous pressure and pulmonary capillary wedge pressure impairing cardiac function because of diminished venous return.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravascular volume and positive end-expiratory pressure (PEEP) influence the degree to which IAH decreases cardiac output. Specifically, cardiac output is reduced at a lower intraabdominal pressure if the patients are hypovolemic, receive excess applied PEEP, or develop auto-PEEP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link&amp;anchor=H5#H5\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Auto-PEEP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link&amp;anchor=H17#H17\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanically ventilated patients with IAH have increased peak inspiratory and mean airway pressures, which can cause alveolar barotrauma. They also have reduced chest wall compliance and spontaneous tidal volumes, which combine to cause arterial hypoxemia and hypercarbia. Pulmonary infection is more common among patients with IAH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These effects are likely due to elevation of the diaphragm causing extrinsic compression of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/44\">",
"     44",
"    </a>",
"    ]. According to animal studies, compression of the lung leads to atelectasis, edema, decreased oxygen diffusion, an increased intrapulmonary shunt fraction, and increased alveolar dead space [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/45\">",
"     45",
"    </a>",
"    ]. These effects are accentuated by prior hemorrhagic shock and resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms contribute to renal impairment in patients with IAH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal vein compression increases venous resistance, which impairs venous drainage. This appears to be the major cause of renal impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Renal artery vasoconstriction is induced by the sympathetic nervous and renin-angiotensin systems, which are stimulated by the fall in cardiac output [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/49\">",
"       49",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiovascular'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The end result is progressive reduction in both glomerular perfusion and urine output [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/50\">",
"     50",
"    </a>",
"    ]. Oliguria generally develops at an intraabdominal pressure of approximately 15 mmHg, while anuria usually develops at an intraabdominal pressure of approximately 30 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to renal impairment induced by other causes of reduced perfusion, the urine sodium and chloride concentrations are usually decreased. In addition, plasma renin activity, aldosterone concentration, and antidiuretic hormone concentration are increased to more than twice baseline levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/52\">",
"     52",
"    </a>",
"    ]. These changes are reversible if the IAH is recognized early and decompression is performed in a timely fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gut appears to be one of the organs most sensitive to increases in intraabdominal pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesenteric blood flow was reduced at an intraabdominal pressure as low as 10 mmHg in one animal study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intestinal mucosal perfusion is decreased at an intraabdominal pressure of approximately 20 mmHg, according to both animal and human studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Celiac artery and superior mesenteric artery blood flow are decreased at an intraabdominal pressure of approximately 40 mmHg, according to one animal study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of intraabdominal pressure on mesenteric perfusion seems to be greatest among patients who had hemorrhage or are hypovolemic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/54,58\">",
"     54,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IAH also compresses thin-walled mesenteric veins, which impairs venous flow from the intestine and causes intestinal edema. The intestinal swelling further increases intraabdominal pressure, initiating a vicious cycle. The end result is worsened hypoperfusion, bowel ischemia, decreased intramucosal pH, and lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoperfusion of the gut may incite loss of the mucosal barrier, with subsequent bacterial translocation, sepsis, and multiple system organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/60\">",
"     60",
"    </a>",
"    ]. Supporting this notion, bacterial translocation has been shown to occur at an intraabdominal pressure of only 10 mmHg in the presence of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hepatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver's ability to remove lactic acid is impaired by increases of intraabdominal pressure as small as 10 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. This occurs even in the presence of a normal cardiac output and mean arterial blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Thus, lactic acidosis may clear more slowly than expected despite adequate resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial pressure (ICP) transiently increases during the short-lived elevation of intraabdominal pressure that occurs with coughing, defecating, or emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/64\">",
"     64",
"    </a>",
"    ]. ICP similarly appears to be elevated in the presence of persistent IAH. The elevated ICP is sustained as long as IAH exists, which can lead to a critical decrease in cerebral perfusion and progressive cerebral ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is desirable to recognize IAH early, so it can be treated before progressing to ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who develop ACS are critically ill and unable to communicate. The rare patient who is able to convey symptoms may complain of malaise, weakness, lightheadedness, dyspnea, abdominal bloating, or abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with ACS have a tensely distended abdomen. Despite this, physical examination of the abdomen is a poor predictor of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1,68,69\">",
"     1,68,69",
"    </a>",
"    ]. In a prospective cohort study of 42 adult blunt trauma victims, physical examination of the abdomen identified a significantly elevated intraabdominal pressure (defined as &gt;15 mmHg) with a sensitivity of 56 percent, specificity of 87 percent, positive predictive value of 35 percent, negative predictive value of 94 percent, and accuracy of 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive oliguria and increased ventilatory requirements are also common in patients with ACS. Other findings may include hypotension, tachycardia, an elevated jugular venous pressure, jugular venous distension, peripheral edema, abdominal tenderness, or acute pulmonary decompensation. There may also be evidence of hypoperfusion, including cool skin, obtundation, restlessness, or lactic acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is not helpful in the diagnosis of ACS. A chest radiograph may show decreased lung volumes, atelectasis, or elevated hemidiaphragms. Chest computed tomography (CT) may demonstrate tense infiltration of the retroperitoneum that is out of proportion to peritoneal disease, extrinsic compression of the inferior vena cava, massive abdominal distention, direct renal compression or displacement, bowel wall thickening, or bilateral inguinal herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of ACS requires measurement of the intraabdominal pressure, which should be performed with a low threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/71\">",
"     71",
"    </a>",
"    ]. This is particularly true for patients who have trauma, liver transplantation, bowel obstruction, pancreatitis, or peritonitis because these conditions are known to be associated with ACS. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Etiology and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Measurement of intraabdominal pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal pressure can be measured indirectly using intragastric, intracolonic, intravesical (bladder), or inferior vena cava catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/72\">",
"     72",
"    </a>",
"    ]. The wall of the hollow viscus or vascular structure acts as a membrane to transduce pressure.",
"   </p>",
"   <p>",
"    Measurement of bladder (ie, intravesical) pressure is the standard method to screen for IAH and ACS. It is simple, minimally invasive, and accurate (additional pressure is not imparted from its own musculature). Because differences in recorded intravesical pressure occur with varying head position, care must be taken to ensure consistent head and body positioning from one measurement to another [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commercial products are available to simplify measurement, however, bladder pressure measurement can be performed with supplies routinely available in the intensive care unit using the following steps (",
"    <a class=\"graphic graphic_figure graphicRef56661 \" href=\"UTD.htm?16/37/16981\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The drainage tube of the patient's Foley (bladder) catheter is clamped.",
"     </li>",
"     <li>",
"      Sterile saline (up to 25 mL) is instilled into the bladder via the aspiration port of the Foley catheter and the catheter filled with fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An 18-gauge needle attached to a pressure transducer is inserted into the aspiration port. With some newer style Foley catheters, this can be done using a needle-less connection system.",
"     </li>",
"     <li>",
"      The pressure is measured at end-expiration in the supine position after ensuring that abdominal muscle contractions are absent. The transducer should be zeroed at the level of the midaxillary line.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These steps require the aspiration port to be punctured twice. Three-way stopcocks can be used to avoid repeated puncturing of the aspiration port. Commercially available systems have also been developed to simplify measurement.",
"   </p>",
"   <p>",
"    There is strong correlation between the bladder pressure and directly measured intraabdominal pressure in both animals and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. However, the bladder pressure may not be accurate in the presence of intraperitoneal adhesions, pelvic hematomas, pelvic fractures, abdominal packs, or a neurogenic bladder because accurate measurement requires free movement of the bladder wall [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronically increased intraabdominal pressure due to morbid obesity, pregnancy, or ascites can complicate the diagnosis. Acute increases in intraabdominal pressure may be less well tolerated if superimposed on chronic IAH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of IAH and ACS consists of supportive care and, when needed, abdominal decompression. Surgical decompression of the abdominal cavity is considered definitive management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some exceptions include escharotomy release to relieve mechanical limitations due to burn scars and percutaneous catheter decompression to relieve tense ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/81-83\">",
"     81-83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264091950\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of supportive care in patients with intraabdominal hypertension include reduction of intraabdominal volume through evacuation of intraluminal contents, evacuation of intraabdominal space-occupying lesions (eg, ascites, hematoma) when possible, and measures to improve abdominal wall compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasogastric and rectal drainage are a simple means for reducing intraabdominal pressure in patients with bowel distension. Hemoperitoneum, ascites, intraabdominal abscess and retroperitoneal hematoma occupy space and can elevate intraabdominal pressure. In some cases, these collections can be evacuated using percutaneous techniques. In one study, percutaneous catheter drainage (PCD) avoided the need for subsequent open abdominal decompression in 81 percent of patients treated. However, failure to drain at least 1000 mL of fluid and decrease intraabdominal pressure (IAP) by at least 9 mmHg in the first four hours postdecompression was associated with failure and the urgent need for open abdominal decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attention should be paid to patient positioning and the patient should be placed in a supine position since elevation of the head of the bed (&gt;20&deg;), which is commonly used to reduce the risk of ventilator-associated pneumonia, increases intraabdominal pressure and also impacts the measurement of intraabdominal pressure. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Measurement of intraabdominal pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Abdominal wall compliance can be improved with adequate pain control and sedation, but for some patients, chemical paralysis will be needed to achieve abdominal wall relaxation and ventilatory support will be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ventilatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;High peak and mean airway pressures can be problematic. Tidal volume reduction, a pressure-limited mode,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    permissive hypercapnia may be necessary. Chemical paralysis, which will decrease carbon dioxide production and permit better ventilation, may be required if hypercapnia is particularly severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=see_link\">",
"     \"Permissive hypercapnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive end-expiratory pressure (PEEP) may reduce ventilation-perfusion mismatch and improve hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/86\">",
"     86",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hemodynamic support",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with intraabdominal hypertension, limiting the amount of fluid administration may decrease the risk of developing ACS. Some clinicians prefer to use colloids under this circumstance; however, although there are accumulating data that large-volume crystalloid resuscitation for shock can lead to ACS, it is not clear that substituting colloid offers any protection, and once the patient develops ACS, the treatment is decompression and the type of fluid is of no consequence.",
"   </p>",
"   <p>",
"    For patients with ACS, volume administration temporarily improves cardiac output, renal blood flow, urine output, visceral perfusion and negates some of the negative effects of positive-end expiratory pressure (PEEP), but compartment syndrome cannot be treated by administration of fluid (regardless of type). Also, there is no role for diuretic therapy in the resuscitation of patients with acute compartment syndrome (ACS) even though central venous and pulmonary capillary wedge pressures are usually elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/87\">",
"     87",
"    </a>",
"    ]. The only appropriate management is to open the abdomen. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgical decompression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SURGICAL DECOMPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that surgical decompression is indicated for ACS. However, a precise threshold for surgical decompression has not been established. Decompressing the abdomen prior to the development of ACS is becoming increasingly common and may improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/73\">",
"     73",
"    </a>",
"    ]. Various approaches include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical decompression for all patients whose intraabdominal pressure is greater than 25 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Many clinicians suggest surgical decompression at a lower intraabdominal pressure (eg, 15 to 25 mmHg), based on their belief that surgical decompression performed at an intraabdominal pressure lower than 25 mmHg is associated with improved organ perfusion, patient outcome, and prevention of ACS.",
"     </li>",
"     <li>",
"      Other clinicians believe that the need for surgical decompression should be determined by the pressure gradient for abdominal perfusion, also called the abdominal perfusion pressure (APP). As described above, the APP is the difference between the mean arterial pressure and the intraabdominal pressure (APP = MAP - IAP). In a retrospective study, an APP below 50 mmHg predicted mortality with greater sensitivity and specificity than either the mean arterial pressure or the intraabdominal pressure alone [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our clinical practice, we begin to consider surgical decompression when the intraabdominal pressure is 20 mmHg or greater, regardless of whether there are signs of ACS. We make our final decision after carefully weighing the potential benefits and the perioperative risks related to this procedure in each individual case.",
"   </p>",
"   <p>",
"    Most surgeons perform decompression and then maintain an open abdomen using temporary abdominal wall closure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/89\">",
"     89",
"    </a>",
"    ]. Maintenance of an open abdomen using temporary abdominal wall closure requires dressings that bridge the fascial edges while preventing evisceration, retaining fluid, and retaining heat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"     \"Management of the open abdomen in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical decompression can be performed in the operating room if the patient is medically stable for transfer or at the bedside in the intensive care unit. The standard technique is to make a midline incision through the linea alba to open the abdominal cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Temporary closure techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques are available for temporary abdominal closure. In some patients, delayed primary closure of the abdominal fascia is possible once edema subsides. However, if closure is premature, abdominal compartment syndrome can recur. Techniques for temporary abdominal closure and timing of closure are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link&amp;anchor=H632146314#H632146314\">",
"     \"Management of the open abdomen in adults\", section on 'Temporary abdominal closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to recognize IAH prior to the development of ACS causes tissue hypoperfusion, which may lead to multisystem organ failure, and potentially death. Although the development of IAH alone is not a predictor of multiorgan failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/90\">",
"     90",
"    </a>",
"    ], mortality for patients who have progressed to ACS range from 40 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/11,14,91-93\">",
"     11,14,91-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One prospective study measured intraabdominal pressure in all patients admitted to the intensive care unit and requiring a bladder catheter. Of the 83 patients studied, 33 percent developed intraabdominal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20761/abstract/7\">",
"     7",
"    </a>",
"    ]. Logistic regression identified maximal intraabdominal pressure as a significant predictor of mortality (odds ratio [OR], 1.17 95% CI 1.05-1.3), which remained significant after adjusting with Acute Physiology and Chronic Health Evaluation II (APACHE II) (OR, 1.15 95% CI 1.06-1.25) and comorbidities (OR, 2.68 95% CI 1.27-5.67).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intraabdominal pressure is called intraabdominal hypertension (IAH). Abdominal compartment syndrome (ACS) refers to organ dysfunction caused by intraabdominal hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACS can impair the function of nearly every organ system. Physiologic consequences include impaired cardiac function, decreased venous return, hypoxemia, hypercarbia, renal impairment, diminished gut perfusion, and elevated intracranial pressure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physiologic consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of ACS requires that intraabdominal pressure be measured. Symptoms, physical signs, and imaging findings are insufficient to diagnose ACS. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management initially consists of careful observation and supportive care. In some cases abdominal compartment decompression is required. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Ventilatory support'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical decompression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that surgical decompression is not delayed until the development of ACS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We evaluate the patient for possible surgical decompression when the intraabdominal pressure is &ge;20 mmHg, regardless of whether ACS exists. We make our final decision only after carefully weighing the potential benefits and the perioperative risks related to the individual patient. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical decompression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following surgical decompression, an open abdomen is maintained using a variety of temporary abdominal closure techniques. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Temporary closure techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/1\">",
"      Malbrain ML, Cheatham ML, Kirkpatrick A, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med 2006; 32:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/2\">",
"      Sanchez NC, Tenofsky PL, Dort JM, et al. What is normal intra-abdominal pressure? Am Surg 2001; 67:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/3\">",
"      Diebel LN, Dulchavsky SA, Wilson RF. Effect of increased intra-abdominal pressure on mesenteric arterial and intestinal mucosal blood flow. J Trauma 1992; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/4\">",
"      Schein M, Ivatury R. Intra-abdominal hypertension and the abdominal compartment syndrome. Br J Surg 1998; 85:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/5\">",
"      Ivatury RR, Diebel L, Porter JM, Simon RJ. Intra-abdominal hypertension and the abdominal compartment syndrome. Surg Clin North Am 1997; 77:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/6\">",
"      Caldwell CB, Ricotta JJ. Changes in visceral blood flow with elevated intraabdominal pressure. J Surg Res 1987; 43:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/7\">",
"      Vidal MG, Ruiz Weisser J, Gonzalez F, et al. Incidence and clinical effects of intra-abdominal hypertension in critically ill patients. Crit Care Med 2008; 36:1823.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.wsacs.org/consensus_summary.php (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/9\">",
"      van Mook WN, Huslewe-Evers RP, Ramsay G. Abdominal compartment syndrome. Lancet 2002; 360:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/10\">",
"      Wilson A, Longhi J, Goldman C, McNatt S. Intra-abdominal pressure and the morbidly obese patients: the effect of body mass index. J Trauma 2010; 69:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/11\">",
"      Sugrue M. Abdominal compartment syndrome. Curr Opin Crit Care 2005; 11:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/12\">",
"      Bailey J, Shapiro MJ. Abdominal compartment syndrome. Crit Care 2000; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/13\">",
"      Malbrain ML, Deeren D, De Potter TJ. Intra-abdominal hypertension in the critically ill: it is time to pay attention. Curr Opin Crit Care 2005; 11:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/14\">",
"      Malbrain ML, Chiumello D, Pelosi P, et al. Incidence and prognosis of intraabdominal hypertension in a mixed population of critically ill patients: a multiple-center epidemiological study. Crit Care Med 2005; 33:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/15\">",
"      Cheatham ML, White MW, Sagraves SG, et al. Abdominal perfusion pressure: a superior parameter in the assessment of intra-abdominal hypertension. J Trauma 2000; 49:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/16\">",
"      Moore AF, Hargest R, Martin M, Delicata RJ. Intra-abdominal hypertension and the abdominal compartment syndrome. Br J Surg 2004; 91:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/17\">",
"      Sugerman HJ, DeMaria EJ, Felton WL 3rd, et al. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology 1997; 49:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/18\">",
"      Malbrain ML, Chiumello D, Pelosi P, et al. Prevalence of intra-abdominal hypertension in critically ill patients: a multicentre epidemiological study. Intensive Care Med 2004; 30:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/19\">",
"      Hong JJ, Cohn SM, Perez JM, et al. Prospective study of the incidence and outcome of intra-abdominal hypertension and the abdominal compartment syndrome. Br J Surg 2002; 89:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/20\">",
"      Balogh Z, McKinley BA, Holcomb JB, et al. Both primary and secondary abdominal compartment syndrome can be predicted early and are harbingers of multiple organ failure. J Trauma 2003; 54:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/21\">",
"      Balogh Z, McKinley BA, Cocanour CS, et al. Secondary abdominal compartment syndrome is an elusive early complication of traumatic shock resuscitation. Am J Surg 2002; 184:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/22\">",
"      Balogh Z, McKinley BA, Cocanour CS, et al. Supranormal trauma resuscitation causes more cases of abdominal compartment syndrome. Arch Surg 2003; 138:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/23\">",
"      Ertel W, Oberholzer A, Platz A, et al. Incidence and clinical pattern of the abdominal compartment syndrome after \"damage-control\" laparotomy in 311 patients with severe abdominal and/or pelvic trauma. Crit Care Med 2000; 28:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/24\">",
"      Markell KW, Renz EM, White CE, et al. Abdominal complications after severe burns. J Am Coll Surg 2009; 208:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/25\">",
"      Kirkpatrick AW, Ball CG, Nickerson D, D'Amours SK. Intraabdominal hypertension and the abdominal compartment syndrome in burn patients. World J Surg 2009; 33:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/26\">",
"      Biancofiore G, Bindi ML, Romanelli AM, et al. Intra-abdominal pressure monitoring in liver transplant recipients: a prospective study. Intensive Care Med 2003; 29:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/27\">",
"      Saggi BH, Sugerman HJ, Ivatury RR, Bloomfield GL. Abdominal compartment syndrome. J Trauma 1998; 45:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/28\">",
"      Morken J, West MA. Abdominal compartment syndrome in the intensive care unit. Curr Opin Crit Care 2001; 7:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/29\">",
"      Djavani Gidlund K, Wanhainen A, Bj&ouml;rck M. Intra-abdominal hypertension and abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2011; 41:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/30\">",
"      Mentula P, Hienonen P, Kemppainen E, et al. Surgical decompression for abdominal compartment syndrome in severe acute pancreatitis. Arch Surg 2010; 145:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/31\">",
"      Regueira T, Bruhn A, Hasbun P, et al. Intra-abdominal hypertension: incidence and association with organ dysfunction during early septic shock. J Crit Care 2008; 23:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/32\">",
"      O'Mara MS, Slater H, Goldfarb IW, Caushaj PF. A prospective, randomized evaluation of intra-abdominal pressures with crystalloid and colloid resuscitation in burn patients. J Trauma 2005; 58:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/33\">",
"      Mao EQ, Tang YQ, Fei J, et al. Fluid therapy for severe acute pancreatitis in acute response stage. Chin Med J (Engl) 2009; 122:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/34\">",
"      Oda J, Yamashita K, Inoue T, et al. Resuscitation fluid volume and abdominal compartment syndrome in patients with major burns. Burns 2006; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/35\">",
"      Coombs, HC. The mechanism of the regulation of intra-abdominal pressure. Am J Physiol 1922; 61:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/36\">",
"      Cullen DJ, Coyle JP, Teplick R, Long MC. Cardiovascular, pulmonary, and renal effects of massively increased intra-abdominal pressure in critically ill patients. Crit Care Med 1989; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/37\">",
"      Richardson JD, Trinkle JK. Hemodynamic and respiratory alterations with increased intra-abdominal pressure. J Surg Res 1976; 20:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/38\">",
"      Barnes GE, Laine GA, Giam PY, et al. Cardiovascular responses to elevation of intra-abdominal hydrostatic pressure. Am J Physiol 1985; 248:R208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/39\">",
"      MacDonnell SP, Lalude OA, Davidson AC. The abdominal compartment syndrome: the physiological and clinical consequences of elevated intra-abdominal pressure. J Am Coll Surg 1996; 183:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/40\">",
"      Kashtan J, Green JF, Parsons EQ, Holcroft JW. Hemodynamic effect of increased abdominal pressure. J Surg Res 1981; 30:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/41\">",
"      Ridings PC, Bloomfield GL, Blocher CR, Sugerman HJ. Cardiopulmonary effects of raised intra-abdominal pressure before and after intravascular volume expansion. J Trauma 1995; 39:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/42\">",
"      Burchard KW, Ciombor DM, McLeod MK, et al. Positive end expiratory pressure with increased intra-abdominal pressure. Surg Gynecol Obstet 1985; 161:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/43\">",
"      Aprahamian C, Wittmann DH, Bergstein JM, Quebbeman EJ. Temporary abdominal closure (TAC) for planned relaparotomy (etappenlavage) in trauma. J Trauma 1990; 30:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/44\">",
"      Obeid F, Saba A, Fath J, et al. Increases in intra-abdominal pressure affect pulmonary compliance. Arch Surg 1995; 130:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/45\">",
"      Quintel M, Pelosi P, Caironi P, et al. An increase of abdominal pressure increases pulmonary edema in oleic acid-induced lung injury. Am J Respir Crit Care Med 2004; 169:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/46\">",
"      Simon RJ, Friedlander MH, Ivatury RR, et al. Hemorrhage lowers the threshold for intra-abdominal hypertension-induced pulmonary dysfunction. J Trauma 1997; 42:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/47\">",
"      Doty JM, Saggi BH, Blocher CR, et al. Effects of increased renal parenchymal pressure on renal function. J Trauma 2000; 48:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/48\">",
"      Doty JM, Saggi BH, Sugerman HJ, et al. Effect of increased renal venous pressure on renal function. J Trauma 1999; 47:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/49\">",
"      Shenasky JH 2nd. The renal hemodynamic and functional effects of external counterpressure. Surg Gynecol Obstet 1972; 134:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/50\">",
"      Bloomfield GL, Blocher CR, Fakhry IF, et al. Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. J Trauma 1997; 42:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/51\">",
"      Richards WO, Scovill W, Shin B, Reed W. Acute renal failure associated with increased intra-abdominal pressure. Ann Surg 1983; 197:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/52\">",
"      Le Roith D, Bark H, Nyska M, Glick SM. The effect of abdominal pressure on plasma antidiuretic hormone levels in the dog. J Surg Res 1982; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/53\">",
"      Smith JH, Merrell RC, Raffin TA. Reversal of postoperative anuria by decompressive celiotomy. Arch Intern Med 1985; 145:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/54\">",
"      Friedlander MH, Simon RJ, Ivatury R, et al. Effect of hemorrhage on superior mesenteric artery flow during increased intra-abdominal pressures. J Trauma 1998; 45:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/55\">",
"      Chang MC, Cheatham ML, Nelson LD, et al. Gastric tonometry supplements information provided by systemic indicators of oxygen transport. J Trauma 1994; 37:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/56\">",
"      Diebel LN, Myers T, Dulchavsky S. Effects of increasing airway pressure and PEEP on the assessment of cardiac preload. J Trauma 1997; 42:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/57\">",
"      Samel ST, Neufang T, Mueller A, et al. A new abdominal cavity chamber to study the impact of increased intra-abdominal pressure on microcirculation of gut mucosa by using video microscopy in rats. Crit Care Med 2002; 30:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/58\">",
"      Ivatury RR, Porter JM, Simon RJ, et al. Intra-abdominal hypertension after life-threatening penetrating abdominal trauma: prophylaxis, incidence, and clinical relevance to gastric mucosal pH and abdominal compartment syndrome. J Trauma 1998; 44:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/59\">",
"      Diebel LN, Wilson RF, Dulchavsky SA, Saxe J. Effect of increased intra-abdominal pressure on hepatic arterial, portal venous, and hepatic microcirculatory blood flow. J Trauma 1992; 33:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/60\">",
"      Diebel LN, Dulchavsky SA, Brown WJ. Splanchnic ischemia and bacterial translocation in the abdominal compartment syndrome. J Trauma 1997; 43:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/61\">",
"      Gargiulo NJ 3rd, Simon RJ, Leon W, Machiedo GW. Hemorrhage exacerbates bacterial translocation at low levels of intra-abdominal pressure. Arch Surg 1998; 133:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/62\">",
"      Luca A, Cirera I, Garc&iacute;a-Pag&aacute;n JC, et al. Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. Gastroenterology 1993; 104:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/63\">",
"      Nakatani T, Sakamoto Y, Kaneko I, et al. Effects of intra-abdominal hypertension on hepatic energy metabolism in a rabbit model. J Trauma 1998; 44:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/64\">",
"      Luce JM, Huseby JS, Kirk W, Butler J. Mechanism by which positive end-expiratory pressure increases cerebrospinal fluid pressure in dogs. J Appl Physiol 1982; 52:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/65\">",
"      Bloomfield GL, Dalton JM, Sugerman HJ, et al. Treatment of increasing intracranial pressure secondary to the acute abdominal compartment syndrome in a patient with combined abdominal and head trauma. J Trauma 1995; 39:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/66\">",
"      Citerio G, Vascotto E, Villa F, et al. Induced abdominal compartment syndrome increases intracranial pressure in neurotrauma patients: a prospective study. Crit Care Med 2001; 29:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/67\">",
"      Joseph DK, Dutton RP, Aarabi B, Scalea TM. Decompressive laparotomy to treat intractable intracranial hypertension after traumatic brain injury. J Trauma 2004; 57:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/68\">",
"      Kirkpatrick AW, Brenneman FD, McLean RF, et al. Is clinical examination an accurate indicator of raised intra-abdominal pressure in critically injured patients? Can J Surg 2000; 43:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/69\">",
"      Sugrue M, Bauman A, Jones F, et al. Clinical examination is an inaccurate predictor of intraabdominal pressure. World J Surg 2002; 26:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/70\">",
"      Pickhardt PJ, Shimony JS, Heiken JP, et al. The abdominal compartment syndrome: CT findings. AJR Am J Roentgenol 1999; 173:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/71\">",
"      Malbrain ML. Is it wise not to think about intraabdominal hypertension in the ICU? Curr Opin Crit Care 2004; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/72\">",
"      Malbrain ML. Different techniques to measure intra-abdominal pressure (IAP): time for a critical re-appraisal. Intensive Care Med 2004; 30:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/73\">",
"      Cheatham ML, De Waele JJ, De Laet I, et al. The impact of body position on intra-abdominal pressure measurement: a multicenter analysis. Crit Care Med 2009; 37:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/74\">",
"      De Keulenaer BL, De Waele JJ, Powell B, Malbrain ML. What is normal intra-abdominal pressure and how is it affected by positioning, body mass and positive end-expiratory pressure? Intensive Care Med 2009; 35:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/75\">",
"      Iberti TJ, Lieber CE, Benjamin E. Determination of intra-abdominal pressure using a transurethral bladder catheter: clinical validation of the technique. Anesthesiology 1989; 70:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/76\">",
"      Iberti TJ, Kelly KM, Gentili DR, et al. A simple technique to accurately determine intra-abdominal pressure. Crit Care Med 1987; 15:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/77\">",
"      Fusco MA, Martin RS, Chang MC. Estimation of intra-abdominal pressure by bladder pressure measurement: validity and methodology. J Trauma 2001; 50:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/78\">",
"      Lacey SR, Bruce J, Brooks SP, et al. The relative merits of various methods of indirect measurement of intraabdominal pressure as a guide to closure of abdominal wall defects. J Pediatr Surg 1987; 22:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/79\">",
"      Sugerman HJ. Effects of increased intra-abdominal pressure in severe obesity. Surg Clin North Am 2001; 81:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/80\">",
"      Chang MC, Miller PR, D'Agostino R Jr, Meredith JW. Effects of abdominal decompression on cardiopulmonary function and visceral perfusion in patients with intra-abdominal hypertension. J Trauma 1998; 44:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/81\">",
"      Hobson KG, Young KM, Ciraulo A, et al. Release of abdominal compartment syndrome improves survival in patients with burn injury. J Trauma 2002; 53:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/82\">",
"      Dries DJ. Abdominal compartment syndrome: toward less-invasive management. Chest 2011; 140:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/83\">",
"      Cheatham ML, Safcsak K. Percutaneous catheter decompression in the treatment of elevated intraabdominal pressure. Chest 2011; 140:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/84\">",
"      Cheatham ML. Nonoperative management of intraabdominal hypertension and abdominal compartment syndrome. World J Surg 2009; 33:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/85\">",
"      Cheatham ML. Abdominal compartment syndrome. Curr Opin Crit Care 2009; 15:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/86\">",
"      Smith PK, Tyson GS Jr, Hammon JW Jr, et al. Cardiovascular effects of ventilation with positive expiratory airway pressure. Ann Surg 1982; 195:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/87\">",
"      Meldrum DR, Moore FA, Moore EE, et al. Prospective characterization and selective management of the abdominal compartment syndrome. Am J Surg 1997; 174:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/88\">",
"      Burch JM, Moore EE, Moore FA, Franciose R. The abdominal compartment syndrome. Surg Clin North Am 1996; 76:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/89\">",
"      Mayberry JC, Goldman RK, Mullins RJ, et al. Surveyed opinion of American trauma surgeons on the prevention of the abdominal compartment syndrome. J Trauma 1999; 47:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/90\">",
"      Balogh ZJ, Martin A, van Wessem KP, et al. Mission to eliminate postinjury abdominal compartment syndrome. Arch Surg 2011; 146:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/91\">",
"      An G, West MA. Abdominal compartment syndrome: a concise clinical review. Crit Care Med 2008; 36:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/92\">",
"      Kron IL, Harman PK, Nolan SP. The measurement of intra-abdominal pressure as a criterion for abdominal re-exploration. Ann Surg 1984; 199:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20761/abstract/93\">",
"      Cheatham ML, Safcsak K. Is the evolving management of intra-abdominal hypertension and abdominal compartment syndrome improving survival? Crit Care Med 2010; 38:402.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2889 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20761=[""].join("\n");
var outline_f20_17_20761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intraabdominal pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264093045\">",
"      Abdominal perfusion pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intraabdominal hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHYSIOLOGIC CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hepatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Imaging findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Measurement of intraabdominal pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264091950\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ventilatory support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hemodynamic support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SURGICAL DECOMPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Temporary closure techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2889|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/42/34479\" title=\"figure 1\">",
"      Intraabdominal hypertension and abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/37/16981\" title=\"figure 2\">",
"      Measurement of intraabdominal pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/61/32732\" title=\"table 1\">",
"      Systemic effects of elevated intraabdominal pressure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=related_link\">",
"      Management of the open abdomen in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_17_20762="Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy";
var content_f20_17_20762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/17/20762/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/17/20762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t(9;22)(q34;q11), resulting in the BCR-ABL fusion gene. This genetic abnormality results in the formation of a unique gene product (BCR-ABL), which is a constitutively active tyrosine kinase. It is this deregulated tyrosine kinase that is implicated in the development of CML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with CML present in a relatively indolent phase termed chronic phase and are treated initially with a BCR-ABL tyrosine kinase inhibitor (TKI), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    . Side effects are generally mild, but there are some patients who must discontinue the drug due to intolerance. In addition, second line therapy is required for the patient who has a suboptimal response (primary resistance) or relapses after an initial response (secondary resistance) to a TKI.",
"   </p>",
"   <p>",
"    The treatment of patients with chronic phase CML who are intolerant of or have a primary or secondary resistance to a TKI will be reviewed here. The initial treatment of chronic phase CML and specific details regarding the pharmacology of TKIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINING INTOLERANCE AND RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term studies of BCR-ABL tyrosine kinase inhibitors (TKIs) have shown that side effects are usually mild and most patients can continue treatment without interruption. When more severe symptoms do develop, the majority resolve rapidly within a few days after stopping the TKI for a brief \"drug holiday\". Often, the drug can then be restarted at the same dose without a recurrence of the side effects. Less than 5 percent of patients treated with a TKI will be unable to tolerate long term treatment. The side effects of TKIs and their management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the TKIs have some side effect profiles in common, there are some notable variations. Common side effects include myelosuppression, gastrointestinal complaints, fatigue, headache, rash, and peripheral and periorbital edema (most notably with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ). Imatinib has been rarely associated with severe heart failure;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    are associated with QT prolongation; nilotinib can occasionally cause pancreatitis; and dasatinib may cause pleural effusions and rarely pulmonary hypertension, as well as gastrointestinal bleeding probably related to an effect on platelet function.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    can cause significant diarrhea during the first one to two months of treatment, as well as transient elevations of transaminases.",
"   </p>",
"   <p>",
"    Myelosuppression is uncommon after patients are in remission, but neutropenia, thrombocytopenia, and anemia can occur during the initial treatment period until the marrow repopulates with normal hematopoiesis. Some side effects, such as severe recurrent rash or hepatotoxicity, necessitate permanent discontinuation of therapy while others, as mentioned above, require only a brief \"drug holiday\".",
"   </p>",
"   <p>",
"    There is no universal definition of intolerance. In general, we consider a patient intolerant when a nonhematologic toxicity of at least grade three recurs despite appropriate dose reductions and optimal symptomatic management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/1\">",
"     1",
"    </a>",
"    ]. However, since these drugs must be taken daily for many years, even grade 1 or 2 toxicities may be considered by individual patients as intolerable, sometimes leading to poor adherence to treatment. Grading of toxicities is based on the United States National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to treatment is divided into two categories: primary and secondary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/3\">",
"     3",
"    </a>",
"    ]. Primary resistance is when a tyrosine kinase inhibitor (TKI) fails to achieve a desired response; this occurs in up to 25 percent of patients with chronic phase CML treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Primary resistance can then be subcategorized depending upon the depth of response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients have primary hematologic resistance if they fail to attain a complete hematologic response after three months of treatment.",
"     </li>",
"     <li>",
"      Patients have primary cytogenetic resistance if they fail to meet any of the following milestones: any cytogenetic response by six months; major cytogenetic response (&lt;35 percent Ph+ cells remaining in the marrow) by 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/5\">",
"       5",
"      </a>",
"      ]; or complete cytogenetic response (no Ph+ cells) by 18 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary resistance occurs when patients with an initial response to a TKI relapse. This proportion has been estimated at approximately 8 percent at two years for patients in chronic phase treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. A discussion of the various mechanisms of resistance is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Mechanisms of resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who appear to have resistant disease should be questioned carefully to assure that they are taking the TKI at the recommended dose and schedule and avoiding other medications or herbal supplements which may impair efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/10\">",
"     10",
"    </a>",
"    ]. A study employing an electronic device to monitor compliance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy in 87 patients with CML in stable complete cytogenetic response on imatinib reported that compliance was an independent predictor of major molecular response (MMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with &ge;90 percent compliance had a significantly higher rate of MMR at six years (95 versus 28 percent). No patients with compliance &le;80 percent attained a MMR. Compliance appeared to decrease among patients who had their imatinib dose escalated. Imatinib blood levels can and should be measured if there are questions about an individual's compliance with the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Plasma trough concentrations &lt;1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are associated with higher rates of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If resistance is identified, the disease phase should be re-evaluated using a complete blood count with differential and a bone marrow biopsy with cytogenetics. In addition, mutational analysis of BCR-ABL should be performed. A newly acquired mutation in BCR-ABL may trigger a change in treatment (eg, dose increase, change to another TKI, transplantation) depending upon the type of mutation found. Specific details on disease phase and mutational analysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Disease phase'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Mechanisms of resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients found to be in accelerated phase or blast crisis at the time resistance is identified are treated differently than those in chronic phase. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENTS INELIGIBLE FOR HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key aspect to the treatment of patients with intolerance of or resistance to a BCR-ABL tyrosine kinase inhibitor (TKI) is whether the patient is a candidate for allogeneic hematopoietic cell transplantation (allo HCT). Eligibility criteria for allo HCT vary by institution. Although data supporting such criteria are limited, patients are often excluded based on age (&gt;70 years old), uncontrolled infection, cardiac, pulmonary, liver or renal dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychosocial variables. Patients who are not candidates for HCT are treated almost exclusively with second generation TKIs. The trials that support the use of second generation TKIs in patients with intolerance or resistance to an initial TKI are discussed below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dasatinib'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Nilotinib'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1349640\">",
"     'Bosutinib'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12149527\">",
"     'Ponatinib'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The administration of a second generation TKI (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    ) is the preferred treatment option for those patients for whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy is not successful. With this approach, approximately half of patients in chronic phase initially treated with imatinib will attain a durable complete cytogenetic response (CCyR) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/18\">",
"     18",
"    </a>",
"    ]. The response rates for patients not responding to initial treatment with dasatinib or nilotinib are less well defined but are considerably lower. Allo HCT is usually reserved for those patients who have failed to respond to two or more TKIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of TKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that have directly compared the efficacy of second generation TKIs in patients with chronic phase CML who experience failure of an initial TKI. Phase II studies in this population suggest that they have similar efficacy. Response rates are generally higher in patients who were switched due to intolerance compared with those switched due to resistance.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    can be used for most patients with intolerance or resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Importantly, patients with the T315I mutation only rarely respond to TKIs other than ponatinib. Thus, ponatinib is preferred for such individuals. (See",
"    <a class=\"local\" href=\"#H12149527\">",
"     'Ponatinib'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The choice of second generation TKI is based upon the side effect profiles and knowledge of comorbid conditions in an individual patient. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       Dasatinib",
"      </a>",
"      might be preferred in a patient with a history of pancreatitis, elevated bilirubin, or hyperglycemia, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      might be chosen for a patient with a history of pleural or pericardial disease or effusions.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       Dasatinib",
"      </a>",
"      crosses the blood-brain barrier and would therefore be preferred in patients with central nervous system involvement at relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      can result in QT prolongation, they should be avoided in patients with baseline QT prolongation that cannot be normalized. Attempts to normalize the QT interval include correction of possible electrolyte imbalances or discontinuation of other medications that may have affected the QT interval.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"       Bosutinib",
"      </a>",
"      is not known to prolong the QT interval.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The side effects from the second generation TKIs differ from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    toxicities and patients who are intolerant of imatinib generally tolerate another TKI without recurrence of the imatinib induced toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/20\">",
"     20",
"    </a>",
"    ]. It is likely that, in the future, the choice of TKI will also be influenced by the presence of a particular",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    mutation which is more sensitive to one drug or the other [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    to 800 mg per day is another potential option for patients for whom 400 mg of imatinib fails due to resistance but are still able to tolerate imatinib, although one randomized trial demonstrated higher response rates in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    compared with those who had their imatinib dose increased from 600 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Increased dose imatinib'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three studies have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    in patients in chronic phase with resistance or intolerance to prior therapy. The reported hematologic and major cytogenetic response (MCyR) rates were approximately 90 and 60 percent, respectively. These rates are comparable to those observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    . Doses approved by the US Food and Drug Administration include both 70 mg twice daily and 100 mg once daily. The latter appears to have equal efficacy but less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/25\">",
"     25",
"    </a>",
"    ]. Detailed information on drug toxicity and management of side effects is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the largest studies that have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II study examined the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      70 mg twice daily in 186 chronic phase CML patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistance (73 percent) or intolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/26\">",
"       26",
"      </a>",
"      ]. The following results were reported at a median follow-up of eight months:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete hematologic response (CHR) was seen in 90 percent of patients. MCyR were seen in 39 and 80 percent of patients who were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      -resistant or intolerant, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       Dasatinib",
"      </a>",
"      was well tolerated and only 9 percent had to discontinue therapy due to adverse events. Grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      side effects included leukopenia (25 percent), neutropenia (49 percent), thrombocytopenia (47 percent), and anemia (22 percent). Six percent of patients developed grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      pleural effusions.",
"      <br/>",
"      <br/>",
"      Extended follow-up of this trial included data from 387 patients followed for a median of 15 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/27\">",
"       27",
"      </a>",
"      ]. Among patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistance, rates of CHR, MCyR, and complete cytogenetic response were 90, 52, and 40 percent, respectively. Among patients with imatinib intolerance, these same levels of response were seen in 94, 80, and 75 percent, respectively. The median duration of response was not reached at 18 months. Among those who achieved a CHR, subsequent disease progression was seen in 9 and 3 percent of patients with imatinib resistance or intolerance, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized phase III study investigated different dosing schedules of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      in 662 patients with chronic phase CML resistant (74 percent) or intolerant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients were randomly assigned to four dosing strategies (50 mg twice daily, 100 mg daily, 70 mg twice daily, or 140 mg daily). The following results were noted at one-year follow-up:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no significant difference in CHR or MCyR rates among the four treatment arms. CHR was achieved in 86 to 92 percent of patients and complete cytogenetic response was achieved in 41 to 45 percent of patients.",
"     </li>",
"     <li>",
"      When compared with 70 mg twice daily, 100 mg daily dosing resulted in significantly less grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      thrombocytopenia, fewer pleural effusions, fewer dose reductions or interruptions, and fewer discontinuations due to toxicity.",
"     </li>",
"     <li>",
"      Further follow-up of the patients taking 100 mg daily reported that approximately 30 percent of patients continued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      for at least six years with estimated six-year progression-free and overall survival rates of 50 and 71 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized phase II trial showed superior response rates with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      compared with increased dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in patients who had failed imatinib therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Increased dose imatinib'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In aggregate, these studies support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    for the treatment of non-transplant candidates with chronic phase CML after the failure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy. Dasatinib can also be incorporated into the treatment of such patients who are candidates for hematopoietic cell transplantation (HCT). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Patients eligible for HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cytogenetic response appears to correlate with survival.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    does not have activity in the highly resistant T315I mutation and has limited activity against the F317L mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/3,29,30\">",
"     3,29,30",
"    </a>",
"    ]. Despite this, in a review of three trials of dasatinib in patients with chronic phase CML who were resistant to, or intolerant of,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , dasatinib was found to be an effective treatment for the majority of patients with CML in chronic phase who developed an imatinib-resistant BCR-ABL mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    in previously untreated disease and the relationship between cytogenetic response and survival are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'IRIS trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Dasatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nilotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled prospective trials have evaluated the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistant or intolerant patients. Nilotinib results in complete hematologic and cytogenetic response rates of 90 and 30 to 40 percent, respectively. This response rate is similar to that observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    . Approximately 15 percent of patients will discontinue nilotinib due to toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/4\">",
"     4",
"    </a>",
"    ]. The dose approved by the US Food and Drug Administration is 400 mg twice daily in the setting of imatinib failure and 300 mg twice daily for previously untreated disease. Information on side effects and their management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the largest studies that have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II study examined the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      in 321 patients with chronic phase CML and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistance (70 percent) or intolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. Patients received nilotinib 400 mg twice daily with escalation to 600 mg twice daily for inadequate response. Results included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A major cytogenetic response, complete cytogenetic response, and major molecular response were attained in 59, 44, and 28 percent of patients, respectively. Response rates were similar in patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistance or intolerance.",
"     </li>",
"     <li>",
"      Grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      side effects included thrombocytopenia (28 percent), neutropenia (28 percent), elevated lipase (15 percent), hyperglycemia (11 percent), hypophosphatemia (10 percent), and QT prolongation (3 percent). Pleural effusion, pericardial effusion, or pulmonary edema occurred in &lt;1 percent of patients.",
"     </li>",
"     <li>",
"      Estimated rates of overall and progression-free survival at two-years were 87 and 64 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/32\">",
"       32",
"      </a>",
"      ]. Corresponding rates at four years were 78 and 57 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/33\">",
"       33",
"      </a>",
"      ]. Responses appeared to be durable with 89 percent of those patients who achieved a complete cytogenetic response by 12 months maintaining it at four years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an international open-label expanded access trial, 1422 patients with chronic phase CML and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistance (60 percent) or intolerance were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      400 mg twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/34\">",
"       34",
"      </a>",
"      ]. A MCyR was achieved in 45 percent (34 percent complete). Progression-free survival at 18 months was 80 percent. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included thrombocytopenia (22 percent), neutropenia (14 percent), elevated lipase (7 percent), hyperbilirubinemia (4 percent). Nonhematologic toxicities were generally mild, but included rash, headache, fatigue, pruritus, nausea, and myalgia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    for the treatment of non-transplant candidates with CML in chronic phase after the failure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy. Nilotinib can also be incorporated into the treatment plan of such patients who are candidates for HCT. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Patients eligible for HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cytogenetic and molecular response appears to correlate with survival. As an example, in the phase II study described above, estimated survival rates at 48 months were 95, 82, and 73 percent for patients with BCR-ABL transcript levels &le;1 percent, 1 to 10 percent, and &gt;10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    's activity in patients with the highly resistant T315I, Y253H, and",
"    <span class=\"nowrap\">",
"     E255V/K",
"    </span>",
"    mutations is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The use of nilotinib in previously untreated disease and the relationship between cytogenetic response and survival are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'IRIS trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Nilotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1349640\">",
"    <span class=\"h2\">",
"     Bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    (previously SKI-606) is a dual kinase inhibitor that targets both the Abl and Src pathways, but does not target kit or PDGFR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/38\">",
"     38",
"    </a>",
"    ]. Uncontrolled prospective trials have evaluated the use of bosutinib in patients in chronic phase with resistance or intolerance to prior therapy. Bosutinib results in complete hematologic and cytogenetic response rates of approximately 85 and 40 percent, respectively. Although the follow-up of patients receiving bosutinib is shorter than for patients in trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , this response rate is similar to those observed with dasatinib and nilotinib. Bosutinib is approved by the US Food and Drug Administration for the treatment of chronic phase CML in adults with resistance or intolerance to prior therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/39\">",
"     39",
"    </a>",
"    ]. The recommended dose and schedule is 500 mg orally once daily with food.",
"   </p>",
"   <p>",
"    A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    (500 mg once daily) in 288 patients with CML with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance (69 percent) or intolerance reported major cytogenetic responses in 31 percent of patients by 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/40\">",
"     40",
"    </a>",
"    ]. After a median follow-up of 24 months, rates of complete hematologic remission, major cytogenetic response, and complete cytogenetic response were 86, 53, and 41 percent, respectively. Of the patients achieving a complete cytogenetic response, 64 percent attained a major molecular response. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included diarrhea (9 percent), rash (9 percent), and vomiting (3 percent).",
"   </p>",
"   <p>",
"    This study demonstrates that more than half of patients with resistance or intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    will attain a complete cytogenetic response after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    . Response rates are lower among patients who have previously received two tyrosine kinase inhibitors. Bosutinib is not active against the T315I mutation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    is also being studied in patients with newly diagnosed CML in chronic phase and in patients with accelerated phase or blast crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Second generation TKIs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12149527\">",
"    <span class=\"h2\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     Ponatinib",
"    </a>",
"    is an orally administered BCR-ABL inhibitor that has demonstrated activity against the native and mutated BCR-ABL proteins, including the T315I mutation. Ponatinib received accelerated approval by the US Food and Drug Administration for the treatment of CML in adults with resistance or intolerance to prior tyrosine kinase inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/41\">",
"     41",
"    </a>",
"    ]. The recommended dose and schedule is 45 mg orally once daily with or without food. Approval was accompanied by a boxed warning alerting patients and clinicians that arterial thrombosis and liver toxicity have occurred in patients treated with ponatinib. Data regarding the use of ponatinib in this population come from phase II trials described below.",
"   </p>",
"   <p>",
"    A phase I dose escalation study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    included 65 patients with relapsed or resistant Philadelphia (Ph) chromosome positive leukemia, including 43 patients with CML in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/42\">",
"     42",
"    </a>",
"    ]. Among those in chronic phase, 98 percent had received two prior TKIs, 63 percent had received three prior TKIs, and 29 percent had a known T315I mutation. At a median follow-up of 66 weeks, the following were noted in patients with chronic phase CML:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common nonhematologic toxicities were typically mild to moderate and included skin changes (rash, dry skin, acneiform dermatitis) and constitutional symptoms (arthralgia, fatigue, nausea). In addition, pancreatitis, ranging from mild to severe, was seen in approximately 14 percent. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thrombocytopenia, neutropenia, and anemia occurred in 28, 14, and 2 percent.",
"     </li>",
"     <li>",
"      Rates of complete hematologic, major cytogenetic, and complete cytogenetic response were 98, 72, and 63 percent, respectively. The median time to major cytogenetic response was 12 weeks (range, 8 to 72 weeks). The median duration of major cytogenetic response was not reached (range, 8 to 117 weeks).",
"     </li>",
"     <li>",
"      Of those who attained a major cytogenetic response, 89 percent (95% CI 69 to 96 percent) were estimated to remain on therapy at one year.",
"     </li>",
"     <li>",
"      Of the 12 patients with T315I mutation, all attained a complete hematologic response. Major cytogenetic response, complete cytogenetic response, and major molecular response were seen in 11, 9, and 8 patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preliminary results of the phase II PACE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    reported major cytogenetic responses in 54 percent of the 270 patients with chronic phase CML resistant or intolerant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    and in 70 percent of the 63 patients in chronic phase with T315I mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/43\">",
"     43",
"    </a>",
"    ]. The median duration of major cytogenetic response has not been reached at a minimum follow-up of one year. The most common toxicities were thrombocytopenia, rash, dry skin, abdominal pain, and headache. Overall, severe adverse events led to the discontinuation of therapy in 11 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased dose imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of second generation tyrosine kinase inhibitors (TKIs), it was common to increase the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    from 400 mg to 600 mg or 800 mg daily in patients who showed a decrease in response but were still able to tolerate imatinib. This approach was supported by data showing that low trough plasma levels of imatinib can be seen in some patients with primary resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/12,13,44\">",
"     12,13,44",
"    </a>",
"    ]. Higher doses of imatinib may improve response by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raising trough levels",
"     </li>",
"     <li>",
"      Controlling increased levels of BCR-ABL produced by genomic amplification",
"     </li>",
"     <li>",
"      Inhibiting BCR-ABL mutations with low orders of resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A non-randomized study evaluated the use of increased dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in 84 patients with CML in chronic phase who had hematologic (21 patients) or cytogenetic (63 patients) failure of standard-dose imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/45\">",
"     45",
"    </a>",
"    ]. At a median follow-up of five years from dose escalation, 40 percent had achieved a complete cytogenetic response (CCyR). In a subset analysis, a CCyR had been achieved by 52 and 5 percent of patients who had cytogenetic and hematologic failures, respectively. Once a major cytogenetic response was attained, 88 percent of patients sustained their response beyond two years.",
"   </p>",
"   <p>",
"    A phase II trial of 150 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -resistant CML in chronic phase randomized to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or increased dose imatinib reported that dasatinib (140",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    resulted in a significantly higher percentage of CHRs (93 versus 82 percent), MCyRs (40 versus 16 percent), and major molecular responses (16 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/24,46\">",
"     24,46",
"    </a>",
"    ]. The benefit of dasatinib was most apparent when compared with the subgroup of patients whose imatinib dose was increased from 600 to 800",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The results were less striking in patients whose initial imatinib dose was 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    When compared with those who received increased dose imatinib, patients treated with dasatinib were more likely to have maintained a major cytogenetic response at 18 months (90 versus 74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally prefer a second generation TKI rather than increased dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , particularly in patients whose disease was resistant to 600",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    This is principally based upon the results of the randomized phase II trial described above showing superior response rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    compared with increased dose imatinib. A trial of dose increase to 800 mg is still reasonable in some patients with close monitoring for response and a switch to a new TKI if complete cytogenetic response is not reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENTS ELIGIBLE FOR HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eligibility criteria for allogeneic HCT vary by institution and are discussed above. There are three main therapy options for the patient who has become intolerant of or resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and is eligible for HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A second generation tyrosine kinase inhibitor (TKI)",
"     </li>",
"     <li>",
"      Increased doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (if the patient is able to tolerate)",
"     </li>",
"     <li>",
"      Allogeneic hematopoietic cell transplantation (HCT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are limited data to guide the choice among these options. As described above, a randomized phase II trial showed superior response rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    compared with increased dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/24,46\">",
"     24,46",
"    </a>",
"    ]. The other two options (TKI or HCT) are acceptable alternatives and a decision should be made after a detailed discussion with the patient. An overview of the trials, clinical outcomes, and experience with second generation TKIs and increased doses of imatinib are discussed above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Patients ineligible for HCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Scoring systems have been devised in an attempt to predict the response of CML to a second generation TKI. As an example, analysis of 123 patients with chronic-phase CML intolerant or resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    who underwent treatment with a second generation TKI identified two risk factors for progression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/47\">",
"     47",
"    </a>",
"    ]: the lack of a cytogenetic response to initial imatinib and an Eastern Cooperative Oncology Group performance status of 1 or more. Patients with zero, one, or two of these factors had rates of event-free survival at two years of 78, 49, and 20 percent, respectively. Another scoring system incorporated information on the best cytogenetic response to imatinib, the occurrence of neutropenia, and the Sokal score at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/48\">",
"     48",
"    </a>",
"    ]. Other factors that might affect the response to a second generation TKI include adherence to imatinib therapy and point mutations in BCR-ABL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/10,22\">",
"     10,22",
"    </a>",
"    ]. Validation of these scoring systems in independent patient cohorts is necessary before they can be widely applied with confidence.",
"   </p>",
"   <p>",
"    HCT is an appealing option for some patients since it is the only proven curative treatment option in CML. Among patients with certain clinical characteristics, five-year survival can be as high as 80 percent. However, early mortality is in the 10 to 20 percent range. Details on the efficacy and risks associated with HCT are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Survival with HCT can be predicted with reasonable accuracy using a scoring system devised by the European Group for Blood and Marrow Transplantation (EBMT) (",
"    <a class=\"graphic graphic_table graphicRef67260 \" href=\"UTD.htm?35/31/36348\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/49\">",
"     49",
"    </a>",
"    ]. This scoring system incorporates the patient's age, stage of disease, time from diagnosis, and the closeness of the donor match. An ideal candidate for transplant would be a young (&lt;40 years old) patient in chronic phase with an HLA identical sibling donor. The five-year overall survival rates for such patients (EBMT score 0-2) ranged at the time of this scoring system's creation from 60 to 80 percent. However, with the advent of newer approaches to HCT, current overall survival rates are likely to be higher. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, second generation TKIs are oral drugs that are well tolerated with no short term mortality. Side effects from the second generation TKIs differ from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    toxicities and patients who are intolerant to imatinib generally tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    quite well without recurrence of the imatinib induced toxicities. Short-term uncontrolled studies have found rates of major cytogenetic responses of 50 to 80 percent with second generation TKIs in patients with imatinib intolerance or resistance. However, follow-up with second generation TKIs is relatively short and long-term side effects are unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'IRIS trial'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Patients ineligible for HCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefits, risks, and side effects of HCT and tyrosine kinase inhibitors should be discussed with the patient in some detail before a treatment decision is made. The main factors when deciding among these options are the patient's age, availability of an appropriate donor, and the patient's interest in undergoing HCT.",
"   </p>",
"   <p>",
"    The most commonly used approach is to initiate therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , and more recently",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    , in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    intolerant or resistant patients rather than initially perform a HCT. Further therapy is dependent upon the cytogenetic response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those without a complete cytogenetic response, we suggest HCT given the likelihood of disease progression without transplantation.",
"     </li>",
"     <li>",
"      Among those with a complete cytogenetic response, options include continued TKI therapy or HCT. Some clinicians prefer HCT immediately in such individuals, primarily due to concerns regarding the durability of these responses, although most suggest close monitoring with HCT offered should there be evidence of disease progression or cytogenetic relapse. Maturing data regarding second generation TKIs suggest that the responses will be durable in the vast majority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Patient age, the availability of sibling versus unrelated donor and other medical factors also influence the recommendation in individual patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with the T315I mutation are usually resistant to treatment with most TKIs and should be considered for allogeneic HCT. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    is",
"    <strong>",
"     NOT",
"    </strong>",
"    an option for patients with the T315I mutation, since this mutation is associated with resistance to these agents, resulting in progressive disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     Ponatinib",
"    </a>",
"    is the only TKI with significant activity in such patients, but trials of ponatinib have short follow-up.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     Omacetaxine",
"    </a>",
"    has also been approved for treatment of patients with the T315I mutation, although the follow-up duration in responders is short and it is unlikely that these responses will be sustained indefinitely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there is a paucity of data on HCT in this setting reported in the literature, outcomes appear to be primarily dependent upon the disease phase at the time of HCT and comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/52\">",
"     52",
"    </a>",
"    ]. In an international retrospective analysis of 64 patients with T315I mutation who underwent allogeneic HCT, the 33 patients who were in chronic phase at the time of transplant had a treatment related mortality rate of 9 and 18 percent at 3 and 12 months post HCT, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/53\">",
"     53",
"    </a>",
"    ]. At a median follow-up from HCT of 26 months, the median overall survival had not been reached for patients in CR at the time of HCT, indicating that patients with this TKI resistant mutation can be transplanted successfully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MONITORING DISEASE STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of degrees of response and a recommended schedule for monitoring disease status is discussed in detail separately. Provisional criteria have been suggested specifically for patients treated with second generation tyrosine kinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/4,48,54,55\">",
"     4,48,54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATIENTS WHO HAVE FAILED ON MORE THAN ONE TKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the management of patients in chronic phase for whom both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and a second generation tyrosine kinase inhibitor (TKI) have failed. In practice, we consider allogeneic HCT for eligible patients. Patients not eligible for HCT are considered for treatment with another TKI, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     omacetaxine",
"    </a>",
"    , or enrollment in a clinical trial. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Patients eligible for HCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24874410\">",
"    <span class=\"h2\">",
"     Use of another TKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonrandomized single-arm trials have investigated the use of a third TKI in patients who have an inadequate response to trials of more than one TKI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single institution observational study reported the outcomes of 48 patients with CML who failed therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and subsequently failed therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      and were then treated with a third TKI (dasatinib or nilotinib) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/56\">",
"       56",
"      </a>",
"      ]. The following data were reported on the 25 patients in chronic phase (CP) at the time the third TKI was initiated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Responses were seen including major molecular response (5 patients), complete cytogenetic response (3 patients), partial cytogenetic response (2 patients), minor cytogenetic response (3 patients), and complete hematologic response (6 patients) (",
"      <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"       table 1",
"      </a>",
"      ); six patients had no response.",
"     </li>",
"     <li>",
"      The time to treatment failure, including discontinuation due to toxicity, was 20 months. After a median follow-up of 16 months, only 10 of the 25 chronic phase patients remained on third line therapy and some of these had worsening of their disease compared with their best response.",
"     </li>",
"     <li>",
"      There was no clear difference between patients treated with either potential sequence of TKIs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      or imatinib, nilotinib, dasatinib).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international phase II trial investigated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      in patients with CML in CP (39 patients) or accelerated phase (21 patients) after the failure of both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/57\">",
"       57",
"      </a>",
"      ]. Among patients in CP, 67 percent had discontinued dasatinib due to toxicity. After nilotinib initiation, 43 percent of patients in CP had attained a major cytogenetic response (24 percent complete). At a median follow-up of 12 months, estimated rates of progression-free and overall survival at 18 months for patients in CP were 59 and 86 percent, respectively. These are overall response rates and it is not clear what the response rate is in patients who were previously refractory to treatment with dasatinib.",
"     </li>",
"     <li>",
"      The phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"       bosutinib",
"      </a>",
"      in patients with failure of initial therapy included a subset analysis of the 118 patients who had been initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      prior to treatment with bosutinib [",
"      <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/58\">",
"       58",
"      </a>",
"      ]. A major cytogenetic response was seen in 32 percent (24 percent complete). After a median follow-up of 28.5 months, estimated two-year rates of progression-free and overall survival were 73 and 83 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, improvements are needed in the management of patients progressing on therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and the decision to use an alternative TKI as third line therapy should take the",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    mutational pattern into consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24874435\">",
"    <span class=\"h2\">",
"     Omacetaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     Omacetaxine",
"    </a>",
"    mepesuccinate (previously known as homoharringtonine) is a protein synthesis inhibitor that has demonstrated activity in patients with CML in chronic phase with a T315I mutation. Omacetaxine is approved by the US Food and Drug Administration for the treatment of chronic phase CML in adults with resistance or intolerance to two or more TKIs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/59\">",
"     59",
"    </a>",
"    ]. The recommended dose and schedule is 1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneous injection twice daily for 14 days of a 28-day cycle for the induction phase and 1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneous injection twice daily for 7 days of a 28-day cycle for maintenance.",
"   </p>",
"   <p>",
"    A phase II trial investigated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     omacetaxine",
"    </a>",
"    in 62 patients with chronic phase CML resistant to an initial TKI who had an identified T315I mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/17/20762/abstract/60\">",
"     60",
"    </a>",
"    ]. Subcutaneous omacetaxine (1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was administered twice daily on days 1 through 14 of a 28-day cycle until hematologic response or a maximum of six cycles. Patients who achieved a hematologic response were then treated twice daily on days 1 through 7 of a 28-day cycle as maintenance. Rates of complete hematologic, major cytogenetic, and complete cytogenetic response were 77, 23, and 16 percent, respectively. Most responses were seen after the first cycle. Median progression-free survival was 7.7 months. Hematologic toxicity was common with severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    thrombocytopenia, neutropenia, and anemia occurring in 76, 44, and 39 percent, respectively. Common nonhematologic toxicities included infection, diarrhea, nausea, pyrexia, fatigue, asthenia, and arthralgia.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     omacetaxine",
"    </a>",
"    in patients with accelerated phase disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H24874649#H24874649\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Omacetaxine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with chronic phase chronic myeloid leukemia (CML) are treated initially with a BCR-ABL tyrosine kinase inhibitor (TKI), such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      . Side effects are generally mild, but there are some patients who must discontinue the initial drug due to intolerance. In addition, second line therapy is required for the patient who has a suboptimal response or relapses after an initial response to a TKI. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no universal definition of TKI intolerance. We consider a patient intolerant when a nonhematologic toxicity of at least grade 3 recurs despite appropriate dose reductions and optimal symptomatic management. Cytopenias are more often a sign of the drug's effectiveness, and less often drug toxicity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Defining intolerance and resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistance to treatment is defined as primary resistance, which is when a patient fails to achieve a desired response to initial treatment, or secondary resistance, which is when a patient with an initial response to a TKI ultimately relapses. All patients with resistance should be questioned carefully to assure compliance with the recommended dose and avoidance of other medications or herbal supplements which may impair efficacy. In addition, patients with confirmed resistance should undergo mutation analysis of BCR-ABL to help direct further therapy. The T315I BCR-ABL kinase mutation is associated with high rates of resistance to most available TKIs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for patients with resistance or intolerance to an initial TKI include a trial of another TKI, allogeneic hematopoietic cell transplantation (HCT), or a sequential combination of these. The choice of therapy is largely dependent upon eligibility for HCT, whether a T315I BCR-ABL mutation is present, and patient preference.",
"     </li>",
"     <li>",
"      For patients with chronic phase CML with resistance or intolerance to an initial TKI who lack the T315I BCR-ABL mutation and are ineligible for allogeneic HCT, we suggest the administration of a second generation TKI rather than increased doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The choice of second generation TKI is made based upon side effect profiles of these agents and knowledge of comorbid conditions in an individual patient. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Patients ineligible for HCT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of TKI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic phase CML who are ineligible for HCT but have either a contraindication to the second generation TKIs (eg, pregnancy) or have failed to respond to treatment with available TKIs, treatment options include the use of interferon alpha plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      monotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=see_link\">",
"       \"Interferon alpha for the treatment of chronic myeloid leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of the treatment of chronic myeloid leukemia\", section on 'Other agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For HCT ineligible patients with chronic phase CML with resistance to an initial TKI who harbor the T315I mutation, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"       omacetaxine",
"      </a>",
"      , a clinical trial of an investigational agent, or a chemotherapeutic regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Patients ineligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with chronic phase CML with resistance to an initial TKI who lack the T315I mutation and are eligible for HCT, most clinicians recommend a trial of a second generation TKI while simultaneously evaluating for a possible allogeneic HCT. If a trial of a second generation TKI is given, further therapy depends upon the attainment of a complete cytogenetic response:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who fail to achieve a complete cytogenetic response with a second generation TKI, we suggest HCT rather than continuation of the second generation TKI or a trial of another TKI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is no clear consensus on the management of those who achieve a complete cytogenetic response with a second generation TKI. Options include immediate HCT or close monitoring followed by HCT at the initial sign of relapse. Patient age, the availability of sibling versus unrelated donor and other medical factors also influence the recommendation in individual patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patients eligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with T315I only rarely respond to available TKIs. In eligible patients, we suggest evaluation for HCT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Long term use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      may be an acceptable alternative if patients achieve at least a complete cytogenetic response and are followed closely, although the follow-up of trials using this agent is limited. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patients eligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/1\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/3\">",
"      Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program 2007; :371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/4\">",
"      Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/5\">",
"      Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008; 112:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/6\">",
"      O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004; 103:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/7\">",
"      Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/8\">",
"      Kantarjian H, Talpaz M, O'Brien S, et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 97:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/9\">",
"      Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/10\">",
"      Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113:5401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/11\">",
"      Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/12\">",
"      Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111:4022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/13\">",
"      Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109:3496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/14\">",
"      Cortes JE, Egorin MJ, Guilhot F, et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009; 23:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/15\">",
"      Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 2012; 107:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/16\">",
"      Larson RA. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. Clin Adv Hematol Oncol 2009; 7:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/17\">",
"      Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 2009; 65:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/18\">",
"      Milojkovic D, Apperley JF, Gerrard G, et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012; 119:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/19\">",
"      Porkka K, Koskenvesa P, Lund&aacute;n T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/20\">",
"      Cortes JE, Hochhaus A, le Coutre PD, et al. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 2011; 117:5600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/21\">",
"      Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/22\">",
"      Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27:4204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/23\">",
"      Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011; 117:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/24\">",
"      Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109:5143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/25\">",
"      Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/26\">",
"      Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/27\">",
"      Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/28\">",
"      Shah NP, Kantarjian H, Kim D, et al. Six-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia receiving dasatinib (abstract 6506). J Clin Oncol 2012; 30:417s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/29\">",
"      Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/30\">",
"      M&uuml;ller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114:4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/31\">",
"      Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/32\">",
"      Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/33\">",
"      Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013; 27:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/34\">",
"      Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 2012; 118:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/35\">",
"      Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/36\">",
"      von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/37\">",
"      Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008; 112:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/38\">",
"      Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66:11314.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf (Accessed on September 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/40\">",
"      Cortes JE, Kantarjian HM, Br&uuml;mmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118:4567.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf?et_cid=30657199&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203469lbl.pdf (Accessed on December 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/42\">",
"      Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/43\">",
"      Kim DW, Cortes J, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (abstract 3749). ASH Annual Meeting Abstracts 2012; 120:3749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/44\">",
"      Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/45\">",
"      Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009; 113:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/46\">",
"      Kantarjian H, Pasquini R, L&eacute;vy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009; 115:4136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/47\">",
"      Jabbour E, Kantarjian H, O'Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011; 117:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/48\">",
"      Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010; 95:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/49\">",
"      Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/50\">",
"      Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. J Clin Oncol 2010; 28:490s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/51\">",
"      Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010; 95:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/52\">",
"      Velev N, Cortes J, Champlin R, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 2010; 116:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/53\">",
"      Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011; 118:5697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/54\">",
"      Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009; 113:5058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/55\">",
"      Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 2012; 30:4323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/56\">",
"      Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009; 114:4361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/57\">",
"      Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010; 24:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/58\">",
"      Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012; 119:3403.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf?et_cid=30334780&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203585lbl.pdf (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/17/20762/abstract/60\">",
"      Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120:2573.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4515 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20762=[""].join("\n");
var outline_f20_17_20762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINING INTOLERANCE AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENTS INELIGIBLE FOR HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nilotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1349640\">",
"      Bosutinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12149527\">",
"      Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased dose imatinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENTS ELIGIBLE FOR HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MONITORING DISEASE STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATIENTS WHO HAVE FAILED ON MORE THAN ONE TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24874410\">",
"      Use of another TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24874435\">",
"      Omacetaxine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/56/3981\" title=\"table 1\">",
"      Response definitions CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36348\" title=\"table 2\">",
"      Risk score CML transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=related_link\">",
"      Interferon alpha for the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_17_20763="Ultrasound features associated with thyroid cancer risk";
var content_f20_17_20763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ultrasound features associated with thyroid cancer risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ultrasonographic features that are associated with an increased risk of thyroid cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoechoic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microcalcifications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Twinkling\" on B-flow imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central vascularity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular margins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete halo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodule is taller than wide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Documented enlargement of a nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ultrasonographic features that are associated with a low risk of thyroid cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperechoic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large, coarse calcifications (except medullary cancer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral vascularity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resembles puff or Napoleon pastry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spongiform appearance&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comet-tail shadowing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20763=[""].join("\n");
var outline_f20_17_20763=null;
var title_f20_17_20764="Initial assessment of primary neurologic involvement in GD";
var content_f20_17_20764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimum clinical protocol for initial assessment of primary neurologic involvement in GD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Clinical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurological examination, preferably by a neurologist with experience in neuronopathic GD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye movement examination, preferably by a neuro-ophthalmologist or a neurologist. At the minimum, elicitation of repeated maximal amplitude horizontal saccades should be performed at the bedside and compared with a healthy subject. It is desirable to add an objective measurement; eg, DC electro-oculography, as clinical examination alone often misses slowed saccades or gaze palsy.",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Additional neuro-ophthalmological investigation, including direct ophthalmoscopy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measurement of peripheral hearing (electro-acoustical emission in small children, pure tone audiometry in older patients).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Brain imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preferably by magnetic resonance imaging (MRI), or, if MRI is unavailable, by computed tomography (CT). In very sick children, the risks of anaesthesia should be considered, and the scan deferred until the child is clinically stable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Neurophysiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electroencephalography (EEG).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Neuropsychometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age-appropriate testing should be assessed by an appropriately qualified psychologist. It may be advisable to defer testing, especially in young children, until the patient's overall health is sufficiently improved to permit meaningful measurement. Widely available protocols, such as the Wechsler Intelligence Scale for Children&reg; - Fourth UK Edition (WISC-IVUK), should be used unless not valid for language or cultural reasons. Specific testing; eg, of speech and language, memory, visuospatial skills, etc, may be required. Such testing should be tailored to the needs of the individual child.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Harris CM, Taylor DS, Vellodi A. Ocular motor abnormalities in Gaucher disease. Neuropediatrics 1999; 30:289.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced from: Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009; 32:660, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2009.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20764=[""].join("\n");
var outline_f20_17_20764=null;
var title_f20_17_20765="Burns epi mort IC";
var content_f20_17_20765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estimated mortality rates from fire-related injuries in 2004, by country, income category, and gender.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality rates are expressed as deaths per 100,000 population.",
"    <br>",
"     HIC = High income countries",
"     <br>",
"      MIC = Middle income countries",
"      <br>",
"       LIC = Low inclome countries",
"       <br>",
"        Mortality rates are highest for women in LIC in comparison to men. In general, mortality rates are higher for both men and women in LIC in comparison to HIC and MIC.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008. Available online at: www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. (Accessed on April 2, 2010).",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20765=[""].join("\n");
var outline_f20_17_20765=null;
var title_f20_17_20766="Management of dyspepsia based on age and alarm features";
var content_f20_17_20766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure 2. Management of dyspepsia based on age and alarm features",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 438px; background-image: url(data:image/gif;base64,R0lGODlhJQG2AcQAAP///39/f4CAgL+/vz8/PwAAAO/v7y8vL9/f38/Pz19fX5+fn09PT6+vrx8fH29vb4+Pj0BAQA8PD8DAwKCgoODg4GBgYLCwsHBwcCAgIDAwMNDQ0BAQEFBQUJCQkPDw8CH5BAAAAAAALAAAAAAlAbYBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b79yJYM/v+/+AgYKDhIWGh30TeIslAgQBkJGSk5SVlpeYmZqbnJAEAoyhAAIBoi8BoKZ4pKotqK13rLAqr7N0srYntblxuLwku79uvsIAwcVrxMLHyGnKIgkDAwlGBtQyCQYlBDzMzWfPAAQKAQoH10IJDzMP1AUj7zAD3Cje32XhBAPQDgYN+wAGNDBGgAG1BQ0YMNBGUIE2gQoIUEvA4BEABAsCVnRIQtrFgRgBLEAwoECAjAUa/4wTgSBiRmMiPAZwEABgCXv3xuSzqQCCShEEGkBgACDBQALrhgJ4UOpnAALWJACQkA1CQG4JEACAoKAjtwcHjJXSh6DANAAFMjLI6GCAgbVoRUASeWCAVhM4c4bZOWKuAwQIHNBdcE2fiHcSIr2bK26AgwdurwIwMPQAPXjiFFDcZzheXLEJ6A0gGm/uvBR59X7hK0LBQK4PrAZ8QLPxYbTSZJZqTJmBBAOnD0AAfhnoggdCBdv2XLqmaG7NJddLpdoM6wVhJzvoV1TbT8MJxcmmNteAVIB1TxfQtqD41nPi6HVmGP23Mav2yQXMrot6dTL5WHYAR62tA0ADAlJDgP9lEk3GwAEHEDXTggM9eMA6py3gwDjuJaCcfrYFcOFncyE4oDYQbMjAbgQQ8NJN/v0nRjgp/IWCYajtBkZqMmpB4wkLdHWjTbro+AWPPWLx4yxIJmnFkrA06SQVUE62QAAQ3JXbWSSdxVJuNZA0AkAGXJnlCAigAyZw0jAUg5RTSgGlhwsM0N4+JkGS0VPlZMcnWC/CEIAEL8VzQE0pjuAbQwGYFBBNIhooaIxxbgGlA+hM9llfu9UllggGeDqCAXxqg9EARgYA1m2ngcqSAwq8GE+rAOhHkUUrwFnpE0smwB8JeZ70qQE2MiYSUSPoV05AEqwIjJ5xmQeZmxAgh+z/Z7QiIBVVlLGg665NLNnqAy26kxt5G0ow0KcxFSeVCOe5J1aonyHwlARCwmcftsW981hkuVIK7hVLaktCZzeNJZuxxwGLGa2cGrOAZyO0VVaLhN4m3UVh9bYvagIPXAWUCgi5XMLa7cOYh3eJwMBAo20ccajvRAPqX9WKEB6/oB4AswiigiyypUaiQGqL42hVANLrrIzphBFmWhTS1EAs126NXsTAhj4DAB+8BhCwNLMtdg2AhZIKPXQWVary7dpHtG3K23AXIbcodNc9xN2h5K13EHwz4vffPwS+yOCE92A4HognvoMjnUQu+eSUV+5JyI4roQcinHfeRwQReC56/+eKZC7MHqanbgPqqrceA+uux84C7LLXfgLttucuAu66285772lsPvrwxAsAevHIj1468CgYn/zz0EcPfejMp/A73NdXn/3Q2wPf/cDf6x7+ruPLnkEB6BfAwd/np79+9SNYkH4BHfwtf/r1wy8CBfN78Df/6fOf/gBQgflt4G8FTN8BBwgADaAvA4lzYAEgyEAAYAB9FkjcBQuQwQpeAH0USNwHCxDCCqKlABVwHPpSaMIIaCBzLjTh7jCQOQHQUIYbuEDmcijDHvrwh0AMohCHeALhSe+ISDzE8mhAgSQ68YmHKCETIGe5Klrxipz4xA0iQA4sevGLYJSEAiLghP/F1WFwESDSPQZAxnAVjRdoVOM32FjGN+YijtWhoxubgUfV6HGKdrRFH/XyxyWYkQ6DzEkhlXDIOSRyjW0EpArStAN7ReJqkGhZDRYQKBw88geU1IElGSMJTfpgkUn40aJ0MID0AMQsbfJkIGnwSR+ssgaUqZorD5MbN/0AlUigUWBiBaqnPOAlKjFICYJkSqtRbJlJu0idjDSacWhjLu3BFWEgII0GRMQoK5nOFuXYg2G+5GjH1FlBpBYTl7SrBM8MAjDjNstq7YwpIuFGQgwQGF8GJCLrIpsC7rI0BqhxAQtxDLOcNYKsbKUrptEGXAhAE1QRIE0Zg0t/xjkEeyL/C5/tOdBC+tmRC2lyABKIJloKQk4ezNMINNKXNuxzGgZ0sS0nQABttGIAFGVHK47RpEGBEg159cYyn7IXRccCEMZEZ6M2SOMQZDqVh3DDppDAKZpc4qaevocljzJlD15qt0BejAAZmxU3CMDNWJagJS4ywTNxBBSA6MNqXhvOaTLpgIHMBUdOvZo4o9pSUS4NrSh5J1t7aYIyWROe2yhsDshKhHDkTKRe24dTkMVPEoRGAUTKxn4uwtOPbWUdxJLZYdjDDUi0sjVMFSyJAlnLHVw2PJ7aLKjE2lCtiPa1gJmMaU8ZSUMG8mtV9ZVC6AGWBWnSoSVA0IKogQABddIA/+boGl41xKFPmaMgsWXXU/GCORdINQjI/Y1yKyKC5h5Ak9mk2oESxLEFdZK4dXwBQ4J0xvK24LxH2K/JvEDZvc3SBNyFSn85ioQE+5MLBRZCI+VQ22JEGHAHbkWFhXFhIEw4Do8EDkNECwN5raHDhcuwDfB6BboCw78sAHBM8FXXGMTTCS6+AYp9oAzsWvMfMfGrSh7g431g5Cl7qmg+ByqXIRe5KBUpGkIU8hA7ZSSZ1PAxR261rgCopCvDfOMj53FR28D1vuQKym3gqsxTlcLLSHkyCVQSlAS8BAFWmfJCnrKwIV8EVqU4swj0fLSFrbMEO1bcGxlglQaAEygDSf/L2RiQJsE4JhuYwo5dEAoc5UhaIZWeSlW2kRQJSeCY++wnow+UlfeGDU9qWUCouEleBo9JH10xTFve0smBEEtpF5mIpZtVik9T2kOe7QdGzHPNdcQZAnX5NVoqNBzh7GPXEyUytN2CM6IYBdHFZeQbFfCyu/wlMBoLbKtcS4+hisMdsvXXtCJ7G8ZgdSYDIHcDtAKBR/BptrapNWERvVYE6CM0MblWTMglATwNOiLvoNVTKaYtWteKLVoxTKsQJhnDIFwjttm4nQ5AGBMkmgfPCFLDHxqbdO8m4vRgd41PJt7JDMW0OFoMi9oaGZWjCrTSAPanciwXGK9AxpLJ913/nzNn+CDsAUyGOWZqTgJ7IdVDO9O4fBze8X206jRar/EAaFO0kz/ujQDBJ7G4A/C4tOocrz2tdlzOKqARCTwSwhpnxbSUmrAd3kMP6Itt/U5x4NQ+WAIGaj31DjWXZWMTrzpP40FRu3p9659puZqrep+Qb120P+lIuFMpZgYxRAGSijxKF8QiF2EXQuuKPNq2wSDy6Mi9Vm8RewQUacFKV+A1QPrXzTLfE5EgVAVhfFE29ACp031T9SX5oPkT9uUsiCO/NxFHqq8P6SI3JqMPpooBYKMVsFgHRB/ChqdATBbceAdm1wGU+MuC8+cg/UJYfxTQ3YL3szL89MRHRqcC/0g3RwAIU+OHNwOYAgXYDPGXAx8GB/qXCw+IAxH4BhNoCxV4AxfoBhk4Cxu4Ov4WRiRYgpugRVHVRSa4giyICWPkBEYERYZwPDLIOUs0A01Ug51DgzrIOVIEC+UTJ0EoO0PoJEXoOkfYI0moOkv4H03oOO2DPu9TN1GoPgx0P+iTP3WDhfTDQACEPgJUN19YAGEIPwmEPgtUN2dYAGmoPxJEQX/zhia0QR30N3RoQiP0g3WThzK0QiqEQjIUQ44jiCZkQzV0QybEQ46jiETUiI74iGEQg9Jzg2AgiT14iYNAiXVARSSIgjoxgi0YipTjiauQgDLQOJKkgKHQgYMHIP+m6IELyAas2BexODKv2AaouBe3eAq1SCW7uAa5CAbKsCXo0ACQcA3R4CXANyNv1CW5wVsr4GPslFMtI1knoA7ROI3BuBpvFCwZESo14U1jQQ7mwE7bKH4mBwl5Ill41ROa4i064n8oYH/QkDa0uIrdWALuOCoB5yH+dI4BiAKe8RRbFmXGoGSvoh/twWRu9ixTNybe1CBnIhJFNRmlEhBWFhLLGAvdGAkZMVwBVyuycY+umALxgE8/wS15VhctM2t2klDDxlByMYLP9BRR0XfCRRy18mYQdWp1YmIAyQXKAEtnEQ/ZlBF0ZSxFhw+zFA+JoY7kN294ZRjuJhF4VQ7/uVGTLGIXgsFfp/EuU8EuLBaURCNXJYApEUNXrgEjTGmSvLQmN6eT9IYjS4cX8YgytrEW8KEemMEYY9mLzpCPJIAdjBJe2LGRwtiUQDEeAWF3cXcw+5AzqXWVd+mQ5hETG/JOLwNyfgmUgIkGQ8k0g4Y0Q7Ug1/dgZFlZiukgEEIUsxcfgWIYr6dd8mIsNck1AdVX7xQa5SKWnomPQJCaBrYFSvlnOSCcSvKLrvCZUTCLPVCc7XcDyEkwyuktzAkFzukF0/kk1RkwbamKjMCJYUSKewGKonieWXSdZWCJ0KOJXsCeOsiDmMgH7gmJAKKe9skLT5ifubCf/DkL/vmf/60QoAJqCgRaoFEAn0kknzVYnwhqgaEznz1IPQ9aOPjpIxdaoSZwoE+SoRpKAhw6Mh76obszoh36oQrqOQyKPA7KAimqohHantpjnuh5gtcpnjWantrTnep3ozzaozuaBX6TnTqwnapBpJ7ko1pgpHqBpNKppEJqopXyDHzXmDo2A0N6YGxijWPyVtDoAkyaE88wKIVCA55hYta5OgfmGKpyAA9mAtzQKpxkA2F6D2O6Kp/BZaMJImkGMyaxJ1txFyVHkG+apSowLqWwkDwVERzxZhUlDXbGElbhYxlWp98wptDyDtWFAK+WavHga+dmFvC2jxKgU03xmzXwI63SE/+cplCr5mhxoWmWZDAPlVk4qTbeY0eQQC/v0G+eEACbiS0Mx3VxgWz89ZRZg5gwoKo0YQ5vYVcJoG8EJR1zARd/4SGQEBG0IKVCqKtvNjHGAHR2kXPzpSDESnmjgSdbAlU0oKp1URiWJxIKsHLOZxoSEaeuNI0kmatFMhkHEHF/p3aLsXh4Qh+jqRxsBQ3sOgOqWhySaWntVWyjxS4b8o1UobC42juYKhdGyXthgxTvgHwPojIj4hkZw5oRsrAy0LDHl11+ZXqf0SJXshuJAg0CcmCW2gyLwxD85wOGGqVBOgMeMl3BCaVYkLPI4KR0arRXgLTFoLQ18LNHy61TgqP/OZoJ5Pk6NHq1mJC1tvOinLOixdOiKwC2YRujz0O2jhiiVEK1D8q2UwC3BboHNDgMxhOhJIoDETA/L9QGe5s+fZu3qTo/iJgMhCu4NjAB86NDbaC46cO4iEsDHJA+H/AGk4s+lRu5NNAB6HOAZ8C5BeC5mrsCHoA+bvsEpVsAp/ufCaS2Y9C6o1sDGTCFbzC7sVsDFqCFb5C7t8tEZegGFPC7vesCH8BCcFC8w5u8dmC2EqpELsC8zfsHrrs2Vsu1leO1t7O11qsJ2Js4UFu0LvC9x7m6SfujTdAk4puksZO+zzmA7Lu062u+TIC+8lsETmug9asE9Hsk5Pu0+ZsE//urnf17Ov+LBAHcBfcrCnKzpaACJkXhVipgDUByXxmrAqq6JVzKArdCSwP8C3LDpmDRaW1aJrCiScVZFPYoW8sZvjj7FP4mKG+EKW+6wkhoioiKqCEJFI/QJZwUEtXUqKZ4wDkyaAlAa4SqEY/VIgFQjX96NAFQZXNawabzwfTQE6tqFTlWMm4xKMd0Gg7FFexCw7OjYoyxVGN3qkXBb12hxW5SFtOgLD2ZTlJcQzbcrG7Kps6aw+zSmTb3IK0VxO5LxlsJL4rRx0h1wk45AlJxwsrqOB/8rjEByTMXMb6ZVzrJyIM1xvA4c0S5D8JxyYLJHGE8x45sw8VhNTmmKv+ypR6sNcre2QJQUsZ2xZjrkU/GkMLxsJkxg8mt2DpU7BUk8AAS8H3VJRF8zF3aysuNvKGCPHNv0ZoisSHaWsyZEg+82SDKvJQ1XAZCTJwdrJ8FfATdvKTf3J/hbATjDLTbTAbpPLXxywLBdQLGmMEs0A5vEsgtYBPx/AL2rAIktq3v7M+JcQKPoIw2gH+kzMz9R8kvgNDtpa+9zIRaOiBvRH9v9RILM5MEcsTg0WgtInhsCcvjN5BFA2frEKkXgcVepxBNZS8Y8aX7KtEpEDYJcMI2xVKQ1QClehoo+RVo3H1U4Y8aqbLWM9KRgCvwQG3MdsuNERiAYSNLs8QOrc3/vjxLxIRNMisey+dLuIYlEFAKyIoYhcxWaFlxktXO8JQbIDJ1p0FMNqIPXy0XVnGmXJrAwIkCKUVRDtBJdEkkWAIVNqWuYNLJhuemLCEiaGoM+Ox+DK0xXtxXyKIPpCSxk5zQhBPLbwTGS91QwnE22ZGwRaHVoQ3XbhpcBuB/aO0wKqwxLWd4lucrRLUpU63YAU0LdtRc91WqtoyyRPHMKWsY5Whdlg2iI93YK2V8dDEChiEih6IxekzUdMzNi20D8RSdO2DX4XnO9jvdNfBMPdsN5WwL73vd3O3NtS0GqV0F2L0I412k5U3O5x0G6U0F612K0s3C/Lu+2ru9kdO9/42w3/xtCf79N9ALo1DkugV+CGKbPNMLRHLbnOG9thEeNxNORA+OnRX+taKz4IbQ4DeQ4HSLtjb4iNW7ggOOcgDeiRlOPtoN3R7W4svsQ+lrpDO+4lMK4yFdVgZs49264wGJzjxetWv6jCYgWokd44p2qEReAkbOiyR+YMEiR/YsjzmumioQ5SYw5U6+tlA+mEo8aMCmZTNM2wh45V6uTWHOqGNe30oI5WASGRPlcK8K0TTu5h4B50gp541G50FuhFB+SUpVGwgjrQBd5iYJ6E8h6A5H6MMtQz/iGYHhV7FllPNaWHVu5q8i6TTnc41eiF0eybB1Mmk3S5fulqC+k/+iHrGdXkGPTgLf5SwIg9gKlslWbuqtYRmw7nCyvuZ9niQ1/uPb/eQ+buhALuzi3MG/zuXDruPHTuIpPp7I/uxgdOImBOIcXggenrijc+2ZGLsXziu97ujhrjjjzurl/jjnPkDfzgRVSLvKa8HpfgNcqLvvbj3xbgNjKLz1vqH3XgNr2Ib7fjv9XgNyGPDwHgd3aPD2Hgd8qPDNM/DdDYgOL/ByQIgT3wgQ366Fe/EjsO5NwIgc3/FBDuLRKwDZ3kMePzvSHuBHnfHVkfIr0N5Y6vJHGuQyf4o036Q2j+PkjaAwb8E8794+v/P5PbdEL8BDLydBP75J35wqxsCT4cD/yTjmozKNUVzoAvrzRV1/NBHCIOymGsJkxo3C/frKWX/0h8pczqHqOabEPDwSGfHD10TGOS+maJ8CV3zFeszGXPyTaVyr2UzmZ6/0XN8nIpzHqYw1u3EaR/XHaWr0hG9+ktxKypj4q8wNn7xXdN/02KliEIPKaqTKlVzLIRX4bA4uWt88nn/KxSHMxGwZNb343IDMjm/2/5n6t7P06gv5Tl/0g9/7SM/7ne/7t3/35od+HMz5vJKACkDlL+D8tM6fuK/QLFAtzzQSAVE1+6CnULZ58eATYm770m/8QNIVWpkZTe1qZKH+DhfCcy7++Tn9jZBhoaENzzQPLREWUuGr/3wCAhARBCNQLIcBKEyDALE8x4FA47m+873/A4PCIfEnuBWTPEGgFzgQCAUCTQJpPBrUgGLgRXC9A1jBoZAtFJKBE6l8w+PyOX12rL+ZwQKOQU0cNA04rAAkDBYmnAAwnLEBPDTx2OBVWl5iFt1lBukB8dFAnAE4PKYQHDQAnKYuGhwoPEUV7lBy3uLm0m3q7nj2KtkCDxMXx/AaH0smBwkzP0PvujH/Rk9OW2drAyEnV2/TOIOPkx9jG3+Xi5ezZ3ejL7evt9NTnxenk8/X8w+/448gIXAgwYIGDyJMeJDAvX4Oc/0jNuEIxYoWL2KsGCFCxo4eLU54KBJYxJE4Sv+aTMkOpUoALFvCtPYS2sSPGTfazBgyJs9bM58JCKhwKFESDHsixfSTWrxb+5JCVbLUW1NOT6NiFTIVXq+rWb/22IqvaiavYM+ebKgtnwwxY3AkWEEFiFm0dl2qdUdWRgGBj2Y8UATqR927Z8USYxtj8KookhaQAWBAAQEFtHAUNvwVsb+9i8UAGLCCwQIABNjwYQABQANFOjJrxsqZpOcTAgGAIeCgyelFLV5ciy1cxuxeihfFQOBAFQnTqGOkWVMr7/DN1KMdHzzgQIxYzhc9ijS9uvDiurLPUACFAe/nsghcDnedPFTzEGtXgk0/pn1cx/PPt19P/fmEHx76Caj/EoGc/HdggAnCtGAmQRVVoUJHQXjYg8nUlJNFOHkIUoYaZiXhiDxlUICKBXAQlYknwmTBigV0kFSKK7YIo4AUzOhBUjKuWKOO+1Uw4wZJ8biij0Pup4GKGUBV5IpHMkkfBipaEJWTBUBZJX0XqEhBVFcWkKWX9KlYQVRgFiDmmeRFoEFWab5JngAYZBVnneRtcEGJeO4ZKD99ClqooYcimug4HYbYqKOPQhqppI3upCgcFFqYqaabctqppwhhaGkeBor62oalnkQqqvKtmkSDrc6AIKyvwlrDqbXSWqusreYK666r9trqr6gGG4cY8Q03bKnFwtFXAMvtp6yozL4B/4oWMWjBgCIIUKatZJRZBkAJ2iJQ2ioweLHAAgP4Ee4ADVD2SLaqJOCHKl3dOquqdIAiCmsMGKBcwIok4AAjq7UGAQOGNDDAXL0FIMEDCyQAg78lIFAwayqUi8ABCBjQmy7SWkqtElNAMVosz7KRhhQsuABDChSH9jAbzUmmMBTiSpLavQCIYNS+cpCsqMlJ8IGIaRAc+4ACka2iBhsDPLCbwzFALMkBEBhwNc58iCxuF1/gW+sQRxfR7xYLS4YAAaogkHQMkcTFGgGASHbAzT2vsMAWPYsdwyGECF622Z0MLcdgCpzxABQfF0zAA3y8Z0ADjyvCwAGa7w2dA5X9vf/Yt1A0wcrPuBSdKNqJpo7o6oi2fujrh8Zu6OyG1l5oOsc+E5ghyMZhgGs71GtA18ciAMMP4ZnL6uHcVOUstMn05jseCTzQw92h7UZCuc3zoAAoryCbu6DpWDtXttt2q8hkla0wLsH21kCAt1q8TQO7DJRyLiRR3Gt/AZBZAxjAABgYoAQBWEG9TFAuQ/ihKQMYxdXawgZujeAvMoDA5NBQFfMFCn0x8FcBA0aIjBnCYKphTQIUxjCPgew0LkxAa04IPhi+gg29UYUBHJC8j+XQNA8wgL+8wwUASCAuq7laEolIgwc8YjteUERz9MaCpqQBOTHgjvOe5wP0oQI+jFj/Wf9cxoffyOwANAuaAme2LStoEGjZ+05vqEaANXAQazqcGhUkIAM/OgCKK7haIEVDg7lwjwSlIQHeeDaDBIiRMYiUAQj3JEKlEYBpXjCA06AWnalVjQRjewvVdoMbWcRKEr05zeUUcRqcrZKPWuQDERkgga5RoZa3nAEiK1iDAFQQZzWAghQQOUlbedEI0Rvh2mIQsPzFLTRzC0DdtKA0Q1STAMmTDGOuBQArvjJ7OfQmOGXpgtAs7BF6u5o6Nfi0GPiSZwbYpXhyIEnM5ItXy+xO4x6Xsc91sHKXQ4UiTDfQA1TsceCDBCzK+Qr7WdFxCuhfHf8Qhe1p7gDZu1pG/+foQXhOsjkpiKAOtDOKWOUTWInTRiF8aAkV8KAQClhoDrSJz2R+caXZ+JwaL3E54HXnABr1gQI8ilKchkWnpapknW5XKKa+yamCguqZpBooqnrJqnvCapUw9amvgjWsYrVQqJCaA0ZNKq2TApFa2yqpSpk1KS+K67RSStfDzfWuqrOrXld1IxXlqK+CBZKKhCTYviZJRUs6rF6lpCIqMVavW+pSZPVKJjNV9q5sclNm70qnzt5VT6C9651Ge1dCmTa1qo0GWt3q2tfCNrYVgWtcvTrW2+I2t2Eta22VKiy+us63q+LqibT6VODKTrioIu6I8pEAEpwuCNtEA02J5/8WGTSAkYKbog4M4C3cQCAACwDqENwCsuHpAAHhZV4OmJuhdJSgYd4ZgrpSGYTK3OYVwIQXb2KhHvTWYDWrSMUAIGCwSRjIWcDEXg8mth0ewrSLdP2GxmQwSAM+IgBaGAX+VOEF3FDGBOKCX2gGUF8ZhI0FAnbmd1J4mVckh3Asbsw7eTmC5FGGpox5YAIlV11ICHgBH0Su7ZoSAKPixofKIUNpSFOwgC2yCVb0jniuFbGJ8XJlTdjlIf+igBWzRhJ5pMECADYIGjBONKXw7kILAJqricdvOECA02jBxaPq9RvCHKEkArAaUHgPjr9sZHMkIBDKVSWToAGF3whQmrD/7RmYv8RaFBjxiO1RsgmQhCfb+HIbJg7ymJJx2M9E7V4IfaPM4ehzEwDdBDDsjATBbPV196zHGThgeM0JmwJOJ+lVdHoRIktxcyoYTy3WDDnHbosxb5rnpszzEQhoDRe35+ptGgDR81yBeDJZOFu3GDoR3rUp7gyd5jmgeXzIYw/DMcdd+pkGjLmaFb3Zlhqc1NRE1l1V6kXMmwkVcDzzGCqiPGADNsG7Ql0YuMNY6cZEgQE6fFy4ZuA2GWAwCuJUTyssDgUaCrXifJnB1QBhwGNmFGDwPCkl930+5Y6jC8AoRBa1pzw8kxbm4FAOgDmxgM+JMXxIRuazK3vqBBl3O6ouD6FQdOv0p0M9Ibw1a2tla/WrYz0ntF0t17vu9a+DPexiHzvZy272s6M97WpfO9vb7va3wz3uMggBADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GERD: gastroesophageal reflux disease; NSAIDs: nonsteroidal antiinflammatory drugs; EGD: esophagogastroduodenoscopy;",
"     <em>",
"      H. pylori",
"     </em>",
"     :",
"     <em>",
"      Helicobacter pylori",
"     </em>",
"     ; PPI: proton pump inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"     Talley NJ. Gastroenterology 2005; 129:1753.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20766=[""].join("\n");
var outline_f20_17_20766=null;
var title_f20_17_20767="Pathogenesis of atherosclerosis";
var content_f20_17_20767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postulated steps in the pathogenesis of atherosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 509px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Mehta, JL, Saldeen, TG, Rand, K. J Am Coll Cardiol 1998; 31:1217.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_17_20767=[""].join("\n");
var outline_f20_17_20767=null;
